Transforming growth factor-beta (TGF-β) induces HIV-1 restriction in Langerhans cells by Czubala, Magdalena Anna
 0 | P a g e  
 
Transforming Growth Factor-Beta (TGF-β) 
Induces HIV-1 Restriction in Langerhans 
Cells 
Magdalena Anna Czubala 
 
 
PhD supervisors: Prof. Vincent Piguet and Dr Fabien Blanchet 
 
A thesis submitted for the degree of Doctor of Philosophy 
(Immunology) Cardiff University 
 
Date 29
th
 September 2015 
 
 
 1 | P a g e  
 
DECLARATION 
This work has not been submitted in substance for any other degree or award at this 
or any other university or place of learning, nor is being submitted concurrently in 
candidature for any degree or other award. 
 
Signed ………………………………………… (candidate)  Date ………………………… 
 
STATEMENT 1 
This thesis is being submitted in partial fulfilment of the requirements for the degree 
of …………………………(insert MCh, MD, MPhil, PhD etc, as appropriate) 
 
Signed ………………………………………… (candidate)  Date ………………………… 
 
STATEMENT 2 
This thesis is the result of my own independent work/investigation, except where 
otherwise stated. 
Other sources are acknowledged by explicit references.  The views expressed are 
my own. 
Signed ………………………………………… (candidate)  Date ………………………… 
 
STATEMENT 3 
I hereby give consent for my thesis, if accepted, to be available online in the 
University’s Open Access repository and for inter-library loan, and for the title and 
summary to be made available to outside organisations. 
 
Signed ………………………………………… (candidate)  Date ………………………… 
 
STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS 
I hereby give consent for my thesis, if accepted, to be available online in the 
University’s Open Access repository and for inter-library loans after expiry of a bar 
on access previously approved by the Academic Standards & Quality 
Committee.  
 
Signed ………………………………………… (candidate) Date ………………………… 
 
 2 | P a g e  
 
Acknowledgments 
I am deeply thankful to Cardiff University for the President’s research PhD 
fellowship, which sponsored my education and academic development. At the same 
note, I would like to thank everyone involved in the success and progress of my PhD, 
including Matt Ivory, who performed skin experiments and Paul Bowden, Tammy 
Easter and Satwik Kar for their contribution to this thesis.   
I thank my supervisors, Vincent Piguet, for affording me an opportunity to do a PhD 
and to develop my scientific writing skills. I am grateful to Vincent for supporting my 
international conferences travel, which gave me an opportunity to widen my 
knowledge and understanding of science.  I thank my second supervisor Fabien 
Blanchet, who taught me research and mediated my development as a young scientist. 
His enthusiasm about science became my inspiration for discovery, which drives the 
success of my research. Motivation and support received from Fabien made it possible 
for me to accomplish this PhD, for which I am sincerely thankful.  
My gratitude also goes to my lab members, especially to my dear friends, Zahra 
Ahmed and Paul J Mitchell, who both showed an exceptional support during my PhD. 
I thank them for their friendship, inspiration and laugh that filled our office every day.  
I particularly thank Zahra, as her drawings decorated my office wall and my heart.  
My success would not be possible without continuous encouragement, motivation and 
unconditional love I am gifted with from my parents, brother Michal and sister 
Muriel. I would like to thank them all for their care and dedicate them this thesis.  
I owe sanity and good spirit to my boyfriend Chris, who never failed to bring on 
adventure and fun during the hard time of writing up. I thank him sincerely for his 
constant care and drive for success that kept me going during most difficult times.   
Finally yet importantly, I thank my viva committee, Prof Greg Towers, Prof Bernhard 
Moser and Dr Ann Ager for their guidance and a critical intake on my thesis. 
 
 
 3 | P a g e  
 
Summary 
Transforming growth factor-beta (TGF-β) drives the development of immature LC 
from hematopoietic progenitor cells and shapes the cells functions. Here I showed that 
two LC model cells, MuLC and MDLC, used exchangeably in the research, differ 
significantly in their phenotype and immune responses. Discrepancies between these 
models were specifically visible during stimulation with type-I IFN, where MuLC 
failed to up-regulate ISG levels. Yet both MuLC and MDLC demonstrated low 
susceptibility to HIV-1 infection, even in the absence of SAMHD-1. This post-entry 
restriction was conferred by the action of TGF-β on differentiation cells as indicated 
by our study. Indeed, in the absence of TGF-β supplementation, derived cells showed 
MDDC phenotype related to high susceptibility of the cells to HIV-1 infection during 
co-infection with SIV-Vpx. Additionally blocking of the TGF-β signalling, reversed 
the restrictive phenotype of LC. Importantly this pattern was also confirmed in skin 
extracted real epidermal LC versus dermal DC, suggesting that SAMHD-1-
independent restriction activity operates in TGF-β derived cells. Accordingly to PCR 
analysis virus replication in LC is interrupted prior to integration, suggesting the role 
of additional restriction factors at early stages of virus infection or lack of essential 
viral dependency factors such as dNTPs. Interestingly maturation of MDLC with a 
synthetic bacterial triacylated lipopeptide or TNF-alpha significantly increased their 
susceptibility to HIV-1 infection, which may explain why HIV-1 acquisition is 
increased during co-infection with other STIs. In summary, our study strongly 
supports the action of SAMHD-1-independent HIV-1 restriction mechanisms in LC. A 
better understanding of the balance between HIV-1 restriction and propagation from 
LC to CD4+ T cells may help in the development of new microbicides or vaccines to 
curb HIV-1 infection at its earliest stages.   
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1. General Introduction 
1.1. HIV Pathogenesis and AIDS 
1.1.1. HIV Origins and Subsets 
Human immunodeficiency virus (HIV) was first described in humans in 1983 as a 
cause of a threatening disease spreading at the time in the homosexual men population 
(Barre-Sinoussi et al. 1983; Popovic et al. 1984). Acquired Immuno Deficiency 
Syndrome (AIDS), as the disease was named, resulted in unusually high susceptibility 
of affected individuals to opportunistic infections (Greene 2007). A few routes of 
transmission of the virus were identified, of which sexual transmission remains the 
most common (Hladik and McElrath 2008; Kaul et al. 2011).  
In 1986 Clavel et al. (Clavel et al. 1986) described HIV type 2 (HIV-2) as a causative 
agent of AIDS in human. The virus was closely related to Simian Immunodeficiency 
Virus (SIV) affecting macaques (Chakrabarti et al. 1987). Not long afterwards, 
scientists were able to link HIV-1 and HIV-2 origin in human to zoonotic transfer 
between primates in Africa and their human hunters (Hahn et al. 2000; Peeters et al. 
2002). Four independent SIVcpz transmissions from chimpanzees to human are 
believed to give rise to presently occurring groups of HIV-1: group M, N, O and P. 
Group M is without a doubt the most commonly diagnosed, estimated to affect 60 
million people worldwide over the decades (Gupta and Towers 2009; Sauter et al. 
2009). The remaining groups appear in a handful of individuals; group O affects 
estimated 100,000 individuals while groups N and P were diagnosed in less than 20 
patients, mostly restricted to South African regions of Cameroon and neighbour 
countries (De Leys et al. 1990; Simon et al. 1998; Mintsa-Ndong et al. 2009).  
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HIV-2 infections do occur in people but the transmission rates as well as progression 
to AIDS in infected individuals are very low compared to HIV-1 infections (Popper et 
al. 2000; Rowland-Jones and Whittle 2007). The HIV-2 genome phylogenetically is 
closely related to SIVmac/SIVsmm suggesting that the origin of HIV-2 is different to 
HIV-1. In fact, SIVsmm does not cause AIDS in its natural host, sooty mangabeys 
(Rey-Cuillé et al. 1998; Silvestri et al. 2003). Observed discrepancies in successful 
spread of HIV-1 and HIV-2 rely on the presence of the effective immune responses 
generated against HIV-2, but not HIV-1. In fact, more effective antibody and CD8
+
 T 
cell responses against HIV-2 are present in infected individuals (Gillespie et al. 2005; 
Duvall et al. 2008), which limit CD4+ T cell depletion. Additionally, HIV-2 shows 
less resistance to interferon responses, which could explain why this virus avoids 
infection of dendritic cells despite the presence of Vpx protein in its genome. The 
function of Vpx in HIV-2 thus is not to increase virus replication in DC, as HIV-2 
does not efficiently enter these cells. Instead, Vpx enhances HIV-2 propagation in 
macrophages and T cells. As an obligate intracellular parasite, HIV depends heavily 
on host factors for its replication. Additionally, virus has to deal with both host 
immune responses and cellular restriction factors (see Section 1.3.2), which can be a 
significant obstacle to virus replication. The absence of Vpx from HIV-1 genome 
could be seen as a disadvantage in terms of adaptation of the virus to its host. About 
60 million people have been infected with HIV-1 in the last 30 years, compared to 2 
million with HIV-2, suggesting that HIV-1 evolved to infect humans more 
successfully than HIV-2. 
Although the date of the initial identification of HIV-1 is recorded as 1983, 
phylogenetic and statistical analyses suggest the presence of HIV-1 and -2 in the west 
central African population up to 70 years before that date (Korber et al. 2000; 
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Worobey et al. 2008). Leopoldville, a city in Africa where HIV-1 is believed to have 
originated, harbours evidence of the earliest strains of HIV-1 group M (Zhu et al. 
1998). The spread of HIV-1 from this location to a worldwide distribution was almost 
certainly related to human migration, development of cities and trading.  
 
1.1.2. Simian Immunodeficiency Virus 
Simian Immunodeficiency Virus (SIV) is a lentivirus affecting over a half of known 
African primates species. Estimated to appear in primates over 77,000 years ago (and 
rather closer to a million years point) (Sharp et al. 2000; Worobey et al. 2010) SIV 
had enough time to spread within different species and co-evaluate with its host. As a 
consequence of host immune pressure, point mutations introduced by error prone 
reverse transcription and recombination between viruses, SIV acquired characteristics 
specific for each natural host it infects. SIVcpz, identified primarily in Chimpanzees 
has arisen as a result of  recombination between SIV from red-capped mangabeys 
(SIVcm) and spot-nosed monkeys (SIVsn) co-infecting these primates (Bailes et al. 
2003). SIVcpz was further transmitted to human in last 100 years resulting in the 
catastrophic pandemic of HIV-1 group M (Keele et al. 2006; Worobey et al. 2008). 
Similarly to HIV-1 in human, SIVcpz infection of chimpanzees causes mucosal 
depletion of CD4+ T cells and consequently AIDS and host death (Keele et al. 2009). 
In contrast, CD4+ T cells depletion is not observed in SIVsmm natural host sooty 
mangabeys (SM) despite detectable levels of virus replication (Rey-Cuillé et al. 1998; 
Duvall et al. 2008). The reason for this “tolerance” to SIVsmm in SM is thought to be 
a consequence of low SIV-specific T-cell immune response and lack of chronic 
immune activation acquired over thousands years of infection of the specie (Dunham 
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et al. 2006; Wang et al. 2006; Paiardini et al. 2009). The importance of virus-host co-
evolution is further highlighted by the fact that SIVmac strains, originating from 
SIVsmm are pathogenic to their non-natural host rhesus macaque. Similarly, HIV-2 
that was acquired in human from SM causes AIDS in infected individuals. However, 
the pathogenicity of HIV-2 is much lower compared to HIV-1, suggesting changes to 
SIVsmm acquired during evolution in its primate host. 
 
1.1.3. HIV-1 Epidemic  
Since its first identification, HIV-1 has spread around the globe infecting millions of 
people. In 2012, the number of infected individuals worldwide reached 35.3 million, 
including an estimated 100,000 people living in the United Kingdom. The most 
affected Sub-Saharan African region sees as many as 25 million people living with 
HIV-1 compared to 860,000 cases in Western and Central Europe (UNAIDS 2015). 
Novel prevention programmes introduced by governments have dramatically 
decreased the number of new HIV infections. Additionally, introduction of 
antiretroviral therapies (Yi et al. 2011), voluntary male circumcision (Auvert et al. 
2005; Bailey et al. 2007; Gray et al. 2007) and pre-exposure prophylaxis (Anderson et 
al. 2010) have proven to be a promising strategy to fight HIV-1 transmission in most 
affected regions. Yet, an estimated 2.3 million new HIV infections were recorded 
worldwide in 2013 (UNAIDS 2013), suggesting that additional steps have to be taken 
before the progression of HIV epidemics can be stopped and reversed. 
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1.1.4. Stages of HIV-1 Infection and Host Immune Responses 
Three distinctive stages of HIV-1 infection have been identified in patients: acute 
phase, chronic phase and AIDS. 
The acute infection phase takes place within 2-4 weeks of HIV-1 acquisition and is 
characterised by flu-like symptoms including fatigue, nausea, fever and skin rashes. 
When the fist symptoms manifest in a patient, HIV-1 already successfully reaches 
lymph nodes and gut associated lymphoid tissue (GALT) where it infects CD4+ 
CCR5+ T cells. The number of CD4+ T cells drops rapidly, in particular in GALT in 
relation to intense HIV-1 replication and bystander cell death effect (Brenchley et al. 
2004; Doitsh et al. 2010; Monroe et al. 2014). Depletion of CD4+ T cells is a 
characteristic feature of early HIV infection and can be triggered by virus replication 
in target cell or cell lysis by cytotoxic T lymphocytes. Non infected CD4+ T cells that 
constitute the majority of depleted cells die through apoptosis induced by pro-
inflammatory cytokines, cytophatic effect of viral gp120 protein (Cao et al. 1996) and 
Fas Ligand-mediated apoptosis (Gasper-Smith et al. 2008). Pyroptosis of abortively 
infected cells was also suggested to play an important role in tonsillar CD4+T cell 
depletion, however this study remains to be confirmed in different T cells subsets 
(Doitsh et al. 2014). Activation of other immune cells by the presence of HIV-1 
infection triggers activation and release of pro-inflammatory cytokines from DC, 
macrophages, Natural killer cells and monocytes that decelerates the HIV-1 
replication rate, but does not clear the virus. HIV-1 infection of activated or resting 
CD4+ T cells leads to establishment of latent reservoirs in patients (Chavez et al. 
2015). This integrated provirus produces minimal or no viral transcripts due to resting 
state of the host cell, meaning it cannot be detected by the immune system or cleared 
with the available antiretroviral drugs. Thus, proviruses can survive undetected in 
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resting CD4+ T cells for prolonged periods of time until new viral progeny is 
produced in response to cell activation (Finzi et al. 1997). 
Eventually the immune response settles and signs of illness disappear. By the end of 
the acute phase, the CD4
+
 T cell count increases and then normalizes usually at lower 
level compared to before infection (Figure 1.1). This set point of CD4
+
 T cells as well 
as the HIV-1 viral load is used to predict the timeline of progression to AIDS for the 
patient. Because symptoms of early HIV-1 infection are brief and very similar to those 
associated with a cold or flu, identification of HIV-1 acquisition is often difficult. 
Following normalization of the infection, the immune system will constantly battle 
with slowly replicating HIV-1 during chronic phase. During that time, further 
decrease in CD4
+ 
T cell numbers caused by the above-mentioned mechanisms is 
observed in patients. There are no symptoms of HIV-1 infection in the chronic phase 
and therefore the virus can remain undetectable in patients for a prolonged time. This 
also gives a great risk for HIV-1 to spread from unaware carriers to their uninfected 
partners.  
As the CD4+ T cell count drops below 350 cells/mm
3
 of blood, the last stage of HIV 
infection, Acquired Immuno Deficiency Syndrome (AIDS) (see Section 1.1.4) begins. 
Once a clinical diagnosis is made and signs of AIDS are apparent, progression to 
death is quite rapid and certain in the absence of antiretroviral therapy. 
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Figure 1.1. HIV Infection Timecourse. (taken from Coffin JM, Hughes SH, Varmus HE, 
editors. Retroviruses. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. 
Course of Infection with HIV and SIV). 
 
1.1.4. Acquired Immuno-Deficiency Syndrome (AIDS) 
Long-term HIV-1 infection inevitably leads to a decrease of CD4+ T cell numbers to a 
level that can no longer adequately battle against normally harmless infections. This 
state is termed Acquired Immuno-Deficiency Syndrome (AIDS), which used to be a 
death sentence. However, advantages of current treatments allow HIV-1 positive 
patients to keep their CD4+ T cell count within the normal range (500 – 1,000 
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cells/mm
3
). A drop to below 350 T cells/mm
3
 of blood increases the risk of 
opportunistic infections, and is a main indication of AIDS. At this stage, virus load in 
a patient’s blood is high, and the risk of sexual transmission increases  (Maartens et al. 
2014).  
The timeline from initial HIV-1 infection towards development of AIDS differs 
between individuals. On average, it takes about 10 years, however in some rapid 
progressors, it may develop within 3 years from sero-conversion. On the other hand, 
about 5% of HIV-1 positive individuals do not develop AIDS and these patients are 
referred to as long-term non-progressors (LTNP) (Zeller et al. 1996).  This ability to 
control virus propagation in LTNP was proposed to depend on multiple factors such 
as genetic factors, cell surface receptors, and the extent of immune response (Pereyra 
et al. 2008; Ntale et al. 2012). However, the exact mechanism of virus inhibition has 
not been yet elucidated. This knowledge could potentially bring on new treatment 
strategies to be used in the group of patients progressing to AIDS.  
With a weakened immune system, AIDS patients are very prone to opportunistic 
infections, which would normally not cause significant disease in a healthy individual. 
Among the most common AIDS-defining conditions classified by CDC (AIDS.gov 
2010) are Candidiasis, Kaposi’s sarcoma, Herpes simplex, pneumonia and more than 
a dozen others. Additionally, those opportunistic infections trigger a positive feedback 
loop by boosting HIV-1 replication (see Section 1.6.). Consequently, constant 
opportunistic infections result in AIDS patient death.  
Despite proof that HIV-1 causes AIDS, sceptics actively try to diminish HIV-1 
research and the existence of the virus itself (Society 2013). Such unscientific 
statements mislead the readers and promote ignorance of HIV-1 prophylaxis among 
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susceptible people. Therefore, accurate education of vulnerable communities is also an 
essential step required for prevention of new HIV infections. 
 
1.1.5. HIV-1/AIDS Treatment 
Current CDC guidelines suggest starting Highly Active Antiretroviral Therapy 
(HAART or ART) when the blood CD4+ T-cell count drops below 350 cells/mm
3
 
(AIDS.gov 2014). Other recommendations apply to pregnant women and children. 
The standard medication combines 3 different antiretroviral drugs (ARV) acting on 2 
separate HIV-1 replication steps. Based on their mode of action ARV can be divided 
into 5 groups: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PI), 
Entry/Fusion Inhibitors and Integrase Inhibitors. Examples of each type of drug and 
their mode of action can be found on the AIDS website 
(http://www.aidsmeds.com/list.shtml).    
Regular and conscientious taking of prescribed antiviral medication is essential for 
successful therapy. Failure to do so may not only lead to an increased viral load in the 
patient’s blood, but also potentiate the risk of HIV-1 resistance to the treatment 
scheme. Healthy lifestyle involving daily exercise, a balanced diet and sufficient rest 
is also recommended to accompany ART therapy.  
Apart from HAART, HIV positive patients, who are prone to opportunistic infections, 
are offered prophylactic treatment to avoid acquisition of such diseases.  Prevention of 
co-infections in those patients is important, because opportunistic pathogens endanger 
the life of an immune-compromised person, while potentially also increasing HIV-1 
viraemia. More detail of this interchangeable mechanism can be found in section 1.6.   
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1.2. HIV-1 Virion Structure and Genome 
HIV-1 is the most significant member of the Retroviridae subfamily, genus Lentivirus. 
The virus consists of a diploid, single-stranded RNA genome enclosed in a capsid 
core. A lipid membrane layer surrounds the viral capsid and other viral proteins form 
the particle (Figure 1.2). The trimeric viral envelope glycoprotein (composed of 
gp120 and gp41) protrudes from the membrane and allows HIV-1 entry into target 
cells. The HIV-1 receptor (CD4) and either one of the co-receptors (CCR5 or CXCR4) 
are required for gp120 interaction with target cells and productive virus entry. Long 
Terminal Repeats (LTRs) flank the RNA genome of HIV-1 at both 5’ and 3’ ends. 
LTR regions are particularly important for HIV-1 integration and transcription 
enhancement. Three major genes (gag, pol and env) are located between both LTRs 
and encode structural proteins (p17, p24, p9, p6), viral enzymes (protease, reverse 
transcriptase, RNase H, and integrase) and envelope glycoproteins (gp120, gp41) 
respectively (Figure 1.2).  Viral enzymes are essential for different steps of HIV-1 
replication within cells. For instance, reverse transcriptase is not normally present in 
cells but is required to convert the HIV-1 RNA genome into DNA. This is followed by 
integration of HIV-1dsDNA into the host cell genome mediated by viral integrase. On 
the other hand, the protease acts at the post-translational stage of HIV-1 replication, 
and cleaves the pol polypeptide into single functional enzymes. In addition to essential 
genes, HIV-1 encodes accessory proteins: vif, vpr, vpu, nef and tat (and vpx present in 
HIV-2 and SIV). Although called accessory proteins, these non-structural proteins are 
critical requirement to HIV-1 replication. Accordingly, Vpu, Vif and Vpx counteract 
the function of cellular anti-viral restriction factors (see Section 1.4), Tetherin, 
APOBEC3G and SAMHD-1, respectively. Thus, Vpu enhances budding and release 
of new viral particles from infected cells by internalization and degradation of tetherin 
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(Neil et al. 2008; Lehmann et al. 2011). Vif on the other hand prevents packaging of 
APOBEC3G to newly formed particles that ensure effective reverse transcription of 
HIV in the consequent target cells (Sheehy et al. 2003). The reverse transcription 
process is also augmented by the function on Vpx, described in detail in Section 1.4.2.  
Viral protein R, Vpr, is present in both HIV-1 and HIV-2 particles and serves multiple 
functions in cellular immune evasion and it operates at several steps of HIV 
replication cycle (reviewed in (Guenzel et al. 2014). Vpr induces G2 cell cycle arrest 
in cells and mediates nuclear entry of HIV pre-integration complex in cooperation 
with viral matrix, integrase proteins and capsid (He et al. 1995; Re et al. 1995; Jenkins 
et al. 1998; Suzuki et al. 2009). Vpr also increases the activity of various gene 
promoters, mainly LTR of HIV (Sawaya et al. 1998; Yao et al. 1998; Cui et al. 2006). 
In context of immune evasion, Vpr induces apoptosis in bystander T cells while acting 
anti-apoptotic in infected cells (Conti et al. 1998; Moon and Yang 2006). Vpr also 
inhibits interferon induction in infected cells preventing expression of interferon-
inducible restriction factors (Mashiba et al. 2014; Harman et al. 2015) On the systemic 
level, Vpr promotes Th2 responses and prevents maturation and activation of 
macrophages and dendritic cells thus supporting viral propagation in the individual 
(Ayyavoo et al. 2002). Therefore Vpr protein has a wide repertoire of functions, all 
aimed at suppression of immune responses and increase of viral replication. The 
importance of this protein in virus life cycle is highlighted by the fact that SIV 
defective in Vpr/Vpx does not cause AIDS in rhesus monkeys (Gibbs et al. 1995). 
Similarly, defects in Vpr of HIV-1 decrease infection rate by 50% in macrophages 
(Eckstein et al. 2001).  
While Vpr and Vpx are both packed into viral particle, Tat and Nef, the other 
accessory proteins are synthesised immediately after provirus integration. The early 
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expression of these proteins relates to their role in stimulating transcription of full 
length virus genome from LTR (function of Tat) and decrease of CD4 and MHCI 
from the cell surface (the role of Nef)(Piguet et al. 1998; Piguet et al. 1999; Piguet et 
al. 2000). Thus, the appearance of accessory proteins is timely regulated depending on 
their function in the viral life cycle. These accessory proteins modify the environment 
of the cell in order to hide the virus from cellular immune responses, counteract 
cellular restriction factors, and promote viral replication and spread (Malim and 
Emerman 2008). 
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Figure 1.2. Structure of HIV-1 Particle and Genome Composition. HIV-1 particle 
comprise membrane with embedded envelope glycoprotein spikes. Matrix underlies 
membrane layer, and sheds capsid core. Two copies of the viral RNA are contained inside the 
capsid. Each RNA strand encodes 3 main genes, gag, pol and env, as well as additional and 
accessory genes. Differential expression of genes and splicing of translated proteins forms 
various viral components. 
 
1.3. HIV-1 Replication Cycle  
The HIV-1 replication cycle starts with the attachment of virus to the CD4 receptor 
and co-receptor on the target cell surface (Figure 1.3. 1). Envelope components gp120 
and gp41 mediate CD4 and co-receptor binding and fusion of the viral and cell 
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membranes, respectively. Gp41 is shed from the environment by the structure of 
gp120. Conformational shift of gp120, triggered by binding of this protein to CD4 and 
either of the co-receptors, reveals gp41 and induces its fusogenic capacity (Sattentau 
and Moore 1991; Doms and Trono 2000). According to co-receptor usage, HIV-1 
strains are divided into R5, X4 or R5/X4 viruses (binding CCR5, CXCR4 or both, 
respectively). Release of the HIV-1 capsid into the cell cytoplasm follows the fusion 
of the virus at the cell surface (Figure 1.3 2). At this point viral capsid does not 
uncoat but it is bound by cleavage and polyaddenylation specificity factor 6 (CPSF6) 
and cyclophilin A (CypA) proteins present in the host cell cytoplasm (Schaller et al. 
2011; Price et al. 2012; Bichel et al. 2013; Rasaiyaah et al. 2013). The attachment of 
the CPSF6 and CypA stabilize the capsid, participate in timing of reverse transcription 
process and mediate particle translocation towards the nuclear pore (Yamashita et al. 
2007; Bichel et al. 2013). The process of reverse transcription, during which reverse 
transcriptase converts single stranded viral RNA into double-stranded DNA (cDNA), 
is a characteristic stage of retrovirus replication (Figure 1.3. 3). Nucleotides present in 
the cytoplasm of the infected cell are required for this process. Subsequent to CPSF6 
binding, interaction of capsid with Nup358 at the nuclear pore triggers isomerisation 
of the capsid and a release of viral cDNA. TNPO3 transportin 3 and Nup153 further 
orchestrate its entry to the nucleus and determine the integration site (Diaz-Griffero 
2012; De Iaco et al. 2013) (Figure 1.3. 4). Thus by “hiding” its nucleic acids in the 
capsid, HIV can avoid recognition by cellular DNA sensors, cGAS and IFTIM16 (Gao 
et al. 2013; Rasaiyaah et al. 2013; Sun et al. 2013). In addition, HIV utilizes the 
function of cellular DNase TREX1 to destroy any excess reverse transcription 
products that would otherwise trigger interferon responses in the cells (Yan et al. 
2010). Although the capsid provides a safe and compact environment perfect for the 
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action of reverse transcription enzyme, at the same time the virus is risking restriction 
by TRIM5α (see Section 1.4). 
Following nuclear entry, viral integrase inserts HIV cDNA into the host genome and 
the cellular machinery transcribes it into mRNA (Figure 1.3 5).Firstly, a short early 
transcript encoding Tat, Rev and Nef is translated. Both Tat and Rev proteins migrate 
back into the nucleus where Tat enhances the transcription of integrated HIV-1, and 
Rev facilitates transport of unspliced transcripts from the nucleus to the cytoplasm. 
Nef, triggers down-regulation of the cell surface marker CD4, and other surface 
proteins required for triggering an immune response to infection such as MHC class I 
(Piguet et al. 2000; Janvier et al. 2001; Malim and Emerman 2008). Smaller 
transcripts of unspliced viral RNA serve as a temple for Tat, Vpu, Vif, Vpr and 
envelope proteins. The second larger transcript encodes gag and pol proteins. Gag 
polyprotein interacts with viral and cellular proteins and moves toward the viral 
assembly point at the cytoplasmic side of the cell membrane. During budding, the 
polyprotein undergoes a series of controlled cleavages and its components form the 
mature viral core. Full-length unspliced RNA represents the genome of new HIV 
particles (Figure 1.3 6 and 7) (Bell and Lever 2013).  
It is important to realize that defined host cellular factors actively participate in HIV-1 
replication and are therefore imperative for this process. Down-regulation, or 
inactivation of any cellular factors involved in virus infection may decrease or 
completely abolish replication. Thus, the biology and activation status of the cell, 
commonly influenced by the local environment, determine cell ability to support HIV-
1 replication. This subject will be further deliberated later when the differences in 
HIV-1 replication kinetics in dendritic cell subsets are considered.  
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Figure 1.3. Simplified Overview of HIV-1 Replication Steps. The steps of HIV-1 
replication in the cells are shown and include 1) Attachment of HIV to receptor/co-receptor 
and fusion with the host cell membrane. 2) Entry of HIV capsid, RNA and enzymes to host 
cell cytoplasm. 3) Reverse transcription process. 4) Nuclear entry and integration of provirus 
in cell DNA. 5) Transcription of integrated provirus and 6) formation of new viral particles at 
the host cell membrane.7) HIV particle budding and maturation. (Adapted from National 
Institute of Allergy and Infectious Diseases). 
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1.4. HIV-1 Restriction Factors 
A number of cellular proteins, termed restriction factors, interfere with HIV-1 
replication. The most investigated are tripartite motif-containing 5α (TRIM5α), 
apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G 
(APOBEC3G) and SAM domain HD domain-containing protein 1 (SAMHD-1) that 
inhibit early steps of HIV-1 replication before integration and tetherin (also called Bst-
2 or CD317), reported to act during the release of new HIV-1 particles from the 
infected cells (Table 1.2). These restrictions are constantly expressed in cells and, for 
some of them, their levels are additionally increased upon interferon-alpha (IFN-ɑ) 
treatment. 
At early stages of infection in human cells, HIV-1 is restricted by the action of 
APOBEC3G. This restriction factor binds viral reverse transcriptase or viral genomic 
RNA and stalls the synthesis of complementary DNA (Mangeat et al. 2003; Newman 
et al. 2005). Also by introducing G to A hypermutations in newly formed reverse 
transcription products, APOBEC3G renders virus non-infectious (Harris et al. 2003; 
Lecossier et al. 2003). Interestingly, APOBEC3G does not mediate this protective 
effect in infected cells, but it has to be incorporated into the forming virus particle to 
inhibit HIV-1 reverse transcription in the subsequent cells. The fact that the levels of 
APOBEC3G are interferon inducible suggests predominant anti-viral function of this 
protein. Reverse transcription of HIV-1 is also controlled by the presence of SAMHD-
1 in cells. This predominant block to virus replication in myeloid cells is described in 
detail in Section 1.4.1.  
TRIM5α is another stably expressed restriction factor present in the cell cytoplasm. 
Similarly to APOBEC3FG, TRIM5α levels can be induced by IFN signalling. 
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Although expressed in human, this restriction factor is thought to be weakly effective 
against HIV-1 and more likely to have a function in inhibition of SIVrm (Kirmaier et 
al. 2010). TRIM5α. binds viral capsid and stabilizes it preventing the process of 
reverse transcription and uncoating (Stremlau et al. 2004). The capsid binding sites of 
TRIM5α dictate the susceptibility of different HIV strains to this restriction. 
Interestingly, CypA binding HIV-1 capsid protects viral particle from Ref-1 
restriction, this mechanism could also explain resistance of HIV-1 to human TRIM5α. 
In contrast to aforementioned restriction factors, tetherin (also referred to as Bst2) acts 
at a very late stage of HIV-1 replication. Indeed, tetherin binds viral envelope in 
endoplasmic reticulum and at the cell surface and prevents release and maturation of 
virus progeny (Neil et al. 2008). Two isomers of tetherin are present in human cells, 
short and long and these arise from the alternative translation. Short tetherin is more 
resistant to Vpu-mediated degradation, but lacks cytoplasmic signalling sequence. In 
contrast, the long isomer can induce NFκβ signalling, but is an easier target for Vpu 
(Gupta and Towers 2009; Mangeat et al. 2009; Miyagi et al. 2009). As described in 
Section 1.2., HIV-1 and HIV-2 down regulate tetherin with the accessory protein Vpu. 
The conservation of this gene in HIV-1 and HIV-2 subsets suggest that down 
modulation of this restriction factor is an important step in ensuring successful 
propagation of HIV. 
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Table 1.1. Summary of Cellular Restriction Factors acting on HIV-1 Replication. 
Restriction 
factor 
Stage of 
HIV 
replication 
affected 
Mechanism of action IFN 
inducible 
HIV 
anti-
protein  
Reference 
APOBEC3G Reverse 
transcription 
Introduces TU 
supermutation in HIV-1 
genome leading to 
abortive reverse 
transcription.  
Yes Vif (Sheehy et 
al. 2003; 
Zhang et al. 
2003).  
Trim5α Uncoating Binds HIV-1 capsid and 
prevents uncoating.  
Yes Unkno
wn 
(Stremlau et 
al. 2004) 
SAMHD-1 Reverse 
transcription 
Depletes dNTP pool; 
directly degrade HIV-1 
RNA. 
No/Yes Vpx (Goldstone 
et al. 2011; 
Beloglazova 
et al. 2013; 
Ryoo et al. 
2014) 
Tetherin Budding Anchors newly 
produced HIV-1 
particles to cell 
membrane, preventing 
virus maturation and 
release.  
Yes Vpu (Neil et al. 
2008) 
MX2 Prior 
integration 
affects nuclear entry of 
viral cDNA or its 
stability in the nucleus 
Exclusively 
expressed 
after IFN 
stimulation 
Not 
known 
(Goujon et 
al. 2013) 
 
In addition to constitutively expressed restriction factors described above, other 
antiviral proteins are induced only in response to interferon stimulation of the cell. 
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IFN-ɑ is a warning cytokine expressed by immune cells in response to pathogen 
sensing. It plays a crucial role in fighting viral infections by inducing an antiviral state 
in cells and expression of interferon-stimulated genes (ISG). The cellular levels of 
APOBEC3G, TRIM5α and tetherin are sensitive to IFN stimulation, but other ISG are 
also expressed upon STAT signalling, such as myxovirus resistance-2, MX2 (Goujon 
et al. 2013). Although the exact mechanism of MX2 mediated inhibition of HIV 
remains to be elucidated, this protein was found to inhibit HIV prior to integration, 
possibly affecting nuclear entry of viral cDNA or its stability in the nucleus (Fricke et 
al. 2014). Interestingly viral capsid governs sensitivity to MX2 and disruption of this 
interaction renders MX2 inactive against HIV-1 infection (Liu et al. 2015). The 
functions and importance of ISG in terms of HIV-1 infection is only now being 
discovered and appreciated. 
 
1.4.1. SAMHD-1  
Recently (2011), two research laboratories identified SAMHD-1 a s a potent viral 
restriction factor (Hrecka et al. 2011; Laguette et al. 2011). SAMHD-1 acts against a 
wide range of pathogens including DNA viruses such as vaccinia virus, herpex 
simplex virus and Hepatitis B virus (Hollenbaugh et al. 2013; Kim et al. 2013; Chen et 
al. 2014), retroviruses including HIV-1 and SIV (Hrecka et al. 2011; Laguette et al. 
2011), as well as retro-elements (Zhao et al.). SAMHD-1 is a triphosphohydrolase 
expressed in myeloid cells such as dendritic cells, macrophages, and is present in 
quiescent CD4
+
 T cells. In cells, SAMHD-1 and related DNase TREX1 deplete RNA 
and DNA, respectively, present in the cytoplasm which prevents activation of immune 
sensing by endogenous retroviruses or gene transcription products. SAMHD1/TREX1 
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deficiency in human leads to development of Aicardi-Goutieres syndrome (see 
Section 1.4.3.). SAMHD-1 is a nuclear protein (Rice et al. 2009; Brandariz-Nunez et 
al. 2012; Guo et al. 2013), also present at lower concentrations in the cytoplasm 
(Baldauf et al. 2012). It consists of two main domains: the sterile alpha motif (SAM) 
domain, and the histidine-aspartic (HD) domain. The SAM domain is involved in 
nucleic acid binding and protein-protein interactions (Qiao and Bowie 2005), whereas 
the phosphor-hydrolase enzymatic activity of the protein localizes to the HD domain 
(Zimmerman et al. 2008). A mutational study performed by White et al., (White et al. 
2013a) showed that the HD domain alone is sufficient for SAMHD-1 restrictive 
properties and SAM is dispensable for that function. The same authors additionally 
demonstrated that nuclear localization of SAMHD-1 is not required for its HIV-1 
restriction function.  
The mechanism of action of SAMHD-1 was proposed to rely on the cleavage of 
deoxynucloside triphosphates into deoxynucleosides and triphosphate (Goldstone et 
al. 2011; Powell et al. 2011). SAMHD-1 mediated depletion of the nucleosides pool 
from cells renders HIV-1 reverse transcription very inefficient (Hrecka et al. 2011; 
Laguette et al. 2011; Lahouassa et al. 2012). The levels of dNTP in SAMHD-1 
expressing macrophages range in very low concentrations between 20 and 50nM. This 
is in contrast to the higher levels of 2-30 μM dNTP concentration observed in 
activated CD4+ T-cells that do not express SAMHD-1 (Nguyen et al., 2014). 
Interestingly, research has shown that SAMHD-1 is present in quiescent T-cells, 
which may have a direct incidence on the formation of HIV-1 reservoirs within these 
cells (Gao et al. 1993; Baldauf et al. 2012; Descours et al. 2012). 
New data are now emerging to suggest that the dNTPase activity of SAMHD-1 may 
not be the only mechanism of HIV-1 restriction by this protein. An alternative mode 
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of action proposed for SAMHD-1 includes direct interaction of the protein with HIV-1 
genomic ssRNA (Beloglazova et al. 2013; Ryoo et al. 2014). Subsequently, RNase 
activity of SAMHD-1 leads to cleavage and degradation of viral ssRNA. This activity 
is regulated by phosphorylation of SAMHD-1 at T592 which renders SAMHD-1 
inactive against HIV-1 infection, without lowering dNTP levels (Cribier et al. 2013; 
Welbourn et al. 2013; White et al. 2013b) (Figure 1.4). SAMHD-1 is phosphorylated 
by cyclin dependent kinase (CDK). As CDK is also involved in regulation of cell 
cycle, inactivation of SAMHD-1 and induction of cell cycle can be related processes. 
In fact, SAMHD-1 activity concentrates at degradation of cystolic RNA and depletion 
of dNTP, therefore inhibition of this protein could be a pre-requisite for efficient 
mitosis. Thus, SAMHD-1 uses 2 separate mechanisms to inhibit early steps of HIV-1 
replication: it depletes dNTP in the cell cytoplasm by dNTPase activity and directly 
destabilizes or degrades the HIV-1 genome using its RNase activity (Figure 1.4.). The 
switch between these mechanisms was proposed to be dependent on SAMHD-1 
oligomerization and the presence of dGTP (Ryoo et al. 2014). In the presence of 
dGTP, SAMHD-1 proteins form tetramers, a requirement for its dNTPase function (Ji 
et al. 2013; Yan et al. 2013; Zhu et al. 2013). On the other hand, in low dGTP 
conditions, SAMHD-1 exists as a dimer or a single protein, which favours its RNase 
activity (Figure 1.4). However, this new model still requires further confirmation.    
It is unknown how SAMHD-1 imposes its RNase activity on viral genomic RNA 
while capsid proteins protect it. If we assume that cytoplasmic sensors and proteins 
have no access to viral nucleic acids, then the RNase function of SAMHD-1 should be 
limited as well. SAMHD-1 is also present in the nucleus however; viral reverse 
transcription product (cDNA) present at this stage of HIV replication cycle is no 
longer a substrate for an RNase, such as SAMHD-1. In that case, SAMHD-1 
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restriction activity on HIV-1 would be limited to depletion of dNTP pool. Degradation 
of HIV-1 RNA could take place if the viral RNA is released from the capsid 
protection or when SAMHD-1 enters a confided area within the viral capsid. If the 
latter is the case then cGAS, which is 10 kDa smaller protein than SAMHD-1, could 
theoretically also gain access to HIV-1 nucleic acids. Consequently, induction of 
interferon response is likely.  However, the exact correlation between SAMHD-1 
function and the presence of CPSF6 is unknown.  
SAMHD-1 successfully keeps HIV-1 replication at the lowest levels in myeloid cells 
and when expressed in virus susceptible T-cells. However, this powerful barrier has its 
dark sides, too. As a “double edged sword”, SAMHD-1 by its action prevents sensing 
of HIV-1. Therefore, the immune system does not respond to the initial virus invasion 
until it is too late to stop its systemic spread. In the case of HIV-2 infection, Vpx-
mediated degradation of SAMHD-1 results in an initial boost of virus replication 
followed by cDNA sensing and release of type-I interferon from infected cells. As a 
result, type-I interferon production generates an antiviral state on neighbouring cells, 
therefore impairing the propagation of infection (Manel et al. 2010; Baldauf et al. 
2012). Other reports suggest that low dNTP levels in SAMHD-1 positive CD4
+
 T-
cells can promote formation of incomplete strands of HIV-1 cDNA during reverse 
transcription. This abortive HIV-1 infection of bystander T-cells consequently triggers 
immune responses in these cells leading to activation of capsase 3 and T-cell death by 
pyroptosis. Pro-inflammatory molecules released from dying T cells additionally 
attract HIV-1 susceptible cells and set chronic inflammation in infected patients 
(Doitsh et al. 2014; Hansen et al. 2014). Accordingly, a drop in T-cell levels happens 
at a quicker rate during HIV-1 infection, compared to Vpx expressing HIV-2 
infection.  
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Figure 1.4. Different Mechanisms of SAMHD-1 Restriction of HIV-1 Replication. In the 
presence of GTP, SAMHD-1 exists in tetramer form able to hydrolase nucleosides to 
nucleotides and triphosphate, simultaneously blocking HIV-1 reverse transcription. In low 
GTP conditions, dimeric form of SAMHD-1 binds and degrades HIV-1 single stranded RNA. 
Phosphorylation of SAMHD-1 at Threonine 592 renders both mechanisms inactive and allows 
HIV-1 replication in the cell.    
 
1.4.2. Vpx Counteracts SAMHD-1-mediated Viral Restriction  
Vpx is a 12-16 kDa accessory protein encoded by HIV-2 and some SIV genomes, but 
absent in the HIV-1 (Zhang et al. 2012; Etienne et al. 2013). Vpx is packaged into 
virions during their assembly (Wu et al. 1994; Singhal et al. 2006a; Singhal et al. 
2006b) and it shuttles between the nucleus and cytoplasm in target cells (Belshan and 
Ratner 2003; Singhal et al. 2006a; Singhal et al. 2006b). Similarly to other accessory 
proteins, Vpx has been proposed to serve multiple functions it mediates SAMHD-1 
degradation and enhances nuclear import of viral genome and reverse transcription 
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independently of SAMHD-1 (Berger et al. 2010; Pertel et al. 2011; Reinhard et al. 
2014). Most likely, the low susceptibility of HIV-2 reverse transcriptase to dNTP 
prompted acquisition of Vpx in the genome. Interestingly, Vpx originates from 
duplication of Vpr that itself has no effect on SAMHD-1 levels in the cells (Lim et al. 
2012).When expressed in target cells, Vpx binds SAMHD-1 and leads to its 
proteasomal-mediated degradation. Vpx was reported to interact with CRL4
DCAF1
 E3 
ubiquitinin ligase (VPRBP, a cullin-RING ubiquitin ligase) thereby recruiting 
SAMHD-1 to the complex (Hrecka et al. 2011). The C-terminal domain of SAMHD-1 
is required for this interaction as showed by mutational studies (Ahn et al. 2012). 
Ubiquitination of SAMHD-1 is followed by its proteasomal degradation, which results 
in an observed HIV-1 replication boost. Recently, it has been suggested that 
neddylation of SAMHD-1 is also required for protein degradation (Hofmann et al. 
2013) but these results have not yet been confirmed.  
Interestingly, mutational studies showed that some modifications in Vpx could 
decrease HIV-2 replication in MDM or MDDC, although SAMHD-1 expression was 
efficiently down regulated (Goujon et al. 2008), which suggest additional roles for this 
protein during HIV-2 infection. One such functions involves transport of HIV-2/SIV 
pre-integration complexes (PIC) to the nucleus (Belshan and Ratner 2003; Belshan et 
al. 2006).  
The absence of Vpx in the HIV-1 genome may be of benefit for successful viral 
spread. Low replication levels imposed by SAMHD-1 restriction in antigen presenting 
cells prevents immune sensing of the infection and induction of type-I interferon 
(Nobile et al. 2005; Manel et al. 2010; Lahaye et al. 2013). Therefore, HIV-1 in the 
absence of Vpx expression remains unnoticed by the immune system until it is too late 
and virus spreads to susceptible cells. Acute immune activation at this point 
 40 | P a g e  
 
temporarily restrains further HIV-1 dissemination but does not allow clearance of 
integrated viruses. In the case of HIV-2 infection, Vpx-dependent SAMHD-1 
degradation boosts virus replication at early transmission sites at the cost of a strong 
immune activation. This allows virus control and seemingly decreases the rate of 
CD4
+
 T-cell death (Manel et al. 2010; Baldauf et al. 2012). Other studies imply that 
high levels of type-I IFN produced by innate immune cells play a part in chronic 
immune activation associated with progression to AIDS (Boasso et al. 2008; Ganesan 
et al. 2010). However, this effect refers to later stages of HIV-1 infection and might 
not be directly related to SAMHD-1 down regulation. The lack of the vpx gene in the 
HIV-1 genome might have triggered a specific adaptation of HIV-1 to replicate in an 
environment with negligible dNTP levels. Accordingly, reverse transcriptase of HIV-1 
shows increased affinity for dNTP, compared to HIV-2 and other viruses reported to 
down-regulate SAMHD-1 expression (Lahouassa et al. 2012). Whether vpx loss is a 
trigger or a result of improved reverse transcriptase function remains unknown. 
Nonetheless, the absence of vpx in the HIV-1 genome may have settled a sine qua non 
condition for its successful propagation.  
 
1.4.3. Vpx as a Tool to Facilitate Genetic Modification of Primary Cells 
Delivery of Vpx via transduction of cells with virus-like particles (VLP) (SIV3-Vpx) 
is a successful way for SAMHD-1 down regulation employed by researchers (Goujon 
et al. 2006; Berger et al. 2011b; Laguette et al. 2011). SIV3-Vpx is acquired via co-
transfection of HEK293T cells with pMD.G plasmid and pSIV3+ packaging construct 
(see Materials and Methods Table 2.1 and Section 2.6.4.). pMD.G is a source of 
Vesicular Stomatitis Virus envelope (VSV-G) (Naldini et al. 1996) that is 
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incorporated into new SIV3-Vpx particles. VSV-G binds to low density lipoprotein 
receptor (LDLR) and fuses with the cell membrane only after a pH change in 
lysosomes (Sun et al. 2005; Finkelshtein et al. 2013). As LDLR is abundantly 
expressed on the cell surface membrane, the entry of pseudotyped VSV-G lentivectors 
is efficient and independent of CD4 or CCR5/CXCR4 receptors.  
pSIV3+ construct has been derived from SIV (SIVmac251) through elimination of 
env and 3’LTR only. 5’LTR and other leader sequences were replaced with 
Cytomegaloma Virus (CMV) early promoter/enhancer sequence that ensures strong 
gene expression in comparison to LTR (Nègre et al. 2000). Thus, in addition to our 
gene of interest, vpx, pSIV3+ also encodes gag, pol, vif, vpr, rev and tat genes. As 
described above (see Section 1.2), both Vpr and Vpx are packed into new virions, as 
they function at early stages of virus infection. Therefore, SIV3-Vpx particles derived 
from pSIV3+ also contain Vpr protein. Vpr is a multifunctional involved in systemic 
immune envision and persistence of HIV-1 infection (Ayyavoo et al. 1997; Ayyavoo 
et al. 2002; Mashiba et al. 2014; Harman et al. 2015). Among its functions Vpr is 
recognised as an important inducer of HIV-1 LTR, particularly in macrophages that 
promotes viral pathogenesis (Varin et al. 2005; Mashiba et al. 2014). A multiple 
transcription binding site at viral LTR are required for this function of Vpr, suggesting 
that replacing LTR with another promoter may cause loss of function. However, on 
top of direct binding to LTR, Vpr also induces NFκβ, which has a pronounced effect 
on gene transcription downstream of other promoters such as CMV and EF-1α 
(Yurochko et al. 1997; Roux et al. 2000; Gangwani et al. 2013). Thus, usage of SIV3-
Vpx in in vitro studies could result in boost to expression of the gene downstream of 
LTR or NFκβ-sensitive promoter. Such effects could then be wrongly accredited to 
the function of Vpx or lack of SAMHD-1 in the cells. Similarly, investigation of 
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cytokine milieu or cell survival in SIV3-Vpx treated cells should be analysed with 
caution as Vpr is a known inducer of TNF-α in DC and a modulator of cell apoptosis 
(Nakamura et al. 2002; Busca et al. 2012). 
In this study I showed that SIV3-Vpx transduction of the cells efficiently depletes 
SAMHD-1 without activating the cells (see Chapter 4). I have exploited this method 
in our research and demonstrated efficient and reproducible Vpx-mediated decrease of 
SAMHD-1 expression in monocyte derived Langerhans cells and monocyte derived 
dendritic cells (see Chapter 4). The effect of the presence of Vpr on the experimental 
outcomes is considered in result chapters.       
 
1.4.4. Aicardi-Goutieres Syndrome (AGS) 
Mutation of the SAMHD-1 gene causes a rare disorder called Aicardi-Goutieres 
syndrome (AGS). AGS can also result from mutations or malfunctions of other 
nucleases including TREX1, RNASEH2A, RNASEH2B and RNASHE2C (Crow et al. 
2006; Rice et al. 2007). Nuclease breaks up unneeded cellular DNA and RNA 
molecules after transcription, replication or other cellular processes. Any abnormality 
in these nuclease triggers accumulation of nucleic acid molecules and may be 
mistaken for viral infection. Thus, immune activation in AGS is related to increased 
systemic levels of IFN-ɑ (Crow and Rehwinkel 2009; Stetson 2012; Lee-Kirsch et al. 
2014). In cases of SAMHD-1 mutations in AGS patients, IFN-ɑ is triggered by high 
dNTP levels and consequent DNA damage (Kretschmer et al. 2014) . AGS onset is 
early, affecting babies in their first year of life. The manifestation of disease includes 
encephalopathy, psychomotor retardation, hepatosplenomegaly, thrombocytopenia 
and in some cases death (Rice et al. 2007) .  
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1.5. Sexual Transmission of HIV-1 
The majority of HIV-1 transmission happen via sexual transmission. The risk of 
acquiring HIV-1 from an infected partner by receptive penile-vaginal intercourse is 
less than 0.1% (CDC.gov 2014) although the probability depends on multiple factors 
described further (see Section 1.6.). This risk of transmission significantly increases 
for man who have sex with man due to easier passage of the virus through the rectal 
and gut mucosa (see Section 1.5.3). In contrast, the physical structure of the female 
reproductive tract poses a very potent barrier to HIV-1 passage, if intact. Additionally, 
mucus and the vaginal environment are unfavourable to HIV-1.      
 
1.5.1. Mucosal Surface: Female Reproductive Tract Biology 
The female reproductive tract anatomically consists of ectocervix, cervix and 
endocervix. Vagina and ectocervix are covered with multi-layered squamous 
epithelium, and a single layered of columnar epithelium lining endocervix (Figure 
1.5). The reproductive tract is covered in dense, acidic mucous that captures 
pathogens and prevents growth of bacteria and fungi. Penetration of SIV-1 through the 
mucus after direct uterine SIV inoculation was demonstrated in monkeys (Joag et al. 
1997; Hladik and Hope 2009), but the efficiency of the process was very low, 
confirming its protective role against SIV-1 acquisition. However, the main 
transmission route of SIV in primates is via contact with infected blood or body fluids 
taking place during fights and hunting. Additionally, the risk of vertical transmission 
in infected primates is lower compared to HIV-1 mother to child transmission in 
human suggesting different adaptation of HIV-1 and SIV to its hosts.  
 44 | P a g e  
 
Underneath the top layer of the reproductive tract lies a connective tissue layer, called 
the lamina propria. This submucosal epithelium contains dense population of immune 
cells including dendritic cell subsets, macrophages and memory T-lymphocytes 
(Figure 1.5). Additionally, high numbers of CD4+ T-cells locate to the zone of 
conversion where ectocervix changes into endocervix, referred to as the 
transformation zone (Figure 1.5). 
Immune cells present at the mucosal surfaces act as a barrier to infection and are the 
first cells to sample invading pathogens. Unfortunately, in the case of HIV-1 infection, 
these cells can become targets and carriers for the virus from the initial infection site 
to more susceptible target cells in lymph nodes (see Section 1.5). High concentration 
of target CD4+ T-cell in the  conversion zone also supports virus entry and settlement 
of founder cells (Haase 2010). Thus, the relatively low transmission rate of HIV-1 
during receptive penile-vaginal intercourse results from the physical barriers posed by 
the epithelial lining as well as the obstructive environment provided by the mucous 
layer. Nonetheless, HIV-1 is able to penetrate genital mucosa and cause an infection. 
Several mechanisms may be involved in helping the virus to cross the epithelial layers 
(see Section 1.5). Furthermore, other factors may increase susceptibility of the 
individual to HIV-1 acquisition. 
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Figure 1.5. Schematic Overview of HIV-1 Transmission Mechanism trough Female 
Genital Tract. The non-permissive epithelial layer in female reproductive tract stops passage 
of HIV-1 into submucosal epithelium. (A) However, a physical breaching of epithelium 
allows passage of free HIV-1 particles and infection of the immune cells. (B) Langerhans cell 
mediated transfer of HIV-1 from the epithelial surface and subsequent transmission to T cells 
promotes virus acquisition. (C) Transcytosis or infection of epithelial cells also increase 
chances of viral passage into susceptible T cells located in the transformation zone and 
submucosa.   
 
1.5.2. HIV-1 Transmission Mechanisms in Vaginal Mucosa 
According to a study in a non-human primate model, it takes 30 to 60 minutes for SIV 
to penetrate the cervico-vaginal epithelium in vivo (Hu et al. 2000). How HIV-1 
bypasses the mucous and epithelial barriers remains a subject of debate as several 
mechanisms have been suggested. These include physical breaching, transcytosis and 
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infection of the epithelial cells due to penetration through cervico-vaginal epithelium 
breaks and uptake by Langerhans and Dendritic cells.  
 
1.5.2.1. Factors Increasing Epithelial Permeability to HIV-1 
The composition and pH of mucous and thickness of the epithelium changes 
accordingly to hormones released at different stages of the menstrual cycle. Rise in 
oestrogens during ovulation makes mucous less viscous and less acidic, to allow 
sperm cells to penetrate. Those changes simultaneously weaken protective barriers of 
the reproductive tract and amplify the chance of acquiring sexually transmitted 
infections (STIs), including HIV-1 (reviewed in (Wira and Fahey 2008). Among other 
factors increasing the permeability of the epithelial barrier to HIV-1 are some 
components of semen (Munch et al. 2007) and co-infections with other STIs. The 
importance of the latter has been emphasized in numerous reports, and will be further 
discussed in Section 1.6.  
 
1.5.2.2. Epithelial Cells Transcytosis  and Infection  
The efficiency of HIV-1 transmission during sexual intercourse is relatively low, 
suggesting that epithelial cells form a relatively successful barrier to the pathogens 
(Gray et al. 2001). However, mucosal breaching arising during sexual intercourse 
allows free virus passage and infection of cells in the submucosal epithelium (Figure 
1.5A). Mechanisms that are more complex are required for passage through an intact 
epithelium. These include transcytosis or productive infection of the epithelial cells 
(Figure 1.5.C), although productive infection of epithelial cells remains controversial 
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as the presence of CD4 on these cells is disputable (Dezzutti et al. 2001; Yeaman et al. 
2004).  
The presence of CCR5 receptors and transmembrane proteoglycans on genital tract 
epithelia is involved in HIV-1 uptake (Bobardt et al. 2007). Bound virus particles are 
sequestered into intracellular compartments where they can survive for a prolonged 
period before the polarized release into submucosal areas (Dezzutti et al. 2001; Wu et 
al. 2003). Thus, the transcytosis process allows free virion passage through the 
epithelium and consequent infection of the underlying immune cells. The exact 
contribution of transcytosis to HIV-1 transmission has not been quantified but it is 
expected to be rather infrequent.  
 
 
1.5.2.3.  Immune Cells Contribution to HIV-1 Transmission 
The immune cell network at mucosal surfaces is complex, comprising a number of 
cell subsets. Focusing on the female reproductive tract, the top layer of the epithelium 
accommodates professional antigen presenting cells Langerhans cells (LC). 
Macrophages, subsets of dendritic cells (DC) and T-cell are also located in the 
submucosa. HIV-1 infection of LC and DC is inefficient, predominantly due to high 
expression of SAMHD-1 in these cells. However, both LC and DC could be transport 
vehicles for the virus to reach sites containing susceptible T-cells. Accordingly, to a 
common model, LC and DC capture HIV-1 at mucosal surfaces and rapidly migrate 
towards the proximal lymph nodes. While in the lymph node, the high concentration 
of T-cells allows for efficient transmission of the virus and its consequent systemic 
spread following active viral replication. Alternatively, LC/DC can transmit HIV-1 
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directly to the mucosal resident T-cells, which then become a virus factory and 
founder cells.  
1.5.2.3.1. Langerhans Cells  
Langerhans cells are professional antigen presenting cells situated at top layers of the 
mucosal and skin epithelia. Due to their location, Langerhans cells are believed to be 
the first targets for HIV-1 during sexual transmission (Zaitseva et al. 1997; Collins et 
al. 2000; Hu et al. 2000; Kawamura et al. 2003). Although LC play an imperative role 
in HIV-1 transmission, the detailed mechanisms involved in this process remains 
debatable.  
As remarkably demonstrated by (Hladik et al. 2007), LC extend and retract their 
dendrites through the epithelial sheet to sample the environment. HIV-1 can be found 
attached to these protrusions via interactions with a C-type lectin, Langerin (Turville 
et al. 2002a). Despite a large amount of research, the fate of the virus from this point 
is still unknown.  In one scenario, Langerin binding leads to endocytosis and 
subsequent degradation of HIV-1 in Birbeck granules (de Witte et al. 2007) (Figure 
1.6). Although this setting would explain the low infection rates of LC, it does not 
clarify how these cells transfer the virus to T cells.  
New data suggests that attachment to the major HIV-1 receptors (CD4 and CCR5) on 
LC accounts for virus uptake and transmission (Hladik et al. 2007; Kawamura et al. 
2008) (Figure 1.6). Endocytosed virus remains infectious in intracellular 
compartments for several days until successfully passed onto T-cell (Hladik et al. 
2007). In line with that statement, it takes about 4 days for subepithelial LC to reach 
susceptible T cells in the lymph nodes (Merad et al. 2002). In addition, LC challenged 
with HIV-1 efficiently transmits the virus even after that time. Studies with mucosal 
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models demonstrated that in the absence of LC/DC infection HIV-1 transmission to 
CD4+ T cells is inefficient (Pope et al. 1994). Also increased replication of HIV in T 
cells is observed if virus is delivered from LC or DC (Pope et al. 1994; Granelli-
Piperno et al. 1998), highlighting an important role of LC and DC in HIV-1 sexual 
transmission. 
It is curious that following HIV-1 binding to its entry receptors on LC, HIV-1 is 
internalized rather than causing productive infection. Only low levels of infection of 
LC have been demonstrated (Kawamura et al. 2003; de Witte et al. 2007; Ballweber et 
al. 2011) despite the presence of CCR5 and CD4 on these cells (Hladik et al. 2007). 
Such a strict restriction of HIV-1 in immature LC may result from virus capture by 
Langerin, or possibly may be due to a replication block imposed by SAMHD-1. 
Nevertheless, some studies speculate that low ongoing productive infection of LC is 
sufficient for HIV-1 transmission, particularly by activated LC (Reece et al. 1998; de 
Jong et al. 2008). In agreement with this, maturation of LC by bacterial antigens down 
regulated langerin expression (de Jong et al. 2008; Ogawa et al. 2009) and increases 
HIV-1 replication in these cells (Hrecka et al. 2011), which could also promote virus 
passage to T cells (see Section 1.6).  
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Figure 1.6. Possible Mechanisms of HIV-1 Transmission from DC and LC to T Cells. (A) 
Receptor mediated entry of HIV-1 settles productive infection and further transmission to t 
cells. (B) Eventually, binding of HIV-1 to its receptors results in its uptake into intracellular 
compartments and release of intact particle at the site of contact of infected cell with T cell. 
(C) HIV-1 virions readily attach to surface expressed DC-SIGN. DC-SIGN bound particles 
are being directly transmitted to T cells. (D) In contrast, Langerin attached HIV-1 is degraded 
in Birbeck granules, which prevents HIV transmission to T cells. HIV-1 efficiently replicates 
in susceptible T cells. 
In summary, LC efficiently transmit HIV-1 to T-cells in the submucosa or after 
migration to lymph nodes (Shen et al. 2011). Tenofovir containing gel is a pre-
exposure prophylaxis soon to be introduced to clinics with hope to prevent new HIV-1 
transmission (Abdool Karim et al. 2010; Rohan et al. 2010; Johnson et al. 2012; 
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Cohen et al. 2013). Tenofovir is a reverse-transcription inhibitor already used in HIV-
1 treatment that efficiently blocks virus multiplication in infected individuals.  
However, if productive infection of LC is not required for successful transmission of 
HIV-1 from mucosa to lymph nodes, LC contribution to systemic spread of HIV-1 
will not be blocked with tenofovir gel. Therefore, detailed understanding of the 
interactions between LC and HIV-1 are necessary for development of new 
preventative measures against HIV-1 acquisition that work against viral replication 
and spread.    
 
1.5.2.3.2. Dendritic Cells  
Other dendritic cell subsets reside in the lower layers of the epithelium and 
submucosa. Together with other immune cells such as macrophages, they provide a 
second line of defence against pathogens. In response to stimuli DCs migrate toward 
lymph nodes, providing an opportunity for HIV transmission. DCs express great 
quantities of a C-type lectin receptor (CLR) called DC-SIGN that functions as an 
HIV-1 attachment site. In contrast to langerin, DC-SIGN facilitates virus binding to 
CCR5 and its productive entry to DC (Lee et al. 2001), or direct transmission of the 
virus to CD4+ T cells (Figure 1.6.). Alternatively, DC-SIGN bound HIV-1 particles 
are internalized and degraded for antigen presentation (Moris et al. 2004; Moris et al. 
2006). Surprisingly, however, a substantial fraction of internalized virions escape 
lysosomal degradation and exist in the endosomal compartments, from where they are 
transmitted to T-cells (Figure 1.6.) (Tacchetti et al. 1997; Turville et al. 2004).  The 
escape mechanism and viral transmission to CD4+ T-cells was suggested to be DC-
SIGN-dependent (Geijtenbeek et al. 2000; Kwon et al. 2002), although DC-SIGN-
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dependent internalization could be dispensable (Arrighi et al. 2004a; Arrighi et al. 
2004b; Granelli-Piperno et al. 2005).  
 
1.5.2.3.3. Other Immune Cells 
Apart from LC and DC, HIV-1 also targets T-cells and macrophages at submucosal 
surfaces. Infection of resident T-cells results in robust replication of the virus in these 
cells. However, mucosal cells get probably infected significantly later compared to 
DC, therefore underlining the role of DC subsets in the initial spread of HIV-1 (Shen 
et al. 2011).  
In conclusion, LC and DC are among the very first cells facing HIV-1 during sexual 
transmission. They capture the virus and efficiently transfer HIV-1 to susceptible 
CD4
+
 T-cells in submucosa or lymph nodes. APC-mediated activation of T-cells 
additionally supports virus replication in these cells. Moreover, co-infections with 
other STI significantly increase HIV-1 transmission from LC/DC to CD4
+
 T cells 
kinetic. 
1.5.3. HIV-1 Transmission in Men Having Sex with Men 
While male to female risk of HIV-1 transmission is 8 in 10,000 exposures (the 
estimate may vary depending on viral load and the presence of co-infection), the risk 
of HIV-1 acquisition during receptive anal intercourse, with the same health 
conditions, rises by almost 18 fold (CDC.gov 2014). For years, this increased 
frequency of transmission was entitled to risky sexual behaviour from men having sex 
with men (MSM), including lack of condom use and multiple partners. Although these 
factors increase the chances for HIV-1 acquisition, biological differences between gut 
and vaginal mucosa remain an important issue. While the female reproductive tract is 
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protected from pathogens by the mucus, pH and thick layer of epithelial cells (see 
Section 1.5.2.), the gastrointestinal tract lacks these features.  
Importantly, the Gastrointestinal tract harbours high proportions of immune cells, 
including activated CD4+ CCR5+/CXCR4+ T cells that are contained in T cell zone 
in Payer’s patches. HIV-1 can gain access to these target cells via transcytosis across 
M cells, (cells that transport antigens from intestine lumen to CD4+ T cells), via 
interactions with intestinal DC or during breaching of epithelial layer (reviewed in 
(Brenchley et al. 2004). Infection with HIV-1 in gut mucosa leads to irreversible 
depletion of CD4+ T cells in this compartment and disturbance of the gut homeostasis. 
In consequence, HIV-1+ individuals develop diarrhoea and other multiple gut 
dysfunctions. Interestingly, irrespectively of the route of HIV-1 acquisition, the 
gastrointestinal tract seems to be a preferential target for the virus due to high number 
of activated target cells (Poles et al. 2001).  
 
1.6. The Effect of Co-infections on HIV-1 Transmission 
As discussed above, HIV-1 passage through mucosal membrane is rather ineffective. 
However, high viral inoculums, semen components and hormones can positively 
influence viral transmission (see Section 1.5). Nevertheless, the pre-existence of 
sexually transmitted disease (STD) at mucosal sites is the most commonly recognized 
trigger of increased HIV-1 transmission. Some of these mechanisms are summarized 
in Table 1.2. STDs can be of bacterial or viral origin. Chlamydia and Gonorrhoea are 
the most common bacterial infections of the lower genital tract, whereas Herpes 
Simplex Virus (HSV) and Human Papilloma Virus (HPV) account for the majority of 
viral infections. 
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STD  Cell  Effect  Reference 
Treponema 
pallidum 
(syphilis)  
macrophages  Increased CCR5 
expression  
(Sellati et al. 2000) 
U937 human 
promonocytic cells  
Increased HIV-1 
transcription via NFκβ 
stimulation  
(Theus et al. 1998) 
H. Ducreyi 
(chancroid)  
T cells  Cell activation  (Van Laer et al. 
1995) 
DC  TNF-ɑ release  (Banks et al. 2007)  
Chlamydia 
Trachomatis  
Epithelial cells  
Mononuclear cells  
Increased CCR5 
expression. 
Increased HIV-1 
replication  
(Schust et al. 
2012) 
Neisseris 
gonorrhoea  
LC  Cell stimulation, TNF-α 
release  
(de Jong et al. 
2008)  
Bacterial 
vaginosis 
LC Increased HIV replication (Ogawa et al. 
2009) 
HSV-1/-2 Epidermis, T cell 
(indirectly)  
Increased HIV-1 shedding 
and mucosal barrier 
permeability. 
Enriched target cell 
population.  
(Schacker et al. 
1998) 
 
 
 
 
Table 1.2. The impact of STD co-infection on HIV-1 transmission and systemic spread. 
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1.6.1. HIV-1 Mucosal Barrier Passage during STD Co-infection.  
Sexually transmitted infections increase the possibility of both HIV-1 transmission 
and acquisition. Considering transmission, increased levels of virus particles in semen 
or vaginal fluids are observed during the acute phase of HIV-1 infection, and it 
correlates with elevated risk of transmitting the virus to a sexual partner. Keeping this 
in mind, any co-infections which enhance HIV-1 viral load in the patient’s blood, such 
as malaria (Hoffman et al. 1999), HSV (Mole et al. 1997), and some STD (Galvin and 
Cohen 2004), significantly contribute to sexual transmission of HIV-1. The risk of 
horizontal transmission, from mother to child, is also higher when the mother is co-
infected with human cytomegalovirus (CMV). However this effect, seemingly relies 
on an elevated proliferation and maturation of HIV-1 target CD4+ cord blood 
mononuclear cells, rather than increased virus replication per se (Johnson et al. 2014).  
STI play an equally important role in boosting HIV-1 acquisition. First, STDs cause 
damage to genital mucosa and therefore increase permeability, which can favour virus 
entry. For instance, ulcers that arise during HSV-1 infection strongly disrupt mucosal 
uniformity and promote HIV-1 passage (Figure 1.7) (Schacker et al. 1998; Schacker 
et al. 2002). Mucosal epithelia cell death set off by Haemophilu ducreyi infection has 
the same effect (Banks et al. 2007). Interestingly, Patterson et al (1998) showed that 
STI can increase the expression of CCR5 in cervical epithelial cells and could 
therefore potentially promote HIV-1 binding and transcytosis (Figure 1.7).   
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Figure 1.7. Mechanism Involved in Increased HIV-1 Acquisition during Co-infections 
with Other Pathogens. Ulcers formed during HSV-1, or HSV-2 infection of reproductive 
tract epithelia breech the mucosal barrier and allow HIV-1 passage to underlying target cells. 
Additionally, co-infections may increase the expression of CCR5 on the epithelial cells 
allowing virus transcytosis. Inflammation induced by bacterial infections weakens muscosal 
barrier and attracts HIV-1 target cells.   
STD antigens are recognised by Toll-like receptors (TLR), which are particularly well 
expressed by epithelial cells and mucosal immune cells. Each of 9 TLR present in 
human immune cells recognise a specific pathogen associated molecular pattern 
(PAMP) such as bacterial cell wall components or viral nucleic acids (See Appendix 
1). TLR are transmembrane proteins distributed accordingly to their ligand specificity.  
And so, TLR recognising intracellular pathogens (viruses and some bacteria) are 
localised to intracellular compartments such as endoplasmic reticulum. Examples of 
these TLRs include TLR3 (ligand: dsRNA), TLR7 (ssRNA), TLR8 (ssRNA) and 
TLR9 (unmethylated CpG oligodeoxynucleotide DNA present in some viruses and 
Ulcers 
ex. HSV-1,-2  
Inflammation 
ex. gonorrhoea 
Pro-inflammatory 
cytokines release 
and accumulation 
of HIV target cells 
Co-infection Effect on Mucosal Barrier 
CCR5 Expression 
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bacteria). The remaining TLRs, TLR-1, -2, -4, -5 and -6 are distributed on the cell 
surface and engage specifically with bacterial signatures such as peptidoglycan of 
gram+ bacteria and lipopolysaccharide (LPS) of Gram negative bacteria. Apart from 
specific distribution of TLR to cell compartments, different immune cells show 
specific repertoire of these PRR. For instance, located at the mucosal surfaces, 
Langerhans cells lack TLR4 as these cells are constantly exposed to commensal 
bacteria (Flacher et al. 2006). In contrast, professional IFN producing plasmacytoid 
DC predominantly respond to TLR7 and TLR9 expressed in these cells (Hemmi et al. 
2002).  
Engagement of TLR with its specific ligand leads to induction of NFκβ signalling 
cascade through intracellular domain of TLR receptor and MyD88 adaptor protein. 
Stimulation of TLRs results in release of pro-inflammatory cytokines and chemokines, 
such as TNFα, IL6, IL-12 and type I IFN in case of TLR 3, 7, 8 and 9 activation. In 
respect to HIV-1 infection, chemokines can recruit HIV-1 target cells to the point of 
infection and enhance the risk of HIV-1 transmission (Zhu et al. 2009; Lavelle et al. 
2010). Cytokines, on the other hand, directly stimulate HIV-1 replication in infected 
cells as described subsequently. Although, inflammation is a protective response to 
pathogens, in case of HIV-1 infection this has a dramatic outcome (see Sections 
1.6.2).  
 
1.6.2. Inflammation and HIV-1 Transmission 
Persistent inflammation likely plays an imperative role in HIV-1 transmission 
facilitated by STI. One of the pro-inflammatory cytokines released by DC in response 
to H. ducreyi infection is TNF-α (Banks et al. 2007). TNF-α is produced by a number 
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of cells including LC, T-cells, epithelial cells and others, in response to bacterial 
lipopolysaccharides. Although this cytokine provides cell-mediated immunity against 
bacteria pathogens, in terms of HIV-1 infection it has a deleterious effect. TNF-α 
activates NF-κβ signalling in macrophages and this subsequently promotes HIV-1 
transcription from the LTR (Mellors et al. 1991; Chang et al. 1994; Herbein et al. 
2008). The same mechanism enhances HIV-1 replication in LC and its further 
transmission to T-cells (de Jong et al. 2008). The ability to process antigens in mature 
LC exposed to TNF-α is impaired, which could be another mechanism involved in 
increased viral transfer from LC to T-cells. However, other reports suggest that TNF-α 
suppresses HIV-1 replication in macrophages via stimulation of RANTES production 
and a decrease in CCR5 expression on these cells (Lane et al. 1999). Other 
inflammatory cytokines differently affect HIV-1 propagation (see Chapter 4). In 
Chapter 4, the role of cytokines, particularly Transforming Growth Factor Beta (TGF-
β), on HIV-1 susceptibility of immune cells will be discussed further. 
 
1.7. Summary 
HIV-1 has effectively propagated in the human population for over 90 years. It has 
successfully spread around the globe and collectively infected more than 60 million 
individuals. HIV-1 treatments that are available today, robustly silence virus 
replication and prolong the life of patients. However, treatment itself has significant 
side effects, which themselves can decrease the quality of life.  
The human body has a few barriers against HIV-1 acquisition. These include physical 
blocks, such as the thick vaginal epidermal layer with mucus; the microenvironment 
of the reproductive tract that negatively affects virus infection capability, and also 
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directly modulates local cell biology functions. On a molecular level, cells are 
equipped with restriction factors, which counteract HIV-1 replication processes. Out 
of a few such identified restrictions, SAMHD-1 potently blocks HIV-1 at an early 
stage of cellular infection. This restriction factor is present in various immune cells. 
SAMHD-1 is constitutively expressed by dendritic cell subsets and macrophages, and 
in resting T-cells. SAMHD-1 mediated depletion of cytoplasmic nucleosides blocks 
HIV-1 reverse transcription. Additionally, SAMHD-1 directly interacts with HIV-1 
genomic ssRNA, leading to its cleavage and degradation.  
The sexual route of transmission is the predominant way of HIV-1 acquisition. Risk of 
HIV-1 transmission is particularly high in men having sex with men due to high 
permeability of gut mucosa to the virus. Male to female transmission is more 
challenging for the virus, as it has to overcome vaginal mucus, physical barriers such 
as thick cell layers, and an unfavourable environment. Yet, the number of female 
carriers increases every year. Langerhans cells are likely the very first immune cells, 
which encounter HIV-1 during sexual transmission. Previously these cells were 
described as not permissive to HIV-1 infection. This function was assigned to 
Langerin, a lectin that captures virus particles and leads to their degradation. 
However, the exact role of SAMHD1 and other restriction factors in HIV-1 resistance 
is poorly investigated in Langerhans cells. As Langerhans cells are the very first cells 
encountering HIV-1 during sexual transmission, it is important to understand the 
events accompanying this process. Mechanisms behind HIV-1 restrictions in 
Langerhans cells, if recognized, may possibly offer the opportunity for development 
of preventative measures against the sexual transmission of HIV-1. 
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1.8. Thesis Aims 
The main aim of this work is to investigate the interaction of HIV-1 with Langerhans 
cells. Tissue resident LC are the first immune cells that are likely to meet HIV-1 in the 
mucosal surfaces as they carry the HIV receptor/co-receptors CD4/CCR5. Some 
studies show these cells can become productively infected with HIV-1 especially in 
the context of co-infections. However, LC are difficult to infect by HIV-1 due to the 
presence of Langerin (de Witte et al. 2007). Langerin binds viral particles and 
mediates their degradation in lysosomal compartments called Birbeck granules (de 
Witte et al. 2007). However, saturation of Langerin achieved by high viral doses 
allows viral infection of these cells. The current available literature does not consider 
post entry restrictions operating in LC despite recognized role of these cells in initial 
viral dissemination during sexual acquisition.  
The principle objectives for this study comprised: 
1. Development of Langerhans cells model systems including skin isolated 
epidermal LC and monocyte derived Langerhans cells (MDLC).  
2. Characterization of the post-entry HIV-1 restriction mechanism operating in 
Langerhans Cells.  
3. Understanding the role of Transforming Growth Factor β (TGF-β) in 
modulation of Langerhans cells susceptibility to HIV-1 infection.  
Accordingly, Chapter 3 of this thesis concentrates on the biology and properties of the 
Langerhans cells systems, describes the methodology and limitations to each LC 
model system in particular in the context of HIV-1 infection. The other two research 
questions are addressed in Chapter 4, which explores the HIV-1 infection pattern of 
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Langerhans cells and describes the novel mechanism of virus restriction operating in 
these cells. 
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2. Materials and Methods 
2.1. Equipment 
Centrifuge 5415R (Eppendorf)  
Heraeus Megafuge 40R (Thermo Fisher, Scientific) 
Beckman Coulter Optima™ L-100XP Ultracentrifuge 
15 ml tubes (Corning Centristar™) 
50 ml tubes (Corning Centristar™) 
Tissue flasks (Nunc™) 
Water Bath (Grant) 
Incubator (Nuaire, Triple Red, Lab Technology) 
pH meter Jenway model 3540, Scientific Laboratories supplies 
Nikon TMS-F Microscope  
 
2.2. Cell Isolation 
2.2.1. Buffers 
MACS buffer – 2.5g Bovine Serum Albumin (BSA) (Sigma-Aldrich), 0.5M EDTA 
(Gibco) in 500 ml Phosphate buffered saline (PBS) (Sigma-Aldrich).  
 
2.2.2. Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
Buffy coats from anonymous, healthy donors were obtained from the Welsh Blood 
Service. Blood was diluted with sterile PBS (Sigma-Aldrich) to a total volume of 180 
ml and gently pipetted onto a Ficoll (Ficoll-Paque Plus; Fisher (GE)) layer. The 
gradient was centrifuged for 30 minutes at 2000rpm (800xg) without the break at 4°C. 
The Peripheral blood mononuclear cells (PBMC) fraction was carefully collected and 
washed 3 times with sterile PBS. Healthy PBMC were counted using a Bright-Line 
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hemacytometer (Hasser Scientific, Harsham) in the presence of Trypan Blue Stain 
0.4% (Gibco Life Technologies), and then subjected to MACS isolation of CD14+ 
cells (see Section 2.2.3).     
 
2.2.3. Isolation of Peripheral Blood Monocytes (CD14+) 
CD14+ monocytes were isolated from blood derived PBMC using CD14 MicroBeads 
(Miltenyi Biotec) according to manufacturer protocol. PBS washed PBMC were 
counted and resuspended in 80µl of MACS buffer per 10
7
 total cells. 20µl of CD14 
MicroBeads per 10
7
 total cells was added and cells were incubated at 4°C for 15 
minutes. Cells were then washed with cold MACS buffer and spun at 1800rpm for 10 
minutes. After re-suspension in 500µl of MACS buffer per 10
8
 total cells the cells 
were applied onto the isolation column and left to flow through with gravity. Column 
was washed 3 times with 3ml of MACS buffer. Column was removed from separator 
and magnetically labelled CD14+ cells were retrieved from the column by flushing the 
column with 5ml of MACS buffer. CD14+ cells were counted and used for generation 
of MDDC and MDLC (see Section 2.3.1 and 2.3.2). 
  
2.2.4. Isolation of CD1a+ MUTZ-3 Derived Langerhans Cells (MuLC) 
CD1a+ MuLC were purified from the MUTZ-3 derived culture (see Section 2.3.3. and 
2.4.1.) using CD1a MicroBeads (Miltenyi Biotec) according to manufacturer protocol. 
Immature MuLC were counted and resuspended in 80µl of MACS buffer per 10
7
 total 
cells. 20µl of CD1a MicroBeads per 10
7
 total cells was added and cells were 
incubated at 4°C for 15 minutes. Cells were then washed with cold MACS buffer and 
spun at 1800rpm for 10 minutes. After re-suspension in 500µl of MACS buffer (per 
10
7
 total cells) cells were applied onto the isolation column and left to flow through 
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with gravity. Column was washed 3 times with 3ml of MACS buffer. Column was 
removed from separator and magnetically labelled CD1a+ cells were retrieved from 
the column by flushing the column with MACS buffer. Enriched CD1a+ Langerin+ 
cells population was used for the experiments.  
 
2.3. Cell Differentiation 
2.3.1. Generation of Monocyte Derived Dendritic Cells (MDDC) 
Blood isolated CD14+ cells were cultured for 6 days in 6 well plates at a density of 2 
x 10
6
 cells per well at 37°C as described before (Blanchet et al. 2013). Iscove's 
Modified Dulbecco's Medium (IMDM; Life Technology Ltd., Paisley, United 
Kingdom) containing 10% Fetal Bovine Serum (FBS; SIGMA), 100U/ml penicillin 
and 100µg/ml streptomycin (Gibco, Life Technologies), 2mM L-glutamine (Gibco, 
Life Technologies), 10mM HEPES Buffer (Sigma-Aldrich), 1% minimum essential 
medium non-essential amino acids (Gibco, Life Technologies), and 1mM sodium 
pyruvate (Gibco, Life Technologies) was supplemented with 50M β-2-
Mercaptoethanol (β-2M) (Sigma, Life Science) (added only on day 0), 500U/ml GM-
CSF (MACS, Miltenyi Biotec) and 500U/ml IL4 (MACS, Miltenyi Biotec). At days 2, 
4 and 6 of culture a third of the culture medium was replaced by fresh medium 
containing GM-CSF and IL4. Differentiated MDDCs were analyzed by flow 
cytometry (see Section 2.10) for expression of cell specific markers at day 7.  
 
2.3.2. Generation of Monocyte Derived Langerhans Cells (MDLC) 
Blood isolated CD14+ monocytes were seeded at 1x10
6
 cells/ml in RPMI1640 
medium (Life Technologies) supplemented with 10% FBS, 100U/ml penicillin, 
100µg/ml streptomycin, 2mM L-glutamine in tissue culture flask. MDLC were 
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generated over 6 days with GM-CSF (500IU/ml), IL4 (500IU/ml) and TGF-β 
(10ng/ml) (Peprotech).Complete medium with cytokines were refreshed at day 3. 
Differentiated MDLC were phenotyped and used at day 6 or 7.  
 
2.3.3. Induction of Immature Langerhans-like Cells from MUTZ-3 Cell Line 
(MuLC) 
MUTZ-3 cell line (see Section 2.4.1) was used to generate Langerhans cells (MuLC) 
as described previously (Masterson et al. 2002). MUTZ-3 cells were harvested and 
seeded in 12 well tissue culture plates at a concentration of 1x10
5
 cells/ml. For 
induction of Langerhans cells phenotype MUTZ-3 culture medium MEM-α (see 
Section 2.4.1) was additionally supplemented with GM-CSF (100ng/ml), TGF-β 
(10ng/ml) and TNF-α (2.5ng/ml) (Peprotech). Cytokines were refreshed at day 4 and 
8. Cells were collected and subjected to phenotyping at day 10. 
 
2.3.4. Generation of CD141
+
 DC Cells 
Blood isolated CD14
+
 cells were cultured for 6 days in 6 well plates at density of 2 x 
10
6
 cells per well at 37°C as described before (Blanchet et al. 2013). Fully 
supplemented IMDM medium (Life Technology Ltd., Paisley, United Kingdom) (see 
section 2.3.1) was supplemented with 50M β-2-Mercaptoethanol (β-2M) (Sigma, 
Life Science) (added only on day 0), 500U/ml GM-CSF (MACS, Miltenyi Biotec) and 
500U/ml IL4 (MACS, Miltenyi Biotec). At days 2, 4 and 6 of culture a third of the 
culture medium was replaced by fresh medium containing GM-CSF and IL4. 100nM 
of active Vitamin D3 (1,25(OH)2D3) (Sigma) was additionally supplemented to cells 
at day 4 to induce CD141
+
 DC phenotype. Differentiated cells were analyzed by flow 
cytometry (see Section 2.10) for expression of cell specific markers at day 7.  
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2.4. Cell Lines Culture and Maintenance 
2.4.1. MUTZ-3 Cell Line Culture 
An immortalized human acute myeloid leukaemia-derived cell line (MUTZ-3) was a 
kind gift from Dr Tania de Gruijl (Dept Medical Oncology, VU University Medical 
Centre, Amsterdam, Holland). For routine culture, MUTZ-3 cells were maintained at a 
concentration of 2x10
5
 cells/ml to 1x10
6
 cells/ml in 12 well tissue culture plates 
(Sigma-Aldrich, Corning Costar). Every 2-3 days cells were collected, spun at 
1500rpm for 5 minutes and reseeded at a density of 2x10
5
 cells/ml in Minimum 
Essential Media alpha with ribonucleosides and deoxyribonucleosides (MEM-α 
GlutaMAX™ nucleosides; Life Technologies) supplemented with 20% heat 
inactivated FBS, 100U/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamine, 
50µM 2-mercaptoethanol and 10% conditioned medium from renal carcinoma cell 
line 5637 (see Section 2.4.3).  
 
2.4.2. 5637 Cell Line Culture 
Renal carcinoma cell line 5637 was a kind gift from Dr Tanja de Gruijl (Dept Medical 
Oncology, VU University Medical Centre, Amsterdam, Holland). Cells were 
maintained in RPMI 1640 medium supplemented with 10% heat inactivated FBS, 100 
U/ml penicillin, 100µg/ml streptomycin, and 50µM 2-mercaptoethanol. At 70-80% 
confluency, cells were removed from tissue flask with 0.05% Trypsin-EDTA (Gibco, 
Life Technologies) treatment and spun at 1500rpm for 5 minutes. Cells were seeded at 
5x10
5
 cells/ml in tissue culture flasks and incubated at 37°C, 5% CO2. 
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2.4.3. Generation of 5637 Conditioned Medium 
5637 conditioned medium for MUTZ-3 culture was generated from 5637 culture 
medium. Briefly, 5637 cells were seeded in 180cm
2
 tissue culture flask at 5x10
5
 
cells/ml in 30ml of fully supplemented RPMI1640 medium. After overnight culture, 
medium was replaced with 30ml of fresh RPMI1640 medium. Cultured medium was 
collected after 40 hours and filtered with sterile 0.2µm filter. Aliquots were stored at -
30°C and used within 14 days.  
 
2.4.4. HEK293 Cell Line Culture 
HEK293 cells were maintained at 40-80% confluency in Dulbecco’s Modified Eagle 
Medium (DMEM; Life Technologies) supplemented with 10% heat inactivated FBS, 
100 U/ml penicillin, 100µg/ml streptomycin and 2mM L-glutamine. Cells were 
harvested from tissue culture flask with short trypsin treatment at 37°C. After spinning 
at 1500rpm for 5 minutes, cells were counted and seeded at 3x10
5
 cells/ml.  
 
2.5. Epidermal Langerhans Cells and Dermal  Dendritic Cells 
Isolation from Skin Explants 
Human skin samples were obtained from female patients undergoing mastectomy or 
breast reduction surgery with informed written patient consent and local ethical 
committee approval (South East Wales Research Ethics Committees Panel C, 
Reference: 08/WSE03/55). Skin was transported following surgery as previously 
described (Pearton et al. 2010). Subcutaneous fat and excess lower dermis were 
removed by blunt dissection. The upper layers of the skin were subsequently removed 
using a dermatome set to a depth of 300µm to collect the epidermis and upper 
papillary dermis. Skin sheets were cut into 1cm² pieces and incubated with agitation in 
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a shaking water bath (at 175 strokes/minute) in RPMI containing collagenase A (10 
mg/ml), DNase I (20 U/ml) and Dispase II (10 mg/ml) for 30 minutes at 37°C, after 
which the epidermis was mechanically separated from the dermis using forceps. 
Epidermal and dermal sheets were cultured separately in RPMI with 10% human AB 
serum (Invitrogen, USA) and 1% Penicillin/Streptomycin/Fungizone (P/S/F) solution 
(DC-RPMI) for 48 hours, after which migratory cells were collected from the media.  
 
2.6. Bacteria Protocols  
2.6.1. Bacteria Culture Media and Reagents 
Luria-Bertani (LB) broth consisted of 10g/l tryptone (Fisher Scientific), 5g/L yeast 
extract (Fisher Scientific), 5g/L NaCl (Fisher Scientific) resuspended in H2O and 
autoclaved before use. LB-broth was supplemented with 100μg/ml ampicillin. 
 
2.6.2. Bacteria Transformation 
Escherichia coli DH5ɑ chemocompetent cells (Promega) were defrosted and heat 
shock transformed in a water bath (at 42°C for 45 seconds followed by 15 seconds on 
ice) with 1ng of relevant plasmid (Table 2.1). Transformed bacteria were left to rest at 
room temperature for 2 minutes. After addition of 130µl of S.O.C medium 
(Invitrogen), bacteria were incubated for 1 hour at 37°C. Bacteria suspension was then 
transferred to 2mls of LB-broth (see Section 2.6.1) supplemented with selective 
antibiotic and shaken overnight. The following day, bacteria were transferred to 
400mls of LB-broth with selective antibiotic and shaken (Orbital Incubator, 
Gallenkamp) at 37°C overnight. After incubation it was spun at 4000xg for 30 
minutes and the resulting bacteria pellet was used for purification of plasmid using 
Maxipreps (see Section 2.7).  
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2.6.3. Plasmids Table 
Table 2.1. List of Plasmids 
Plasmid name Product Antibiotic 
resistance 
Reference/obtained from 
pMD.G VSV-G 
envelope 
ampicillin (Naldini et al. 1996) 
pR8.91 gag-pol ampicillin (Naldini et al. 1996) 
plox.EW.delta.Sal 
GFP 
GFP ampicillin (Salmon et al. 2000) 
SIV3-Vpx Vpx, Vpr ampicillin (Nègre et al. 2000) 
pR8Bal R5/X4 dual 
tropic HIV-1 
ampicillin  
 
2.6.4. Plasmids Maps 
pMD.G plasmid encodes VSV-G envelop protein downstream of Cytomegaloma 
Virus (CMV) promoter (Naldini et al. 1996). Plasmid is used in delivery of 
lentivectors and viral like particles transduced with VSV-G envelop.  
 
Figure 2.1. Schematic Representation of pMD.G Construct. pXF3 (poison sequence minus 
pBR322, low copy plasmid); hCMV human Cytomegaloma Virus (CMV) promoter; human 
beta globin sequence, VSV-G envelop, poly A sequence.  
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pR8.91 is a packaging construct used for production of lentivirus, such as VSV-G 
HIV-GFP used in this study. Plasmid encodes Gag-Pol proteins under control of CMV 
promoter. 
 
  
Figure 2.2. Schematic Representation of pR8.91 Construct. AmpR Ampicilin resistance 
gene; RRE Rev-responsive element; CMV promoter; Gag-Pol genes of HIV. (Adapted from 
http://plasmid.med.harvard.edu/PlasmidRepository/file/map/dR8.91.pdf) 
 
plox.EW.delta.Sal.GFP encodes GFP protein downstream of EF-1α promoter. 
EF-1α promoter ensures robust, constitutive and long-term expression of downstream 
genes (Kim et al. 1990; Kim et al. 2007). EF-1α is often used where CMV promoter is 
silenced. pLox.EW.delta.Sal.GFP plasmid is co-transfected with pMD.G and pR8.91 
when producing VSV-G HIV-GFP lentivirus (see Section 2.8.1).  
 
 
Figure 2.3. Schematic Diagram of pLox.EW.deltaSal.GFP. ψ packaging signal; RRE Rev-
responsive element; CMV promoter, GFP green fluorescent protein; Adapted from (Salmon et 
al. 2000).  
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SIV3-Vpx – SIV3-Vpx construct (Figure XX) originate from SIV (SIVmac251) 
and was derived through elimination of env and 3’LTR, and replacement of 5’LTR 
promoter with more potent CMV early promoter/enhancer sequence (Nègre et al. 
2000). Therefore, SIV3-Vpx construct encoded gag, pol, vif, vpr, rev and tat genes, of 
which vpr and vpx gene products are packed into viral like particles. Vpx protein 
delivered in SIV3-Vpx particles acts on SAMHD-1 leading to its ubiquitinin-mediated 
degradation (Hrecka et al. 2011). Vpr has not known effect on SAMHD-1, however it 
suppresses innate immune in macrophages and DC (Mashiba et al. 2014; Harman et 
al. 2015) (see Introduction, Section 1.4.3). Due to these properties of Vpr, SIV3-Vpx 
should perhaps be considered to be used in parallel with SAMHD-1 siRNA/shRNA. 
The consequences of the presence of Vpr protein on the experiments performed in this 
study will be discussed in the following Chapters.  
 
Figure 2.4. Schematic Diagram of SIV3-Vpx Construct. pCMV Cytomegaloma Virus 
promoter; Gag – Tat – SIV structural and accessory proteins; RRE Rev-responsive element; 
poly A sequence. Adapted from (Nègre et al. 2000).  
 
pR8-Bal is a culture adapted construct derived from pR8 plasmid by inserting Bal 
envelope sequence (C.Aiken, Vanderbilt University, Nashville, Tenn). Construct 
encodes full-length HIV-1 virus.  
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2.7. Plasmid DNA Isolation 
2.7.1. Maxiprep Procedure 
QIAGEN® Plasmid Purification Kit (QIAGEN) was used to perform Maxipreps. The 
procedure was done according to the manufacturer instructions. Briefly, transformed, 
centrifuged bacteria were resuspended and lysed in 10ml Buffer P1. 10ml of buffer P2 
was added to lysates and samples were mixed vigorously by inverting tubes 4-6 times. 
Bacteria lysates were incubated for 5 minutes at room temperature. After incubation, 
10ml of chilled Buffer P3 was added to lysates and mixed. The mixture was incubated 
for 20 minutes on ice and then centrifuged at 4540xg at 4°C for 30 min. Precipitated 
material was separated from the supernatant using a QIAfilter filter. A QIAGEN-tip 
500 was equilibrated with 10ml Buffer QBT and filtered lysates were added onto the 
resin and left to pass through by gravity. The QIAGEN-tip was washed twice with 2 x 
30ml of Buffer QC in order to remove the contaminants. Elution of resin bound DNA 
was achieved using 15ml of Buffer QF. 12ml of room temperature isopropanol was 
added to DNA-buffer QF mix and centrifuged for 30min at 4540xg at 4°C.  Formed 
pellet was washed with 5ml of room temperature 70% ethanol and centrifuged at 
4540xg for 10min at 4°C. After spin, the pellet was air dried for 10-20 minutes and re-
dissolved in TE buffer (Invitrogen, Life Technologies). Plasmids were stored at -30°C. 
 
2.7.2. Quantification of Plasmid Preparations 
Plasmid quantification was performed using Nano-drop spectrophotometer (ND-1000, 
Labtech International) blanked with TE buffer. Three readings were taken for each 
Maxiprep samples and the mean value was noted for future use.  
 
 
 73 | P a g e  
 
2.8. Virus Production 
2.8.1. Viral Strains 
All viruses were produced by calcium phosphate transfection of HEK293T cells with 
corresponding plasmids as described previously (Blanchet et al. 2013). VSV-G HIV-
GFP was obtained by co-transfection of 30μg pMD.G (vesicular stomatitis virus 
envelope protein, VSV-G) expression vector (Naldini et al. 1996), 32μg pR8.91 (gag-
pol expression vector; (Naldini et al. 1996) and 45μg plox.EW.delta.Sal GFP (a 
retroviral expression vector encoding green fluorescent protein) per 1 flask of 
HEK293T cells. VSV-G-pseudotyped SIV3 lentivector encoding the Vpx gene (Nègre 
et al. 2000; Goujon et al. 2003; Goujon et al. 2007) was produced by co-transfection 
of 20μg pMD.G and 40μg SIV3+ packaging construct. Proviral plasmid pR8BaL, 
encoding HIV-1 R5 strain provirus was used for wild type HIV-1 virus production at 
90μg per HEK293T flask. 
 
2.8.2. Buffers 
0.5M CaCl2 was prepared by dissolving 36.75g of CaCl2 (SigmaUltra C5080) in 
500ml of distilled H2O and it was stored at -70°C until use; 2x HeBS was prepared by 
mixing 16.36g NaCl (SigmaUltra S7653) (final 0.28M), 11.9g HEPES (SigmaUltra  
H7523) (final 0.05M), and 0.213g anhydrous Na2HPO4 (SigmaUltra S7907) (1.5mM 
final) in 1000ml distilled H2O. pH was adjusted to 7.00 with NaOH solution. Solution 
was stored at -70°C until use; HEPES H2O was prepared by adding 125µl of 1M 
HEPES (Gibco-BRL. Ref 15630-056) (final 2.5mM) to 50 ml of distilled H2O. 
HEPES H2O was stored at 4°C until use.  
 
 
 74 | P a g e  
 
2.8.3. HEK293T Cells Transfection: Virus Production Protocol 
HEK293T cells were seeded in 180cm
2
 tissue flask at 8x10
5
 cells/ml in 15 ml of fully 
supplemented DMEM medium (see Section 2.4.4) and left overnight to reach 70-80% 
confluency.  Transfection mix was prepared by mixing required amount of plasmids 
DNA (see Section 2.8.1) with HEPES buffered dH2O (2.5mM) to a final volume of 
750µl per tissue culture flask. After 5 minutes incubation at room temperature, DNA-
HEPES mix was added to 750µl CaCl2 per flask, and the resulting mix was added 
drop-by-drop into a tube containing 1.5ml of 2xHBS per flask while continuously 
vortexing at a low speed. Following 30 minutes incubation at room temperature, 3ml 
of transfection mix was distributed equally on growing HEK293 cells in a tissue 
culture flask using disposable transfer pipettes (VWR International). Cells were then 
incubated at 37°C for 6 hours. Afterwards, all medium from flask was carefully 
removed without disturbing HEK293 layer, and cells were washed with sterile PBS. 
Fresh 15ml of DMEM medium was added to each flask of HEK293 and cells were left 
for 48 hours at 37°C.  
Cell supernatant was collected, filtered using 0.45µm sterile millex
®
GP filter 
(Millipore Ireland Ltd.) and overlaid on top of 20% sucrose (Sigma) gradient in 
Beckman ultracentrifuge conical tubes (Beckman Coulter). The gradient was 
centrifuged in ultracentrifuge at 26000rpm, 4°C for 90 minutes. The supernatant and 
sucrose were then aspirated using VACUSAFE™ Vacuum aspiration system 
(INTEGRA Biosciences), avoiding the viral pellet. Tubes were inverted for 10 
minutes and viral particles were resuspended in 300µl DMEM per tube. The pellet in 
medium was left at room temperature for 20 minutes and resuspended viral particles 
were aliquoted into sterile o-ringed screw tubes (Fisher Scientific). Viral preparations 
were stored until use at -80°C.  
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2.8.4. Virus Quantification by p24 ELISA  
A Lenti-X p24 rapid titre ELISA kit (Clontech Laboratories, Inc) was used to quantify 
HIV-1 Gag p24 according to the manufacturer’s instructions. Briefly, virus 
preparations were lysed with Triton x10 (BDH Limited) at 1:10 ratio. A serial dilution 
of the sample was prepared using DMEM culture medium ranging from 1:1000 – 
1:100000 depending on the virus production. Dilutions of 0 – 200pg/ml for the p24 
standard curve were prepared by diluting the p24 control (provided with the kit) in 
complete DMEM culture medium.  
 
For the p24 ELISA assay 20µl of lysis buffer was aliquoted into each well designated 
for the samples. 200µl of p24 standard curve dilutions and virus production samples 
were aliquoted into appropriately labelled duplicate wells and incubated at 37 (±1)°C 
for 60 (±5) minutes. The content of the wells was aspirated and the plate was washed 
with 1x wash buffer. 100µl of Anti-p24 (Biotin conjugate) detector antibody was 
added into each well and plate was incubated at 37 (±1)°C for 60 (±5) minutes. Plate 
was washed again, as described above. 100µl of Streptavidin-HRP conjugate was 
dispensed into each well and the plate was incubated at room temperature for 30 (±5) 
minutes. Plate was washed once again and 100µl of Substrate Solution was added into 
each well. After incubation at room temperature for 20 (±2) minutes, the reaction was 
stopped by addition of 100µl of Stop Solution to each well. The absorbance values at 
450nm of each well were measured using a microtitre plate reader (Fluostar Optima) 
blanked on the negative control well. The standard curve was constructed based on the 
values acquired for a p24 control dilution, which allowed the calculation of p24 
content in virus samples. 
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2.8.5. Vpx-expressing SIV-derived Lentivectors Efficiency Assessment 
MDLC and MDDC were used to investigate the efficiency of new Vpx-expressing 
SIV-derived lentivectors (SIV3-Vpx) production to degrade SAMHD-1. Accordingly, 
cells were seeded in 96 well plates (100,000 cells/well) in RPMI or IMDM for MDLC 
and MDDC, respectively. New SIV3-Vpx stock was added to cells at different doses 
raging from 3-20μl. After 4 hours, cells were lysed (see Sections 2.11.3) and 
SAMHD-1 levels were investigated by western blotting (see Section 2.11.4). The 
lowest amount of Vpx-expressing SIV-derived lentivectors resulting in complete 
degradation of SAMHD-1 in both cells was used for further experiments. SIV3-Vpx 
stock efficiency was further controlled every 3-4 weeks.  
 
2.9. Cell Infections and Assays 
2.9.1. HIV-1 Infection and VSV-G HIV-GFP Transfection of Cells 
Cells were seeded in U-bottom 96-well plates (Thermo Scientific) at 1x10
5
cells/well 
in 100µl of differentiating medium. Where indicated, AZT (1μM) and Vpx-expressing 
SIV-derived lentivectors were added at least 4 hours prior to infection. Cells were 
infected with 20-40ng p24gag of R5 HIV-1 (R8Bal) or 17-63ng p24 of VSV-G HIV-
GFP. If indicated, cells were pre-treated with compounds before infections.  
The following reagent was obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: Zidovudine (AZT). 
 
2.9.2. Cell Stimulation with Interferon 
For IFN treatment, cells were incubated with 1000U/ml of one of IFN-α2a (Sigma-
Aldrich), human IFN-α2a, human IFN-β1a, human IFN-β1b, or human IFN-γ1b (all 
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MACS, Miltenyi Biotec) for 24 hours or 48 hours in 96 well plate. Consequent SIV3-
Vpx treatment and infections were carried out when required.   
 
2.9.3. Cell Stimulation with Toll-like Receptors (TLR) Agonists and TNF-α 
For TLR stimulation experiments, 1x10
5
cells/well in 100µl of medium were treated in 
96-well plates for indicated times with the following agonists: TLR1 – Synthetic 
triacylated lipoprotein Pam3CSK4 (1µg/ml) (InvivoGen); TLR2 – Peptidoglycan  
from Bacillus subtilis (10µg/ml) (SIGMA-Aldrich); TLR3 – Poly I:C (HMW) (2.5 
µg/ml) (Invivo Gen); TLR4 – Lipopolysaccharide (LPS, 1µg/ml) (InvivoGen); TLR5 
–Flagelling (1µg/ml) (InvivoGen); TLR6 – Synthetic diacylated lipoprotein FSL1  
 (1µg/ml) (InvivoGen); TLR7 – ssRNA40 (1µg/ml) (Ivivo Gen); TLR 8 – R848 
(1µg/ml) (Ivivo Gen); TLR9 – E.coil ssDNA (5µg/ml) (InvivoGen).  For maturation 
assays, 1x10
5
cells/well in 100µl of medium were treated in 96-well plates for 
indicated times with human recombinant human TNF-α (Peprotech).   
 
2.9.4. MDLC Delivery in the Presence of TGF-β Signalling Inhibitor LY2109761 
Delivery of MDLC in the presence of LY2109761, TGF-β signalling inhibitor, was 
performed in 12 well plates (1mln cells/well in 1 ml of RPMI1640) for 7 days in the 
presence of TGF-β, GM-CSF and IL-4 (see Section 2.3.2). Prior to addition of 
cytokines, monocytes were pre-treated with 5 μM or 10μM of LY2109761 for 5-10 
minutes. Medium was replaced every second day in addition to LY2109761 and 
cytokines. Experiments were performed at day 7. 
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2.10. Flow Cytometry 
2.10.1. Buffers 
FACS buffer used for cell surface staining and sample storage consists of 1% bovine 
serum albumin BSA (Sigma-Aldrich) and 0.025% sodium azide (Sigma) resuspended 
in sterile PBS.  
Phosflow Perm/wash buffer (BD biosciences) was prepared according to 
manufacturer indications. 10x Phosflow Perm/wash buffer stock was diluted 1:10 in 
sterile H2O and stored at 4°C until use.  
Paraformaldehyde (PFA) (Fisher Scientific) was prepared by diluting PFA stock in 
H2O to reach desirable final concentration. 1% solution was used for fixing 
experiments performed in category 2 laboratory, whereas 2% solution was used for 
experiments involving HIV-1 infections and treatment. 
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2.10.2. Flow Cytometry Antibodies Table 
Table 2.2. List of Flow Cytometry Antibodies  
Marker Fluorochrome Company clone dilution 
Isotypes 
mIgG 
(isotype) FITC 
BD 
Pharmingen X40 1/200 
mIgG 
(isotype) PE 
BD 
Pharmingen X40 1/200 
mIgG 
(isotype) APC 
BD 
Pharmingen X40 1/200 
Cell phenotype 
CD1a FITC 
BD 
Pharmingen HI149 1/50 
DC-SIGN PE eBiosciences eB-h209 1/50 
CD14 FITC ANCELL UCHM1 1/50 
CD83 PE Immunotech HB15a 1/50 
HLA-DR APC 
BD 
Bioscience G46-6 1/50 
CD19 FITC DAKO HD37 1/50 
CD16 PE 
BD 
Pharmingen 3G8 1/50 
CD1a APC 
BD 
Pharmingen H1149 1/50 
CD3 FITC DAKO UCHM1 1/50 
HLA-ABC PE Pharmingen G46-2.7 1/50 
CD4 APC Immunotech 13B8.2 1/50 
Langerin PE Immunotech DCGM4 1/50 
CCR5 FITC Pharmingen 2D7/CCR5 1/50 
CD141 PE MACS 
AD5-
14H12 1/50 
CD45 APC eBioscience 2D1 1/50 
Cytokines 
TNF-ɑ FITC Pharmingen MAb11 1/50 
IL-10 APC Biolegend JS3-19FI 1/50 
IL6 APC BioLegend MQ2-13A5 1/50 
IL8 APC BioLegend E8N1 1/50 
 
2.10.3. Cell Surface Antibody Staining 
Cell surface staining was performed by mixing required antibodies in FACS buffer 
(see Section 2.10.1). 50µl of prepared staining mix was applied per 1x10
5
 cells in U-
bottom 96 well plate (Cell Star). Staining was performed over 30-40 minutes at 4°C in 
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dark. Afterwards, 100µl of FACS buffer was added to each staining well and cells 
were spun at 15000rpm for 5 minutes. Washing step was repeated with additional 
200µl FACS buffer. Cells were resuspended in 300µl FACS buffer and transferred to 
FACS tubes (Gosselin).   
 
2.10.4. Cell Intracellular Antibody Staining 
Intracellular staining was performed similarly to surface staining (see Section 2.10.3) 
with use of 1x Perm buffer (see Section 2.10.1) instead of FACS buffer for antibody 
mix preparation and the first wash. Second wash and final sample resuspension was 
done with FACS buffer.  
 
2.10.5. Flow Cytometry Acquisition and Analysis 
Acquisition of the samples was carried out on a BD FACS Canto™II (BD 
Biosciences) instrument. Isotype control was set up and used for each experiment. At 
least 5000 events were recorded. Collected data was analysed using FlowJo 
programme (FlowJo Enterprise).    
 
Recorded cells were gated on the side and forward scatter C (SSC and FSC, 
respectively) and selected population was analysed for expression of the desirable 
markers. Gates were set on isotype controls for each of the individual fluorochrome.  
 
2.11. Immunoblotting 
2.11.1. Buffers  
Lysis Buffer combined 20 mM Tris (pH 7.5) (Fisher), 150 mM NaCl (Fisher), 1% 
Tergitol-type NP40 (Sigma-Aldrich), 1 mM MgCl2, 1mM EGTA (Sigma), 1 mM 
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NaVO4, 10mM Na4P2O7, 1% n-dodecyl-β-D-Maltoside (Sigma-Aldrich) and 1x 
Protease Inhibitor (Roche). 
MOPS SDS Running buffer (20x) (NuPAGE Novex, Life Technology) was diluted 
1:20 in distilled H2O before use and stored in the fridge.  
Pierce® Western Blotting Transfer Buffer (10x) (Thermo Scientific) was stored at 
4°C and made up to 1x with H2O before use.  
Washing buffer was made using 1 tablet of phosphate buffered saline  (Fisher 
Scientific, UK) and 100µl of Tween®20 (Sigma, Life Science) per 100ml of H2O.  
Restore™ Western Blot Stripping Buffer (Thermo Scientific) was used as described 
below (see Section 2.11.5). 
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2.11.2. Immunoblotting Antibodies List and Preparation  
Table 2.3. List of Immunoblotting Antibodies 
antibody dilution host company clone 
NFκβ signalling 
IKKα 1:1000 rabbit Cell Signalling 3G12 
 
IKKβ 1:1000 rabbit Cell Signalling D30C6 
 
p-IKKα/β 
(Ser176/180) 
1:1000 rabbit Cell Signalling 16A6 
 
NFκβ 1:1000 rabbit Cell Signalling D14E12 
 
p-NFκβ(Ser536) 1:1000 rabbit Cell Signalling 93H1 
 
IKβa 1:1000 rabbit Cell Signalling L35A5 
 
p-Ikβ-α (Ser32) 1:1000 rabbit Cell Signalling 14D4 
 
Restriction factors 
APOBEC3F 1:1000 rabbit abnova  
 
APOBEC3G 1:1000 rabbit abcam mAbcam
75560 
SAMHD1 1:1000 mouse abcam  
 
TRIM5α 1:1000 mouse ImmunoDiagnostic
s 
 
Clone 4.1 
Tetherin /BST2 1:1000 rabbit Strebel & AIDS 
reagent program, 
2009. 
 
 
MX2 1:1000 mouse Santa-Cruz H-7 
TGF-β signalling 
p-SMAD3 
(Ser423/425) 
1:1000 rabbit Cell Signalling C25A9 
 
SMAD3 1:1000 rabbit Cell Signalling C67H9 
 
SMAD2/3 1:1000 rabbit Cell Signalling D7G7 
 
SMAD2/3 1:1000 rabbit Cell Signalling D43B4 
 
p-SMAD2 
(Ser465/467) 
1:1000 rabbit Cell Signalling 138D4 
 
SMAD4 1:1000 rabbit Cell Signalling  
 
Controls 
ACTIN 1:2000 mouse Millipore MAB150
1R 
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RIG-I 1:1000 mouse Alexis 
Biochemicals 
Alme-1 
Secondary antibodies 
polyclonal anti-
rabbit - HRP 
1:3000 Goat Dako PO448 
 
polyclonal anti-
mouse -HRP 
1:5000 Goat Dako PO447 
 
Antibodies were diluted in PBS containing 1% BSA and 0.025% NaN3. Prepared 
antibody solution was stored at 4°C and used 2-4 times depending on antibody 
efficiency.  
 
2.11.3. Cells Lysis  
For western blot analysis 2 x 10
5
- 3 x 10
5
 cells per condition were washed with PBS 
and spun at 1500rpm for 5 minutes in 1.5 ml o-ringed screw tubes (Simport). Cell 
pellet was lysed for 20 minutes with 24µl of lysis buffer (see Section 2.11.1). Samples 
were then spun at 13200 rpm for 18 minutes at 4°C. Samples were transferred to fresh 
tubes avoiding cell debris pellet. 6µl NuPage
®
 Sample reducing agent (Invitogen) 
(10x) and NuPage
® 
LDS Sample buffer (Novex, Life Technologies) (4x) mix was 
added to each sample and the proteins were denatured for 10 minutes at 80°C in 
analog heat block (VWR). Prepared samples were stored at -30°C until use. 
 
2.11.4. Immunoblotting Protocol  
Prepared samples were loaded onto pre-cast, polyacrylamide NuPAGE® 4-12% Bis-
Tris gels (Novex, Life Technologies) using Gel saver tips (Star Lab). SeeBlue
®
 pre-
stained standard ladder (Novex, Life Technologies) and Mark12
™
 unstained standard 
ladder (Novex, Life Technologies) were loaded on the gel for molecular size 
reference. Gel was run in X Cell SureLock™ running system (Invitrogen, Novex 
Mini-cell) in MOPS running buffer (see Section 2.11.1) at 150 V for 60 minutes in 
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Power350 system (Fisher Scientific). Proteins were transferred from the gel into 
0.45µm Nitrocellulose Blotting Membrane (Amersham™ Hybond ECL, GE 
Healthcare, Life Sciences) using Mini ProteanII™ transfer system (Bio-RAD) in 
Pierce® Western Blotting Transfer Buffer (see Section 2.11.1). Transfer was 
performed at 90 V for 50 minutes, and transfer efficiency was confirmed by 0.4% 
Ponceau red solution stain. Membrane was blocked in 5% milk for 30 minutes prior to 
overnight incubation with primary antibody (see Section 2.11.2). 
 
2.11.5. Immunoblotting Results Acquisition 
After overnight primary antibody incubation at 4°C, the membrane was incubated for 
1 hour at room temperature with the relevant secondary antibody conjugated to HRP. 
Following extensive washing, bands were revealed on high performance 
chemiluminescence film (Hyperfilm ™ ECL, GE Healthcare Amersham) using 
SuperSignal West Pico Solution (Thermo Scientific) in AGFA SRX 101A (Konica). 
An Unstained Standard Mark12™ Ladder was used for molecular weight 
identification. Where required antibodies were removed from membranes using 
Restore™ Western Blot Stripping Buffer (Thermo Scientific) by 5-15 minutes 
treatment at room temperature. Before re-use of the membrane it was blocked on the 
rocking platform with 5% milk for 30-40 minutes. Band intensity was analysed using 
image processing and analysis software Java ImageJ 1.48 (National Institute of 
Health).  
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2.12. Quantitative Real Time PCR  
2.12.1. RNA Extraction from Cells 
6x10
5
 of MDDC and MDLC per condition, were used for RNA extraction using 
RNeasy Mini Kit (Qiagen) according to manufacturer instructions. Cells were 
centrifuged at 1500pm for 5 minutes, the supernatant was removed and the pellet 
lysed in RLT buffer (provided). After homogenization of samples by pipetting, lysates 
were added directly to a QIAshredder spin column and spun for 2 minutes at full 
speed. Passed through lysates were mixed with 1ml of 70% ethanol. The mix was 
applied to an RNeasy spin column and centrifuged for 15 seconds at 10,000rpm. RNA 
trapped in spin column was successively washed with 700μl of Buffer RW1 and twice 
with 500μl of Buffer RPE with 15second spin at 10,000rpm between 1 wash and with 
2 minutes spin at the same speed after second wash. RNA was extracted from spin 
column to a 1.5ml clean tube using 50μl RNase-free water applied to the column 
before 1 minute spin at 10,000rpm. Pure RNA was quantified using nano-drop system 
(see Section 2.7.2) and was used for cDNA synthesis (see Section 2.12.2).  
 
2.12.2. cDNA Synthesis Reaction 
RNA isolated from cells (see Section 2.12.1) was used as a template for cDNA 
synthesis using qPCR BIO cDNA synthesis kit (PCR BIOSYSTEMS). Mastermix for 
the reaction was prepared according to manufacturer protocol and comprised of 
reagents indicated in Table 2.4. 
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Table 2.4. Components of cDNA synthesis reaction mix  
Reagent 20μl reaction 
5c cDNA synthesis mix 4.0μl 
20x RTase 1.0μl 
Sample RNA (1μg) xμl 
PCR grade H2O Up to 20μl final volume 
 
Total 20μl reaction mix for each sample was incubated at 42°C for 30minutes, 
followed by 10minutes incubation at 85°C. The products were quantified using Nano-
drop system (see Section 2.7.2) and used for qPCR reaction (see Section 2.12.4). 
 
2.12.3 DNA Extraction from Cells  
DNA extraction from MDLC and MDDC was achieved using QIAamp DNA Mini Kit 
(QIAGEN). Accordingly, 200μl of cells suspension (4x105 cells/sample) was added to 
20μl of Proteinase K (provided) and mixed using a pipette. 200μl of Buffer AL was 
added to homogenous sample and pulse-vortexed for 15 seconds. The samples were 
then incubated at 56°C for 10 minutes before addition of 200μl of ethanol (96-100%). 
Pulse-vortexed samples were applied to the QIAamp spin column and centrifuged for 
1 minute at 8000rpm. Then spin column containing DNA was washed with 500μl of 
Buffer AW1 and centrifuged at 8000rpm for 1 minute. 500μl of Buffer AW2 was 
added to spin column and centrifuged at 14,000rpm for 3 minutes. DNA was extracted 
from QIAamp spin column after 1 minute room temperature incubation in Buffer AE 
(200μl) and centrifugation at 8000rpm (1 minute). DNA was quantified using nano-
drop system (see Section 2.7.2) and was used for qPCR (see Section 2.12.4). 
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2.12.4 Quantitative PCR 
Real-time PCR was performed on ViiA7 Real-Time PCR system (ΔΔCt methods) 
using qPCRBio SyGreen Mix Lo-Rox (PCR Biosystems). 
For analysis of IFN- and MX2mRNA products:  
50ng of sample cDNA (section 2.12.2) was used with primers: 
IFN- forward primer 5’-AGCACAGGATGAACTTTGAC-3’, and  
IFN- reverse primer 5’-TGATAGACATTAGCCAGGAG-3’ (Eurofins MWG 
Operon, Germany).  
MX2 forward primer 5'-AAGCAGTATCGAGGCAAGGA-3'  
MX2 reverse primer 5'-TCGTGCTCTGAACAGTTTGG-3' (Eurofins MWG Operon, 
Germany). 
For GFP DNA quantification: 
10ng of sample DNA (section 2.12.3) was used with primers: 
GFP forward primer 5’-aagttcatctgcaccaccg-3’ 
GFP reverse primer 5’- tccttgaagaagatggtgcg-3’  
(Eurofins MWG Operon, Germany). 
PCR was performed in the conditions indicated in Table 2.5.  
Table 2.5. Quantitative PCR settings 
Step Denature PCR 
HOLD 
Cycle (40) 
Denature Anneal/Extend 
Time 20 sec 1 sec 20 sec 
Temp 95°C 95°C 60°C 
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Results of qPCR were analysed using ExpressionSuite Software v1.0.3, and data were 
normalized to β-actin expression (QuantiTect human ACTB2SG primer, QIAGEN) or 
GAPDH expression (Hs_GAPDH_1_SG QuantiTect Prime primer, QIAGEN).  
 
2.13. Statistical Analysis 
Student’s t-tests were used to evaluate the significance of differences between 
experimental groups. p-values <0.05, <0.01 or <0.001 were considered significant and 
marked with *, ** or ***, respectively. NS indicated no significant difference. 
 
2.14. Ethics Statement 
Human skin samples were obtained from female patients undergoing mastectomy or 
breast reduction surgery with informed written patient consent and local ethical 
committee approval (South East Wales Research Ethics Committees Panel C, 
Reference: 08/WSE03/55). 
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3. Immunological Properties of Langerhans Cell Model 
Systems: Cell Lines, Monocyte-derived LC and ex vivo 
Human LC 
3.1 Introduction 
Dendritic cells were first described in 1973 in mice by Steinman and Cohn (Steinman 
and Cohn 1973), who observed “an adherent nucleated cell [population] whose 
morphological features are quite distinct [to granulocytes, lymphocytes and 
mononuclear phagocytes]”. In general, DC are antigen presenting cells (APC) and 
critical immune regulatory cells which are important in innate immunity and 
specialized in stimulating T cells responses as well as in promoting tolerance. 
According to their phenotype, location, function and origin, dendritic cells populating 
the human body are divided into different subsets, which also include Langerhans 
cells (Ziegler-Heitbrock and Hofer 2013).  
For research purposes, model cell lines have been developed to mimic LC and DC 
subsets in laboratory and culture conditions. Some recognized model systems include 
monocyte-derived Langerhans Cells (MDLC) and Dendritic Cells (MDDC), and 
described MUTZ-3 derived cells (Masterson et al. 2002; Santegoets et al. 2006). 
MDLC and MDDC show the closest resemblance to their in vivo counterparts, 
perhaps due to their origin from blood-isolated monocytes. In fact, MDDC used in this 
work express CD1a, HLA-DR, DC-SIGN, and other markers characteristic of some 
tissue-resident myeloid DC. Responses of MDDC to interferon or pathogen were also 
similar to those described in the literature for blood isolated DC.  Although MDLC 
were positive for Langerin and presented an immature phenotype, these cells were 
also expressing significant amounts of DC-SIGN, a notion known already but, in fact, 
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poorly relayed in scientific publications (Turville et al. 2002b; Ganor et al. 2013). This 
could be, however, of particular importance considering that langerin and DC-SIGN 
were reported to have seemingly opposing roles on HIV-1 replication and transfer 
toward target CD4
+
 T cells (Geijtenbeek et al. 2000). Maturation of these cells 
occurred when induced with a specific set of Toll Like Receptors (TLR) agonists and 
correlated with the simultaneous release of pro-inflammatory or tolerogenic cytokines. 
Importantly, MDLC responded to Interferon-α treatment as evidenced by the increase 
of expression of Interferon-inducible restriction factors and to our surprise, Langerin. 
The interferon response was much less pronounced in the MUTZ-3 derived LC 
population, although their phenotype was closely related to LC.  
Furthermore, a successful method for isolation of primary dermal DC and epidermal 
LC from skin samples is detailed in this Chapter. This method allowed isolation of 
antigen presenting cells from the heterogeneous population that also included tissue-
supporting cells, such as keratinocytes. Immune cells consisted of a population of 
dermal DC or epidermal LC, obtained from dermis and epidermis, respectively.   
Thus, in the context of this research, the cell model systems are validated and their 
properties and limitations discussed. 
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3.2 Results  
3.2.1. MUTZ-3 Cell Line Shows Characteristics of Monocytes 
The MUTZ-3 cell line used in my studies was a kind gift from Dr Tania de Gruij 
(Dept. Medical Oncology, VU University Medical Centre, Amsterdam, Holland). 
Flow cytometry analysis demonstrated that this cell line was composed of mixed 
populations of CD14
+
 (mean 41.6%, SEM=15.9) and CD14
- 
(mean 59.4%, 
SEM=15.9) cells (Figure 3.1A and B), similar to published observations (Santegoets 
et al. 2006; de Jong et al. 2010b). Remarkably, MUTZ-3 revealed the trend of higher 
proportions of CD14
+
 cells at lower MUTZ-3 culture densities, suggesting that culture 
conditions may influence the proficiency of MuLC differentiation (data not shown).  
On average 40.5% (SEM=2.72) MUTZ-3 cells stained for HLA-DR, but no 
expression of CD1a was detected (Figure 3.1A and B). Furthermore, the mean 
fluorescent intensity analysis revealed the presence of approximately 200 molecules of 
HLA-DR per cell (MFI=211.6 +/- 17.7) supporting the notion that these cells might be 
differentiated into APC (Figure 3.1. C). Further analysis failed to identify the 
presence of CD83 marker in total MUTZ-3 population, suggesting that this cell line 
remains immature during culture propagation. The undifferentiated state of MUTZ-3 
was also confirmed by the absence of cell lineage specific markers for Langerhans 
cells, Langerin (mean 0.07%), Dendritic cells, DC-SIGN (mean 0.05%, MFI= 
5.79SEM=0.34), Natural killer cells (CD16) (mean 0.5%) and B cells (CD19) (mean 
0.1%) (Figure 3.1). 5.3% (SEM=2.02, MFI=34.2) of MUTZ-3 expressed HIV-1 entry 
receptor, CD4, and 1.2% were positive for HIV-1 co-receptor (CCR5) (Figure 3.1B), 
suggesting that undifferentiated MUTZ-3 could be productive targets of HIV-1 
infection.  
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Figure 3.1. Undifferentiated MUTZ-3 Cell Line Express Only a Few Markers. (A) 
Representative flow cytometry analysis for chosen markers and (B) summarized data (n=5) 
are shown. (C) Mean fluorescent intensity for selected markers is showed (n≥2). Error bars 
represent ±SEM.   
 
Taken together, MUTZ-3 showed a naïve, monocyte-like phenotype profile, with 
predominant and exclusive expression of CD14 and HLA-DR. Similar to monocytes, 
MUTZ-3 cells also have a potential to differentiate into cell types resembling 
Langerhans cells or Dendritic cells, when cultured with the appropriate differentiation 
medium. MUTZ-3 derived LC used in my study are characterized in the following 
section (see Section 3.2.2).   
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3.2.2. MUTZ-3 Derived LC Phenotypically Resemble Langerhans Cells 
Production of MuLC from MUTZ-3 cells is done over 10 days in medium 
supplemented with GM-CSF, TGF-β and TNF-α (see Material and Methods Section 
2.3.3). Once fully differentiated, MuLC almost completely down-regulated expression 
of CD14 (7.5%, SEM=2.146, SD= 4.79) and increased the levels of HLA-DR (80.2%, 
SEM=4.96, SD=8.59) (Figure 3.2A and B). MuLC also became positive for CD1a 
(63.7%, SEM=6.01, SD=13.4) and Langerin (61.687%, SEM=3.144, SD=7.701), and 
stained weakly with anti-DC-SIGN antibody (6.68%, SEM=1.45, SD=3.254) (Figure 
3.2A and B). Thus, differentiated MuLC acquired Langerhans cells phenotype while 
losing monocytic/MUTZ-3 characteristic features. 
Only a small proportion of MuLC (4.63%, SEM=1.879, SD=3.785) underwent 
culture-induced maturation, as demonstrated by the low occurrence of CD83 marker 
(Figure 3.2B), suggesting immature, or semi-matured phenotype of MuLC.  
MuLC derived in our laboratory expressed substantial levels of HIV-1 entry receptor 
CD4, comprising a mean of 60.4% (SEM=5.22) CD4 positive cells (Figure 3.2B). 
MuLC also stained for HIV-1 co-receptors, CCR5 and CXCR4, however at lower 
levels; 3.6% (SEM=1.51, SD=3.38) and 2.3% (SEM=0.485, SD= 1.086), respectively.  
Apart from phenotypic similarity to primary LC, differentiated MuLC also acquire a 
star-like appearance similar to their in vivo counterparts (Figure 3.2C). Additionally, 
previous studies demonstrated occurrence of Birbeck granules in MuLC (Santegoets et 
al. 2006). 
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Figure 3.2. MuLC Phenotype Resembles this of Langerhans Cells. MuLC were isolated 
and stained for surface expression of selected markers. (A)  Representative flow cytometry 
analysis for chosen markers and (B) summarized data (n=5) are shown. (C) Light microscope 
(40x) view on differentiated MuLC, showing extended dendrites protruding from the cells. 
Error bars represent ±SEM.   
 
3.2.3. MDLC are Double Positive for Langerin and DC-SIGN 
In contrast to the high percentage of Langerin
+
 MuLC, around one third (26.8% 
(SEM=5.6)) of monocyte-derived Langerhans cells (MDLC) obtained routinely were 
positive for langerin, as recorded by intracellular staining, and also expressed 
significant amounts of DC-SIGN (53.4%, SEM=6.4) (Figure 3.3A and B). A higher 
amount of Langerin was observed inside MDLC, when analysed with intracellular 
staining, compared to surface staining (Figure 3.3A). Interestingly, CD14 expression 
on MDLC remained relatively high (mean 60.5%, SEM=23.5) after differentiation, 
although CD1a and HLA-DR markers were present on most of the MDLC population 
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(97.2%, SEM=0.7; 69.58% SEM=11.7, respectively) (Figure 3.3B). MDLC derived 
in our lab were immature, comprising 1% (SEM=0.8) CD83
+
 and 2.9% (SEM=1.4) 
CD86
+
 population. Thus, differentiation of MDLC in IL-4, GM-CSF and TGF-β 
cytokine cocktail results in immature phenotype of the cells. Further analysis of 
MDLC evidenced low percentage of CD11c
+
 population (32.7%, SEM=18.9), and 
high number of CD11b (99.3%, SEM=0.3) and e-cadherin (98.6%, SEM=0.5) positive 
cells (Figure 3.3B). MDLC were also analysed for expression of HIV entry 
receptors/co-receptors. The results demonstrated that an average of 15.6% 
(SEM=11.3) of these cells were positive for CD4, 6.8% (SEM=2.6) expressed CCR5, 
and less than 1% stained for CXCR4 (0.9%, SEM=0.2), making them a likely target 
for R5 tropic HIV infection (Figure 3.3C). 
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Figure 3.3. MDLC are Double Positive for Langerin and DC-SIGN. Intracellular and 
surface expression markers were investigated by flow cytometry in fully differentiated 
MDLC. (A) Representative dot plots of Langerin, CD1a and DC-SIGN staining in MDLC are 
shown, and (B) combined data for cells specific markers is illustrated (CD83 n=2, the rest 
n≥3). (C) Graph represents maturation status of MDLC and expression of HIV-1 entry 
receptor and co-receptors (CD4 n=2, the rest n≥3). Error bars represent ±SEM.   
 
 
3.2.4. Phenotype of MDDC Shows Characteristics of Myeloid Dendritic Cells  
Analysis of monocyte-derived Dendritic Cells (MDDC) revealed a phenotype similar 
to that observed from blood isolated myeloid DC. Indeed, MDDC presented high 
expression of CD1a (74.0%, SEM=8.7%), HLA-DR (87.0%, SEM=4.9%), DC-SIGN 
(93.3%, SEM=1.6), and lacked Langerin (mean=4.43%, SEM=3.998) (Figure 3.4A 
and C). Upon differentiation, MDDC showed an immature phenotype (CD83 5.5%, 
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SEM=1.5) and, in contrast to their MDLC counterparts, they almost completely lost 
expression of CD14 (2.8%, SEM=1.6) (Figure 3.4B).  
DC are known to support transmission and replication of HIV-1 during early stages of 
virus acquisition (Cameron et al. 1992; Pope et al. 1994). R5 tropic HIV-1 particles 
are predominantly found in newly infected individuals, most likely due to selection of 
these viruses by the availability of entry co-receptors on mucosal DC. Accordingly, 
substantial expression of main HIV receptor, CD4 (43.2%, SEM=16.9), and low levels 
of CCR5 (3.46%), but no CXCR4 (0.4%) were detected on MDDC (Figure 3.4B and 
C). Therefore, MDDC could be a target for infectious R5-tropic HIV-1. 
 
Figure 3.4. MDDC Resemble the Phenotype of Myeloid DC. MDDC were collected after 
differentiation and were surface stained with a panel of antibodies for phenotypic 
characterization. (A) Mean expression of markers in different donors is represented in graph 
(Langerin n=2, the rest n≥ 3), and (B) (n≥ 3). (C) Example of flow cytometry analysis is 
shown. Error bars represent ±SEM.   
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3.2.5. Cell Walkout Method for Isolation of Skin Immune Cells  
Primary cells were obtained from skin samples from healthy donors undergoing breast 
or abdominal reduction. Cells were collected as described in materials and methods 
(see Section 2.5), and as explained below. The isolation protocol and further 
experiments with primary cells were performed with the help of Matt Ivory (PhD 
student, Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, 
Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, United Kingdom) 
and under supervision of Professor James Birchall. 
 
Figure 3.5. Skin Epidermal LC and Dermal DC Isolation Method. Isolation of epidermal 
LC and dermal DC from healthy donor skin explant was performed as shown in the diagram. 
Removal of fat and excess lower dermis was followed by enzymatic digestion of skin collagen 
with Collagenase and Dispase. After 30 minutes incubation in a shaking water bath, epidermis 
dermis were separated using forceps and cultured separately in RPMI medium for 48 hours. 
Walkout cells were then phenotyped and used for the experiments.  
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Upon patient consent and local ethical committee approval, the skin sample was taken 
to the laboratory within a few hours post operation and processed (Figure 3.5). 
Primary, subcutaneous fat and excess lower dermis were removed by blunt dissection, 
followed by separation of upper layers of the skin with a dermatome. When possible, 
the dermatome was used directly before excision of the skin from the patient. The 
upper layers of skin were incubated in the presence of dispase and collagenase, in 
order to facilitate dissociation of dermis and epidermis. These two layers were then 
separated from each other using forceps, and independently cultured in supplemented 
medium (see Materials and Methods Section 2.5). After 24 hours, Langerhans cells 
migrating from epidermis, and dermal DC leaving dermis were collected and used for 
phenotyping and functional studies. 
 
3.2.6. Skin Isolated Dermal DC Express CD141 Marker 
Total population of dermal sheet walkout cells was phenotypically analyzed to 
identify emigrated antigen presenting cells. Dermal T cells were gated out during 
analysis on the basis of their size/granularity (lower than dDC FSC and SSC values) 
and based on their HLA-DR negative staining.  Dermal DC were detected by selection 
of CD141 positive population within HLA-DR and CD45 positive cells (Figure 
3.6A). On average, 66.7% (SEM=3.8) of total dermal walkout cells were HLA-DR 
and CD45 double positive (Figure 3.6B), of which 20.6% (SEM=6.1) expressed both 
CD11c and CD141 (Figure 3.6C). Dermal DC were previously characterized by 
expression of CD141, CD11c and the presence of substantial amount of CD14 (Chu et 
al. 2012). In agreement, CD14 surface expression was observed on most of CD141
+
 
population (Figure 3.6A).  
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Figure 3.6. Dermal DC Express CD141 and CD14.  Dermal walkout cells (Figure 3.5, 
materials and methods 2.5) were stained with panel of antibodies to distinguish dendritic cells 
population. (A) Total walkout cells were gated on live and single cells, and HLA-DR, CD45 
double positive population was further analysed for expression of CD141 and CD11c. 
Expression of CD14 within populations was investigated. (B) Expression profiles for CD45 
and HLA-DR markers for 3 skin samples are shown  (n=4). (C) Expression of CD11c and 
CD141 within HLA-DR+CD11c+ cells is represented in graph (n=4).  Error bars represent 
±SEM. 
 
Dermal DC were reported to be from myeloid origin, therefore expression of 
monocytic markers on their surface is not surprising. Interestingly, these CD14
+
 
dermal DC have demonstrated the potential to differentiate into Langerhans cells in 
the presence of TGF-β (Klechevsky et al. 2008) thus may represent progenitors for 
inflammatory LC. 
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A large proportion of HLA-DR
+ 
CD45
+
 cells included CD141
-
 CD11c
+
 positive cells 
(63.83%, SEM=3.7) (Figure 3.6B). These cells may represent undifferentiated dermal 
DC or cells that have lost their CD141 expression during migration from tissue 
sample. In fact, monocyte-derived dermal DC in vitro (Chu et al. 2012) stain highly 
for CD141 after differentiation, but lose expression of this marker within short time 
span of experiment (data not shown). Alternatively, CD141
-
 population may represent 
different subsets of antigen presenting cells within this tissue. 
 
3.2.7. Epidermal Langerhans Cells Constitute only a Small Fraction of Epidermis 
in the Skin Walkout System 
Phenotypic profiling of epidermis walkout cells identified a minor population of 
HLA-DR and CD1a double positive cells (Figure 3.7A). Proportions of these HLA-
DR
+
CD1a
+
 cells varied from 3.94% to 6.26% (mean=4.85%, SEM=0.7) between 
donors (Figure 3.7B). The majority of HLA-DR
+
 CD1a
+
 cells were langerin
+
 (mean= 
81.6%, SEM=1) and the variability between donors was low (Figure 3.7A and C). 
Two conclusions can be drawn from these results: 1) Langerhans cells exist at low 
density in epidermis, and 2) Langerhans cells represent the major professional antigen 
presenting cells in the epidermis. Keratinocytes and some epidermal cells most likely 
accounted for the remaining HLA-DR and CD1a double negative cells (Figure 3.7B). 
Further information provided by Matt Ivory suggests that walkout LC were semi-
matured as they evidenced expression of some maturation markers such as CD83 or 
CD86. 
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Figure 3.7. Epidermal Langerhans Cells Constitute Small Fraction of Epidermal 
Walkout Cells, but Express High Levels of Langerin and CD1a. Epidermis walkout cells 
(see Figure 3.5, Material and Methods 2.5) were fixed and stained with panel of antibodies for 
determining Langerhans cells population. (A) Total walkout cells were gated on live and 
single cells, and HLA-DR, CD1a double positive population was further analysed for 
expression of Langerin. (B) Proportion of total CD1a HLA-DR double positive and double 
negative populations for 3 skin samples (n=2), and a fraction of Langerin positive and 
negative cells within CD1a+HLA-DR+ population (n=2) are shown. Error bars represent 
±SEM.  
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3.2.8. Interferon alpha Up-regulates Expression of Restriction Factors in MDLC 
and MDDC, but not in MuLC  
Interferon (IFN), particularly type I, is released from virally infected cells and induces 
an anti-viral state in surrounding cells. A wide array of immune defence genes, 
including restriction factors, such as APOBEC family members, BST-2/tetherin and 
myxovirus resistance members (MX1 and MX2) (Pavlovic et al. 1990; Haller and 
Kochs 2011; Goujon et al. 2013) are all induced by type-I IFN. Consequently, 
expression of those cellular factors, concomitantly with other defence mechanisms, 
interferes with viruses’ replication and transmission.  
To further characterize my cell models, the response of MuLC, MDLC and MDDC to 
type-I IFN-α treatment was investigated. Cells were pre-treated for 24 hours with 
1000U/ml of IFN-α, and restriction factors expression was investigated by western 
blot (Figure 3.8). Relative quantification of proteins was performed by IMAGE J and 
normalized to the same actin value between cells for comparison.  
The results showed a significant level of SAMHD-1 protein expression in MDDC 
(16847.2) and MDLC (14956.28) that was almost unchanged in response to IFN-α 
(MDDC=13958.58; MDLC=19785.3) (Figure 3.8A). Correspondingly, SAMHD-1 
expression in MDDC seemed to insignificantly decrease after IFN-α stimulation, 
while a moderate increase was noted in MDLC. Steady state MDDC and MDLC, both 
expressed a minor amount of APOBEC3G and BST-2/Tetherin (APOBEC3G: MDDC 
4515.57, MDLC 3609.79; BST-2/tetherin: MDDC 10629.5; MDLC 15463.42) (Figure 
3.8A). However, in contrast to SAMHD-1, the level of expression of these restriction 
factors was strongly up-regulated upon IFN-α treatment in both cell types, although 
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the increase of APOBEC3G expression in MDLC (1.39 fold increase) was much 
lower compared to MDDC (6.29 fold increase).  
IFN-inducible RIG-I protein served as a positive control for our experiments, and its 
expression was significantly up-regulated after IFN-α challenge in MDDC 
(ns=7451.642, +IFN=30385.32) and MDLC (ns=4661.21, +IFN= 8225.6) (Figure 
3.8A). Actin detection served as a loading control and was used for normalization 
purposes.  
Western blot analysis of differentiated, untreated MuLC showed constitutively high 
expression of BST-2/tetherin (40468.91), which was not drastically changed in 
response to IFN-α (45557.07) (Figure 3.8B). High expression of BST-2/Tetherin on 
MuLC was unexpected and may be a characteristic acquisition for these cells during 
differentiation. Also, cell activation with TNF-α, present in the differentiation 
medium, might contribute to this phenotype, although this hypothesis was not tested.  
MuLC exposed to IFN-α also showed an increase in APOBEC3F expression (5628) 
compared to non-stimulated cells (2166). Although western blot representation 
inferred only an apparent marginal enhancement of this protein, IMAGE J analysis 
revealed 2.59 fold increase in APOBEC3F between untreated and treated MuLC 
(Figure 3.8B and C). Although expression of this restriction factor was slightly 
induced in MuLC upon IFN-α treatment, all tested interferon-stimulated genes (ISG) 
did not evidence any signal, like MX2 and positive control RIG-I whose expression 
were not up-regulated (Figure 3.8B and C). In fact, higher levels of RIG-I 
constitutive expression (13880.74) were observed in unstimulated MuLC, compared 
to MDLC (see above), and were unchanged upon IFN-α treatment (12104.73). In 
comparison, activated MDLC showed higher levels of all investigated ISG products, 
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namely MX2, APOBEC3F, BST-2/tetherin and RIG-I (Figure 3.8B). Again, 
SAMHD-1 levels were not, or only slightly increased after treatment in both MDLC 
and MDDC. 
From this data, it is possible to conclude that both MDDC and MDLC are fully 
responsive to type-I IFN treatments as evidenced by the significant increase in 
expression of many ISG, therefore supporting that these cells could be highly effective 
during an antiviral immune response. In contrast, the cell line model MuLC, although 
being phenotypically and morphologically related to LC, are seemingly impaired in 
their capacity to respond to IFN-as evidenced by the lack of increased expression of 
ISG such as RIG-I, BST-2/Tetherin or MX2. However, these cells presented elevated 
expression levels of RIG, BST-2/Tetherin, even when unstimulated. This would 
nevertheless correlate with the observation that MuLC could be semi-matured maybe 
due to the presence of the pro-inflammatory cytokine TNF- in the differentiation 
medium.  
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Figure 3.8. IFN-α Induces Expression of Restriction Factors in MDDC, MDLC, but not 
MuLC. MDDC, MDLC and MuLC were treated with IFN-α for 24 hours, and total lysates 
was analysed by Western blot for expression of restriction factors. MDDC and MDLC 
respond to IFN by up regulating IFN-inducible restriction factors, APOBEC3G and BST-
2/tetherin, but not SAMHD-1. IMAGE J quantification was performed on all samples and 
normalized to actin. (A) Relative values are shown. (B) MuLC failed to respond to IFN, 
compared to MDLC, and showed constant high expression of BST-2/Tetherin. Relative 
quantification of bands was performed with IMAGE J and normalized to the same actin level 
in all samples. (C) Representation of quantified levels are demonstrated. RIG-I served as a 
positive control for IFN response. Actin was a loading control. 
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3.2.9. Langerin is a New Type I Interferon Inducible Factor in MDLC 
In addition to the above IFN-α-induced changes in cells, stimulated MDLC also 
showed a notable and significant enhancement of surface (mean 32.4%, SEM=6.12, 
p=0.01), and intracellular (mean 60.5%, SEM=5.6, p=0.019) levels of Langerin 
(Figure 3.9A and B). In steady-state MDLC, the percentage of intracellular Langerin 
was considerably higher compared to surface expression of this lectin, as expected. 
However, the fold increase of surface langerin expression on IFN-α treated MDLC 
was equal to 6.5 (SEM= 2.02) and was greater than that observed inside the cell (mean 
3.5 fold, SEM=1.5) (Figure 3.9C).  
Further experiments demonstrated that enhanced langerin expression was most 
apparent and significant in response to type-I interferons, that is IFN-α2a (p=0.006), 
IFN-α2b (p=0.02) and IFN-β1a (p=0.02) (Figure 3.10A and B). The effect of IFN-
β1b on Langerin was also evident (almost a 100% increase), but remained just above 
statistical significance (p=0.074) for the number of experiments performed. Type-II 
interferon treatment (IFN-γ), in contrast, did not induce any significant effect as 
langerin expression remained similar to untreated MDLC (mean langerin = 12.6%, 
SEM=1.64) (p=0.48). Thus the above results suggest that Langerin is a type I 
interferon inducible gene and it might account to the defence mechanism in the 
mucosa. Verification of the results with freshly isolated epidermal LC would have to 
be undertaken to confirm this phenomena.   
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Figure 3.9. Interferon-α Stimulates Surface and Intracellular Expression of Langerin in 
MDLC. MDLC were treated for 24 hours with 1000U/ml of IFN-α, fixed and stained for 
langerin. (A) A representative experiment showing surface and intracellular levels of langerin 
in unstimulated cells (MDLC) and in IFN-α treated cells (MDLC + 1000U/ml IFN-α) is 
shown in, and (B) pooled data is represented in graph  (n=3). (C) The fold increase of surface 
and intracellular langerin is shown in graph (n=3). MDLC indicate non treated cells. Error 
bars represent ±SEM. * p ≤ 0.05.  
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Figure 3.10. Intracellular Langerin Expression in MDLC Treated with Type-I or Type-
II IFN. MDLC were treated for 24 hours with 1000U/ml of different IFNs, fixed and stained 
intracellularly for langerin. (A) Flow cytometry analysis of representative experiment is 
shown in. (B) Pooled data for langerin positive MDLC is represented in graph (n=4). Error 
bars represent ±SEM. * p ≤ 0.05, ** ≤ 0.01. 
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3.2.10. MuLC Fail to Significantly Up-regulate Langerin after IFN-α Stimulation  
Consistent with the viral restriction factors expression analysis reported above, MuLC 
did not significantly respond to IFN-α treatment in terms of langerin levels (Figure 
3.11A and B). Indeed, the slight 5.25% increased expression of total langerin 
expression observed was not significant (p=0.22).  
Although langerin levels on MuLC in these experiments were lower compared to 
above results, MuLC usually express high levels of langerin which again correlates 
with a possible increased semi-matured status of these cells. Also, as a cell line, 
Langerin levels and responsiveness could be significantly influenced by the duration 
of MUTZ-3 cell line maintenance in culture. This would likely affect the 
differentiation efficiency of MUTZ-3 into MuLC.  
 
Figure 3.11. IFN-α Does Not Induce Significant Increase of Langerin in MuLC. MuLC 
were treated for 24 hours with 1000U/ml of IFN-α, fixed and stained intracellularly for 
langerin. (A) Flow cytometry analysis of representative experiment is shown in. (B) Pooled 
data for MuLC stimulation is represented in graph (n=2). Error bars represent ±SEM.  
Therefore, the results demonstrate that IFN-α triggers up-regulation of restriction 
factor expression in MDLC and MDDC. In contrast, stimulated MuLC remained 
unresponsive to IFN type-I treatments suggesting a defect of these cells in integrating 
IFN type-I-mediated signalling. In fact impaired IRF8 and STAT responses were 
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described in MUTZ-3 cell line derived DC confirming perturbation of immune 
responses in this model (Rasaiyaah et al. 2009). Thus, despite phenotypical resembles 
of MuLC to epidermal LC, the immortalized biology of MUTZ-3 poses significant 
limitations to the range of studies these cells could be used for.  
 
3.2.11. Responses of MDLC to TLR Agonists are Limited 
Finally, responses of MDLC and MDDC to microbial components were investigated. 
For that reason, MDLC and MDDC were treated with agonists to TLR 1–TLR 9 (see 
Materials and Methods Section 2.9.3 and Appendix 1 (p.241)) and the levels of 
cytokines produced and expression of maturation markers were measured by flow 
cytometry after 24 or 48 hours, respectively.  
The results showed a significant stimulation of MDLC with TLR2 (peptidoglycan) 
(p=0.02), TLR4 (LPS) (p=0.002), TLR6 (FSL1) (p=0.005) and TLR8 (ssRNA) 
(p=0.01) agonists, a weaker response upon TLR1 (Pam3CSK4), TLR3 (poly I:C) and 
TLR5 (flagellin) stimulation and no response at all when TLR7 (Imiquimod) or TLR9 
(E.coli ssDNA) agonists were used (Figure 3.12A). A previous report claimed that 
MDLC coming into contact with peptidoglycan released mainly the supposed anti-
inflammatory cytokine IL-10 (Flacher et al. 2006). Indeed, after TLR2 
(peptidoglycan) agonist stimulation 28.2% (SEM=7.3) of in vitro MDLC stained 
positive in FITC channel which included anti-IL-10 and anti-TNF-α antibodies. Closer 
analysis showed that an average of 15.4% (SEM=5.2) of MDLC produced TNF-α in 
response to TLR-2 (peptidoglycan) challenge (Figure 3.12.B), and 62.2% (SEM=5.9, 
p=0.012) expressed CD86. Less noticeable maturation of MDLC was observed after 
challenge with TLR-6 agonist, FSL1. Typically, 33.9% (SEM=0.45, p=0.0017) of 
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these cells expressed CD86 (Figure 3.12C), and 28.6% (SEM=5.0) produced TNF-
α/IL-10. In agreement, a study by Rose and colleagues (Rose et al. 2009) 
demonstrated that vaginal application of FSL-1, in mice, triggers significant 
production of pro-inflammatory cytokines, including TNF-α.  
Surprisingly, the addition of LPS (TLR4 agonist) to MDLC triggered production of 
IL-10/TNF-α (25.3%, SEM=3.4%, compared to 1.2% NT, p=0.002) (Figure 3.12A). 
It was an unexpected result as previous research claimed the lack of TLR-4 transcripts 
in primary LC (Flacher et al. 2006). Addition of TLR8 agonist (ssRNA) to MDLC 
resulted in a 59.5% (SEM=4.05, p=0.0048) increase in CD86 expression and 
functional activation of these cells (Figure 3.12C and D). Production of TNF-α from 
ssRNA stimulated MDLC was at the base level (0.347%, SEM=0.09, p=0.87), 
suggesting that IL-10 might be a major cytokine expressed upon TLR8 agonist 
challenge in MDLC (48.5%, SEM=10.4%, p=0.01).  
Viral mimicking TLR3 agonist, poly I:C, induced little production of cytokines 
(12.6%, SEM=4.5, p=0.06) (Figure 3.12A), and pronounced increase of CD86 
expression (mean CD86=50.1%, SEM=39.1) (Figure 3.12C). Perhaps other cytokines 
are released in MDLC in response to TLR3 stimulation, although the efficiency and 
cytokine profile reported appeared quite controversial particularly when considering 
the origin of LC (CD34
+
 or monocyte-derived)(Flacher et al. 2006; Renn et al. 2006; 
Rozis et al. 2008). According to the literature, type-I interferons would be prospective 
candidates, as they are readily produced in viral infections. However, as demonstrated 
in Chapter 4, poly I:C does not trigger a major production of IFN in MDLC (see 
Chapter 4 Figure 4.13), and in agreement with previous reports shows that LC are not 
type-I IFN producer cells. TLR3-mediated activation of LC was, nevertheless, shown 
to produce some inflammatory cytokines (IL-6, IL-8, TNF-…) (Flacher et al. 2006) 
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and interestingly, IFN-inducible chemokines, such as CXCL9 and CXCL11, therefore 
suggesting a role for LC in IFN- mediated antiviral responses (Renn et al. 2006).  
Challenge of MDLC with TLR1 and TLR5 agonists (Pam3CSK4 and flagellin, 
respectively) caused partial maturation of cells (mean CD86, TLR1=12.0%, 
TLR5=14.9%), which appeared statistically significant in the case of TLR5 
stimulation (p=0.02). Release of cytokines from Pam3CSK4-treated MDLC was 
moderate (mean=16.29, SEM=7) and not significant (p=0.097). On the other hand, 
little IL-10/TNF-α production was recorded for the TLR5 agonist, Flagellin 
(mean=3.32, SEM=1.14), despite an apparent maturation of the cells (Figure 3.12).  
Further analysis demonstrated that neither Imiquimod (TLR7 agonist), nor E.coli 
DNA (TLR9 agonist) induced activation of MDLC (IL-10/TNF-α production: 
mean=1.0%, SEM=0.29, p=0.6; mean=1.69, SEM=0.15, p=0.07, respectively) 
(Figure 3.12A, C and D). Maturation of MDLC, measured by CD86 expression, was 
also low in both conditions (Figure 3.12C and D), suggesting unresponsiveness of 
MDLC to these TLR agonists which is reminiscent of results obtained with MDDC. 
Of note, LC were described as lacking mRNA encoding for TLR7 and TLR9 
(Kadowaki et al. 2001), which would explain the above results.  
Thus, the data shows a limited and specific TLR response profile of MDLC. While 
some of the results match those described in the literature, some inconsistencies were 
evident. Although the in vitro-derived LC progenitors should be considered (CD34
+
 
versus monocytes), nevertheless, only a limited array of cytokines and maturation 
markers in the presented experiments have been analysed, compared to other studies.  
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Figure 3.12. MDLC Mature and Become Activated after TLR Stimulation. MDLC were 
treated with TLR agonists (see Appendix 1) for 24h in the presence of brefeldin A (BfA) for 
cytokine production analysis, and for 48h for monitoring of maturation. Following the 
treatment, cells were fixed and stained, and production of TNF-α and IL10 and expression of 
CD86 and HLA-DR was measured by flow cytometry. (A)Pooled data for TNF-α/IL-10 and 
(B) TNF-α only release are shown in graphs (n=3). (C) Up-regulation of CD86 in MDLC is 
presented in graph (n=3). (D) A representative stimulation of MDLC for selected TLR agonist 
treatment is shown. NT indicates non treated cells. Error bars represent ±SEM. * p ≤ 0.05, ** 
≤ 0.01. 
 
 
 
 
 
 
 
 115 | P a g e  
 
3.2.12. MDDC Recognise Wide Range of Pathogen Molecules Through Toll-like 
Receptor Activation 
Similarly to MDLC, MDDC did not respond to TLR7 (Imiquimod) (mean=1.76%, 
SEM=0.6, p=0.78) and TLR9 (E.coli ssDNA) (mean=1.58%, SEM=0.4, p=0.9) 
challenge as measured by TNF-α/IL-10 production (Figure 3.13A and B). The TLR 
repertoire of MDDC does not include TLR7, and these cells are found unresponsive to 
Imiquimod (Cunningham et al. 2013).  
In contrast, only a minor increase in cytokine release was observed in MDDC after 
stimulation with flagellin (TLR5 agonist) (mean=9.25%, SEM=5.5, p=0.23). 
Although weakly, TLR5 agonist activated MDDC, suggesting the presence of this 
PRR in the cells. Contradictory information is being published about the TLR range in 
different dendritic cell subsets. Most notably, cells differentiated from monocytes may 
differ between laboratories, likewise experimental settings and readouts. Nevertheless, 
a consensus, supporting a role for TLR5 in MDDC, is emerging from the literature 
and is in line with my results.  
The addition of Pam3CSK4 (TLR1 agonist) into MDDC culture did not generate a 
significant response, although the mean percentage of TNF-α/IL-10 positive cells was 
high (mean=37.6%, SEM=13.9, p=0.053). Variations in TLR1 expression and 
responses from MDDC derived from different donors may explain the standard 
deviation. Nevertheless, these results tend toward a functional presence and activation 
of TLR1, which could also contribute to the production of different molecules once 
engaged. Indeed, TLR1 mRNA was detected in MDDC (Rozis et al. 2008) and 
agonists for TLR1 (Pam3CSK4) (and TLR5 – Flagellin) demonstrated robust 
production of IL-23 (Deifl et al. 2014), a cytokine not considered in my profiling. 
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Therefore, it is apparent that different PAMPs trigger various cytokine release profiles 
in MDDC and a wide array of cytokine production upon TLR stimulation would be 
necessary to conclude on the exact functionality for each TLR. 
Figure 3.13. MDDC Respond to Selective TLRs Agonists’ Repertoire.  MDDC were 
stimulated with TLR agonists for 24h in the presence of brefeldin A (BfA). Following the 
treatment, cells were fixed and stained, and production of TNF-α and IL10 was measured by 
flow cytometry. (A) A representative stimulation of MDDC for selected TLR agonist 
treatment is shown. (B) Pooled data for MDDC in represented in graph (n=3). NT indicates 
non treated cells. Error bars represent ±SEM. * p ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001. 
Furthermore, a significant stimulation of MDDC with TLR2 agonist peptidoglycan 
(mean=40.3%, SEM=3.9, p=0.0006), TLR4 agonist LPS (mean=70.5%, SEM=6.0, 
p=0.0003) and TLR8 agonist ssRNA (mean=41.6%, SEM=4.4, p=0.0009) were 
recorded, supporting the notion that MDDC are readily prone to highly respond to 
these components. Although at a lower level, viral-mimicking compound, poly I:C 
also significantly activated MDDC (p=0.0026). On average, 19.4% (SEM=2.6) of 
cells stained positive for TNF-α/IL-10 after 24 hours stimulation with poly I:C 
(Figure 3.13B). As demonstrated in the following Chapter 4, poly I:C also prompted 
type-I interferon production in MDDC. 
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The aim of the above study was to investigate responsiveness of MDLC and MDDC 
to TLR agonists. TNF-α/IL-10 are the cytokines usually released during the pathogen 
infection therefore these were used in the above profiling. The ability of my model 
systems to respond to TLR agonists will be further employed in Chapter 4 in the 
context of HIV-1 and co-infections.  
 
3.3. Discussion 
The complex system of skin immunology provides both tolerance and inflammatory 
responses, and involves several subsets of DC and Langerhans cells. Although an 
efficient method for isolation of these cells from skin samples was developed, the 
obtained skin layers often present mixed populations of epidermal or dermal antigen 
presenting cells in addition to keratinocytes (Chu et al. 2012). Accordingly, antigen-
presenting cells obtained from the epidermal and dermal walkout represented the 
minority of the cells among heterogeneous populations in our settings. Low density of 
DC and, in particular, LC in skin samples requires usage of high number of walkout 
cells in order to obtain a good quantity of Langerin
+
 cells and CD141
+ 
population. 
Additionally, depending on the nature of the experiment, an immune-based isolation 
of LC, such as MACS CD1a-beads, might be required in order to avoid contamination 
of results with residual keratinocytes or epithelial cells (de Jong et al. 2010a). Despite 
low numbers, immune walkout cells presented a typical and expected phenotype, 
including the presence of CD14, CD141 and CD11c markers on dermal DC, and 
langerin and CD1a on epidermal LC. The validity of this system is further confirmed 
by other studies demonstrating immunological functions of these cells, such as antigen 
processing and presentation, up-regulation of MHC class I and II in the presence of 
maturation stimuli, and T cell stimulation (Peña-Cruz et al. 2001; Chu et al. 2012). 
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However, the semi-matured status of primary skin isolated immune cells, possibly 
obtained during skin processing, was observed here (data not shown) and by others 
(Chu et al. 2012). LC are known to spontaneously mature in the steady-state epidermis 
and migrate to the lymph nodes (Kel et al. 2010; Bobr et al. 2012). Similarly, CD141
+
 
dermal DC take part in elimination of auto-reactive T lymphocytes via the process of 
homeostatic maturation (Probst et al. 2003; Waithman et al. 2007). Although LC 
migrating from steady state tissue increase expression of CD86, those cells display no 
stimulatory capacities, and lead to induction of tolerance and prevention of 
hypersensitivity development (Kaplan et al. 2005; Cumberbatch et al. 2006; Bobr et 
al. 2010). Thus, the semi-matured phenotype of walkout cells might be a natural 
behaviour of these cells. Importantly, matured DC show different susceptibility to 
HIV-1 infection, and the virus itself can block full maturation of these cells to prevent 
immune activation. Thus, matured status of primary LC and DC requires 
consideration when analysing the results, especially in the context of HIV-1 infection.  
Although results obtained in primary cells are desirable, working with these cells is 
problematic, time consuming and often provides variable results. It does not come as a 
surprise then that laboratory models for these cells have been developed (Romani et 
al. 1994; Sallusto and Lanzavecchia 1994). Monocyte-derived cells, mimicking 
dendritic cells and Langerhans cells phenotypes and functions, have definitely become 
the most reliable and invaluable tools used in related research. In fact, MDDC 
partially solved the problems related to isolation of blood DC from patient samples, 
and skin explants, although inherent fluctuations in variability of the results could still 
occur due to the primary nature of these cells. MDDC are widely accepted as a 
relevant in vitro DC model, quite similar to some blood or dermal DC-SIGN
+
 subsets 
and used for equivalent studies. The results presented above confirm that MDDC 
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display the phenotype observed in some DC subsets, including expression of CD1a, 
HLA-DR and DC-SIGN. Absence of CD14 in MDDC distinguish these cells from 
inflammatory DC, a monocyte-derived DC subset differentiating at the site of 
inflammation (Hespel and Moser 2012; Mildner and Jung 2014). On the other hand, 
the majority of MDLC stain positive for this molecule, possibly suggesting their 
relationship to short-lived LC. Short-lived LC derive in vivo from monocytes that 
repopulate epidermis during infection and tissue inflammation (Romani et al. 2012; 
Seré et al. 2012). Both, MDLC and inflammatory LC originate from monocytes, 
express low levels of Langerin and survive for a relatively short time, in contrast to 
steady-state LC (Merad et al. 2002; Kanitakis et al. 2011; Seré et al. 2012). However, 
MDLC are immature in our settings, while inflammatory LC would be expected to 
have an activated phenotype due to their localization in inflamed tissues. Importantly, 
MDLC expressed higher levels of DC-SIGN than Langerin, which could skew the 
interpretation of HIV-1 entry in these cells, as both lectins were reported to have the 
opposite role in this respect (Geijtenbeek et al. 2000; Kwon et al. 2002; de Witte et al. 
2007; van den Berg et al. 2014). The reverse DC-SIGN/Langerin ratio was observed in 
MuLC. MuLC are derived from an acute myelomonocytic leukemia cell line, MUTZ-
3, and were used in this work. Langerin was expressed well by MuLC and was 
accompanied by a high expression of CD1a. According to the literature, MuLC were 
found to be semi-matured, although I recorded low levels of CD83 expression in these 
cells. Although the phenotyping of MuLC was limited, levels of expression of other 
common maturation markers, such as CD80 or CD86, might indeed be higher and 
therefore lead to an underestimation of matured cells in this study. In fact, MuLC are 
derived in the presence of TNF-α, and this cytokine triggers maturation of cultured 
MDDC. Depending on the maturation trigger, activated cells respond differently to 
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HIV infection, which could be translated into higher or lower virus replication. Some 
pro-inflammatory stimuli, like TNF-α, were previously described to increase HIV-1 
productive infection of LC (de Jong et al. 2008; Ogawa et al. 2009). In agreement, 
MuLC have higher susceptibility to HIV-1 infection, when compared to immature 
MDLC, yet the total infection remained significantly lower than in MDDC (see 
Chapter 4). All together, the interpretation of results obtained with MuLC should take 
into account an activation status of these cells and their potential consequences on the 
experimental data. 
Several technical challenges are associated with primary cells work. Firstly, 
acquisition of skin or blood samples involves setting of reliable and tested sources. 
Even if these conditions are met, the quality of sample can vary from donor to donor 
providing insufficient numbers or unsatisfactory quality of the cells. Genetic 
variability between primary cells samples additionally results in variation with the 
results. Although these donor specific differences reflect the situation normally 
occurring in the population, it can significantly prolong the number of experiments 
required to obtain statistically significant results. Limited life-span and non-
proliferative properties of terminally differentiated MDLC additionally add on to the 
limitations of these systems. MuLC obtained from MUTZ-3 monocytic cell line were 
described before (Masterson et al. 2002; Santegoets et al. 2006; de Jong et al. 2010b) 
and were employed in this study for a reliable comparison across available LC 
models. Infections studies with these cells uncovered some limitation in these models 
including limited IFN response (Rasaiyaah et al. 2009) and activated state upon full 
differentiation (see Chapter 3), which could make them unsuitable for some 
experiments (see Chapter 4). 
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Importantly for this research, all investigated cell models including MUTZ-3, 
expressed HIV-1 entry receptor CD4, and co-receptor CCR5, at variable levels. Yet, a 
recent study challenged the presence of CCR5 in MuLC (Nasr et al. 2014), although 
these cells were reported to be susceptible to productive HIV-1 infection (de Jong et 
al. 2010a). The levels of HIV-1 infection of MDDC, MDLC and MuLC remain low, 
suggesting post-entry restriction mechanisms operating in these cells (Pion et al. 2006; 
Coleman and Wu 2009; Hrecka et al. 2011; Laguette et al. 2011)(see Chapter 4). 
Similarly, research on blood monocytes demonstrated that these cells are not 
permissive to HIV-1 infection in vitro (Filion et al. 1990; Sonza et al. 1996; Naif et al. 
1998), suggesting the same profile in monocytic cell line, MUTZ-3.  
Functional analysis of MuLC showed fundamental alteration of their immune 
responses, including lack of response to type-I interferon and consequently failure to 
up-regulate antiviral cellular factors such as MX2 and RIG I. It is plausible that an 
“activation priming” of these cells occurs during differentiation and therefore 
influences their responsiveness toward a second inflammatory “recall”. Indeed, the 
modulation of gene expression upon type-I IFN in myeloid cells, previously treated 
with TNF-, was recently reported to be different compared to untreated cells, with a 
significant decrease in expression of genes related to immune responses, cell 
migration and proliferation (Henig et al. 2013). Previous studies described the 
impaired expression of genes encoding immune sensing and signalling in MUTZ-3 
derived cells (Rasaiyaah et al. 2009). Among other genes such as STAT family 
members, interferon regulatory factor 8 (IRF8) was down regulated at the mRNA and 
protein levels, possibly affecting regulation of interferon inducible genes (Rasaiyaah 
et al. 2009). In such cases, the observed irresponsiveness of MuLC to IFN-α 
stimulation could be a consequence of disturbed type-I interferon signalling in these 
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cells. Another IRF transcription factor, IRF9, also locates downstream from the 
Interferon Receptor (Platanias 2005) and its function might explain the observed up-
regulation of APOBEC3F expression in MuLC. While the lack of expression or 
functionality of IFN receptor(s) or IFN signalling proteins cannot be excluded, it is 
conceivable that MuLC have reached a saturating activated state upon differentiation 
that would therefore dampen a subsequent re-stimulation. 
In contrast, interferon stimulation of MDLC and MDDC resulted in up-regulation of 
all investigated Interferon-inducible proteins, however, a marked difference was seen 
in the amount of APOBEC3G expression upon IFN-α challenge of MDLC and 
MDDC. Both MDLC and MDDC derive from monocytes isolated from the same 
donor, and differ only in the growing conditions by the presence of TGF-β in the 
medium of MDLC. TGF-β was reported to exert a strong immunosuppressive effect 
on immune cells (Letterio and Roberts 1998; Kobie et al. 2003; Li et al. 2006b), which 
may facilitate the progression of HIV-1 infection in patients (Card et al. 2012).  It 
shapes the function and phenotype of LC (Letterio and Roberts 1998; Li et al. 2006b) 
and was also demonstrated to decrease the ability of DC to mature in response to TLR 
agonists (Sewankambo et al. 1997). Perhaps, due to these properties, TGF-β also 
exerts a direct or indirect negative effect on APOBEC3G expression in MDLC. 
However, this theory requires verification.   
Unexpectedly, Langerin was identified as a type-I, not type-II, interferon inducible 
molecule, suggesting an antiviral role for this receptor. IFN-α/β and IFN-γ share some 
common signalling components and induce similar genes. Nonetheless, they also 
differ in several aspects, including binding receptor, promoter and in the nature of the 
immune responses they induce and contribute to (Goodbourn et al. 2000). Therefore, 
modulation of Langerin may be dependent on type-I Interferon induced signalling, but 
 123 | P a g e  
 
irresponsive, or weakly responsive, to type-II Interferon stimulation. It would be 
interesting to see whether other pro-inflammatory signals trigger similar induction of 
Langerin in these and other myeloid cells. The possible increase in total Langerin 
during inflammation might imply a role of this molecule as yet another IFN-inducible 
defence mechanism in the mucosal area. This aspect is novel, as Langerin has never 
been classified as an interferon-stimulated gene. Nevertheless, Langerin was already 
known for its ability to bind pathogens and target them toward Birbeck granules, 
specific LC structures thought to participate in the degradation of internalized foreign 
entities (de Witte et al. 2007). Thus, a more pronounced Langerin expression observed 
on MDLC cell surface could be of importance regarding viral infection and 
inflammation. Such a mechanism would reinforce the binding of microbes to this C-
type lectin receptor and their consequent degradation. Accordingly, short lived LC 
populating the epidermis during inflammation express higher amount of Langerin 
(Romani et al. 2012; Seré et al. 2012). Thus, the ability to up-regulate Langerin could 
be an adaptation of Langerhans cells acquired during infection. Intracellular Langerin 
possibly serves as a recycling source or contributes to formation of Birbeck granules. 
Further investigation of this phenomenon would be interesting to decipher the role of 
this CLR in infection and inflammation. 
Other TGF-β-dependent differences distinguishing MDLC from MDDC were 
reflected in TLR profiles, as well as HIV-1 infection susceptibility (see Chapter 4). 
Regarding TLR agonist responses, both MDLC and MDDC displayed TLR-induced 
activation similar to those described in the literature (Flacher et al. 2006), but slightly 
different to their in vivo counterparts (Kadowaki et al. 2001; Zarember and Godowski 
2002). The main inconsistencies between MDLC and primary LC were observed in 
their response to TLR4 agonist lipopolysaccharide (LPS). Skin and mucosal LC are 
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thought to lack TLR4 receptor in their repertoire, due to constant exposure of these 
cells to commensal bacteria. In contrast, a significant production of pro-inflammatory 
cytokines from MDLC upon TLR4 engagement was observed in this work. TLRs can 
form heterodimers and extend their repertoire and responses (Triantafilou and 
Triantafilou 2002; Zarember and Godowski 2002). In the case of LPS, several clusters 
of receptors are involved in sensing and signalling. One of the potent LPS binding 
molecules is CD14 (Wright et al. 1990), which forms activation clusters with other 
components, usually including TLR4. However, recognition of Leptospira interrogans 
in macrophages is independent of TLR4 expression, but instead requires CD14 and 
TLR2 (Werts et al. 2001). Perhaps similarly, CD14-dependent mechanisms of LPS 
recognition operate in MDLC, as these cells express high amounts of this molecule. 
Whether sensing is TLR4-dependent, and involves TLR2 or other receptors, was not 
investigated further.  
MDLC stimulated with TLR8 agonist, ssRNA, led to predominant IL-10 production, 
suggesting a tolerogenic response to this molecule. However, simultaneous up-
regulation of CD86 on these MDLC might indicate concomitant maturation and 
stimulatory properties of these cells. According to the literature, LC-induced tolerance 
occurs despite up-regulation of co-stimulatory molecules CD86 and CD80, and is 
consistent with the failure to translocate NF-B family member RelB from the 
cytoplasm to the nucleus (Shklovskaya et al. 2011). Based on this information and the 
above results, it seems that TLR8 stimulation of Langerhans cells might result in 
tolerogenic functions of these cells. Data available on TLR8 in MDLC are 
contradictory in terms of expression of this receptor, therefore interpretation of this 
result should be supported by a TLR8 mRNA expression profile.   
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Interestingly, neither MDLC nor MDDC were activated after challenge with E.coli 
ssDNA, which could have perhaps resulted from problems with agonist stock, or its 
dose used in our research. Other TLR9 agonists, such as CpG-A ODN D19 might 
have been a better choice as it has been previously reported to activate MDDC (Hoene 
et al. 2006). Intracellular localization of TLR9 might also make it challenging to 
successfully deliver the agonist, therefore could be responsible for observed lack of 
activation in MDDC and MDLC. The reports on TLR9 expression in some primary 
DC subsets and LC are contradictory, but most indicate absence of this PRR in these 
cells. Therefore, the results might indicate a normal response observed in cells.   
MDDC mimicked their primary counterparts in all, but one, response to TLR agonists. 
Accordingly, flagellin stimulation of MDDC induced cytokine release from these 
cells, which is generally not observed in dendritic cells. However, the cytokine release 
in MDDC in response to TLR5 agonist was low, suggesting that MDDC may express 
only low levels of this PRR.  
The above results demonstrate that MDDC provide a reliable model for DC in context 
of their phenotype, TLR responses, and Interferon induced up-regulation of viral 
restriction factors. On the other hand, MDLC have to be used with greater caution due 
to their conflicting C-type lectin receptor phenotype (expressing both DC-SIGN and 
Langerin), and a different TLR repertoire. Interferon responses of these cells seem to 
be unaffected and match those expected from primary LC. The opposite situation 
applies to MuLC, for which the phenotype is like the one observed in skin LC, but 
Interferon responses are distorted. Thus, depending on the nature and requirements of 
the study, MuLC or MDLC may be a preferable system. Primary cells isolated from 
tissue samples still provide a great tool, however due to difficulties related to their 
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acquisition, these cells are mostly used to confirm the findings acquired in cell 
models, MuLC or MDLC.  
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4. TGF-β Induces HIV-1 Restriction in MDLC 
4.1. Introduction 
Due to their mucosal distribution, Langerhans cells (LC) are likely early cellular 
targets for HIV-1 during sexual transmission (Kawamura et al. 2005; Hladik et al. 
2007; Piguet and Steinman 2007). In common with other myeloid dendritic cell (DC) 
subsets, LC do not readily support virus infection. However, LC are also potential 
carriers promoting HIV-1 transfer to susceptible CD4+ T cells (Niedecken et al. 1987; 
Miller and Shattock 2003). Low HIV-1 infection of LC was previously attributed to 
the presence of Langerin (a LC-specific C-type lectin receptor), which forms a 
protective barrier against the virus (Kawamura et al. 2000; de Witte et al. 2007). 
Indeed, Langerin expressed on LC surface efficiently binds incoming viral particles 
leading to their internalisation and degradation in LC lysosomal compartments called 
Birbeck granules. Other DC subsets restrict HIV-1 infection due to the presence of 
cellular restriction factors, such as SAMHD1 (Berger et al. 2011a; Hrecka et al. 2011; 
Laguette et al. 2011), APOBEC3G (Pion et al. 2006), Bst-2/tetherin (Neil et al. 2008) 
and the Interferon-inducible MX2 protein (Goujon et al. 2013; Kane et al. 2013). 
SAMHD1 was shown to be highly expressed in cells of myeloid origin, as well as in 
quiescent CD4
+
 T cells, in which it mediates depletion of the cellular deoxynucleoside 
triphosphate (dNTP) pool, leading to a drastic impediment to HIV-1 reverse 
transcription (Goldstone et al. 2011; Lahouassa et al. 2012). Additionally, SAMHD1 
imposes an antiviral activity independent of its effect on deoxynucleotide levels but by 
direct binding and cleavage of HIV-1 ssRNA (Beloglazova et al. 2013; Reinhard et al. 
2014; Ryoo et al. 2014). The primate lentivirus auxiliary protein (Vpx), which is 
expressed in HIV-2 and some SIV viral genomes, triggers degradation of SAMHD1 
and consequently rescues viral infection in resistant myeloid cells and quiescent T 
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cells (Hrecka et al. 2011; Laguette et al. 2011; Descours et al. 2012). Therefore, the 
absence of a Vpx gene in the HIV-1 genome makes SAMHD1 a major restriction to 
HIV-1 in myeloid cell lineages (Berger et al. 2011a) but it also prevents efficient viral 
sensing in these cells (Manel et al. 2010). The only cellular restriction described so far 
in LC involves Langerin, which induces viral degradation after capture and 
internalization of incoming virions (de Witte et al. 2007), although particularly 
functional at low viral doses (de Jong et al. 2008). Little is known about post-entry 
restrictions to HIV-1 in LC. Previous work indicates that high viral titres of HIV-1 can 
lead to productive LC infection, despite the presence of Langerin, and consequently, 
increased HIV-1 transmission to T cells (Collins et al. 2000; de Witte et al. 2007; de 
Jong et al. 2008; Kawamura et al. 2008). Importantly, de novo HIV-1 production in 
LC is also reported in cells that are matured in response to sexually transmitted 
infections (STIs), in particular gram-positive bacteria (de Jong et al. 2008; Ogawa et 
al. 2009; Ogawa et al. 2013) or herpes simplex virus (HSV) (Ogawa et al. 2013). STIs 
are strongly associated with increased risk of HIV-1 acquisition (Sewankambo et al. 
1997; Galvin and Cohen 2004; Peretti et al. 2005), and LC susceptibility to HIV-1 
infection might play a role in the context of co-infections. Productive HIV-1 infection 
of LC also promotes viral transfer to CD4
+
 T cells (Kawamura et al. 2000; de Jong et 
al. 2008; Ogawa et al. 2009; Ganor et al. 2013). Therefore understanding the balance 
between cellular restrictions and viral dissemination by LC may be central to better 
understand the early events of HIV-1 infection, especially during co-infection with 
other bacterial or viral pathogens.  
 
 
 
 129 | P a g e  
 
4.2. Results  
4.2.1. SIV3-Vpx-mediated Degradation of SAMHD1 Uncovers a 
Novel HIV-1 Restriction Mechanism in Immature Langerhans Cells 
To explore the role of SAMHD1 in LC I used two well-established cell models of LC: 
monocyte-derived Langerhans cells (MDLC) and Mutz-3-derived Langerhans cells 
(MuLC) (Masterson et al. 2002; Santegoets et al. 2006; de Jong et al. 2010a) (see 
Chapter 3). Both models were previously reported to be relevant to analyze 
interactions between LC and HIV-1, and both display significant phenotypic and 
functional similarities to skin-resident Langerhans cells, as verified by us (see Chapter 
3) and others (Geissmann et al. 1998; Ginhoux et al. 2006). First, I demonstrated that 
MuLC, and autologous MDLC and MDDC express the SAMHD1 protein. Of note, 
expression in MDDC was slightly more abundant than in LC, as quantified by ImageJ 
(Figure 4.1A and B). I then confirmed that SAMHD1 expression was down-regulated 
in MuLC and MDLC after transduction with Vpx-expressing SIV-derived lentivectors 
(SIV3-Vpx), to a similar extent compared to MDDC (Figure 4.1A and B) for which 
Vpx-mediated SAMHD-1 degradation was previously described (Miyagi et al. 2009; 
Hrecka et al. 2011; Laguette et al. 2011). Indeed densitometry quantification on 
western-blotting experiments showed that the SAMHD1 signal was down-regulated 
on average by 87.6% (SD=12, SEM=8.5) in MDDC, 94.6% (SD=2.2, SEM=1.9) in 
MDLC and 94.6% (SD=2.7 SEM=1.55) in MuLC (Figure 4.1B). Vpx-mediated 
SAMHD1 degradation in DC and LC was highly reproducible and very rapid, as 
shown by the down-regulation of expression already observed 30 minutes after 
transduction with Vpx-expressing SIV-derived lentivectors and almost complete 
degradation after 3h (Figure 4.1C). In addition, SAMHD-1 was absent from MDLC 
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and MDDC even after 6 days post transduction with SIV3-Vpx, suggesting a long-
lasting down-regulation of this restriction factor in cells (Figure 4.1D). Therefore, the 
system of SAMHD-1 degradation used in my study was effective, reproducible, time-
dependent and long lasting. SAMHD-1 down modulation was achieved in all cell 
systems at the comparable level proving the reliability of this method. To assure the 
consistent performance, SIV3-Vpx stocks were rigorously calibrated throughout its 
storage with satisfactory outcome. Accordingly, the efficiency of SIV3-Vpx to down 
regulate SAMHD-1 in MDLC and MDDC was tested every few weeks in these cells 
by western blot (see Materials and Methods, Section 2.8.5). For that reason, 
SAMHD-1 western blot controls were not run with each individual experiment. 
Although the outcomes were reproducible between donors, I cannot exclude 
incomplete degradation of SAMHD-1 in some untested samples.  
Apart from Vpx, SIV Vpr protein is packed to the SIV3-VLP particles during stock 
production and it is therefore delivered to target cells (see Introduction, Section 1.2). 
Although Vpr is not known to have an effect on SAMHD-1 in the cells, this accessory 
protein is a potent modulator of immune biology (see Introduction, Section 1.2). 
Thus, the presence of Vpr in the SIV3-Vpx could have some unwanted effects on the 
experimental system, such as increasing the viral infection of cells and dampening of 
cell immune activation (Ayyavoo et al. 2002; Majumder et al. 2005; Kogan et al. 
2013; Harman et al. 2015). Therefore, the potential impact of the Vpr on my 
experimental outcomes will be considered in this Chapter. 
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Figure 4.1. Effective Vpx-mediated Degradation of SAMHD-1 in Different Myeloid 
Cellular Models.  MDDC, MDLC and MuLC were treated with Vpx-expressing SIV-derived 
lentivectors for 4 hours, unless stated otherwise on the figure, followed by cell lysis and 
western blot analysis of SAMHD-1 expression. (A) A representative experiment and (B) 
pooled data  for SAMHD-1 down-regulation are shown (n=3). (C) Lysates of MDLC treated 
with Vpx-expressing SIV-derived lentivectors for 30min, 1.5hour, 3hours and 24hours were 
analysed by western blot, and the results are shown. (D) Similarly, MDLC and MDDC treated 
as above for 3 and 6 days were analysed for SAMHD-1 expression. In all experiments actin 
served as a loading control. Quantification of SAMHD-1 was performed by densitometry 
analysis using IMAGEJ software, and was normalized to actin levels. Error bars represent 
±SEM.  
Although comparable Vpx-mediated degradation of SAMHD1 was evident in both 
MDDC and MDLC (Figure 4.1B), I noticed a significantly lower HIV-1 (R5) 
infection of MDLC (5.9%, SD=3.2%, SEM=1.84) compared to MDDC (55.5%, 
SD=11.9, SEM=6.84) (Figure 4.2A (a representative experiment) and B (pooled 
data)). SIV3-Vpx delivery into MDDC caused a 9.3 fold enhancement of HIV-1 
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infection (SEM=1.0) compared to non-transduced cells similar to the effect observed 
in other studies (Hrecka et al. 2011; Laguette et al. 2011). In contrast, MDLC remain 
in part refractory to HIV-1 infection, even in the absence of SAMHD-1 as 
demonstrated by the average 5.5 fold increase (SEM=3.3) of gag positive MDLC 
(Figure 4.2C) when compared to the 9.3 fold increased observed in MDDC. 
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Figure 4.2. SAMHD-1-Independent Restriction Activity in HIV-1-R5 Infected MDLC. 
Autologous MDLC and MDDC were infected with full length HIV-1 (R5) (strain R8Bal at 
25ng p24/10
5
 cells), both with (HIV+SIV3-Vpx) and without (HIV) pre-treatment for 4 hours 
with VSV-G pseudotyped Vpx-encoding SIV3 lentivector (SIV3-Vpx), or left uninfected 
(NI). Four days later, cells were fixed, washed, stained with anti-HIV-1-Gag and infection 
levels were measured by flow cytometry. (A) A representative experiment and (B) 
quantification of pooled data for MDLC and MDDC are shown (n=3). (C) Fold increase of 
HIV-1 infection in MDLC and MDDC in the presence of SIV3-Vpx is showed in graph 
(n=3). The statistical significance of the results was calculated using student t-test and 
significant values indicated (*) as described in Materials and Methods. NS= insignificant. 
Error bars represent ±SEM.  
The same resistance to HIV-1 infection was observed when using the MuLC cell line, 
with only 6% (SEM=0.866) of cells infected in the presence of SIV3-Vpx (Figure 
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4.3A and B). In contrast, an average 66% (SEM=8.079) of MDDC stained positive 
for HIV-1 p24 gag-FITC (Figure 4.3B). Interestingly, while infected MDDC appear 
as a separate population on flow cytometry analysis, Gag
+
 MuLC do not present a 
clearly distinguished infected population suggesting that gag expression is also low at 
the cell level or that gag staining in case of MuLC infection is a result of 
pseudotransduction and not a productive infection (Figure 4.3A) (and see Figure 4.7).  
Low percentage (0.2-0.3%) of uninfected MuLC and MDDC stained positive for gag 
despite the lack of HIV-1 in experimental conditions. These obvious false positive 
populations may represent autofluorescent cells or cells that uptake KC57 gag 
antibody. Due to use of primary cells that often form complex population in terms of 
side and forward scatter (SSC and FSC, respectively) minimal background staining 
and GFP expression appear in the non infected populations. Possibly, a stricter gating 
strategy could be applied when necessary. However, the drawback of a stricter gating 
could be a significant loss of detection of truly infected population. For that reason, 
the cut off point was set as close to the main population as it allows for the accurate 
measurement of infection. I assessed that my gating strategy has no significant impact 
on the patterns of infection observed in the experiments, and it provides the optimal 
balance between low background and accurate detection of Gag/GFP positive 
populations.  
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Figure 4.3.  Non-premissiveness of MuLC to HIV-1 Infection.  MuLC and MDDC were 
infected with full length HIV-1 (R5) (strain R8Bal at 25ng p24/10
5
 cells), both with (HIV+ 
SIV3-Vpx) or without (HIV) pre-treatment for 4 hours with VSV-G pseudotyped Vpx-
encoding SIV3 lentivector (SIV3-Vpx), or left uninfected (NI). Four days later cells were 
fixed, washed, stained with anti-HIV-1-Gag and infection levels were measured by flow 
cytometry. (A) A representative experiment and (B) quantification of pooled data for MuLC 
and MDDC are shown (n=3). The statistical significance of the results was calculated using 
student t-test and significant values indicated (*) as described in Materials and Methods. Error 
bars represent ±SEM.  
In order to verify MDDC as an appropriate infection control used alongside MDLC 
and MuLC I infected MDDC and a Vitamin D induced monocyte-derived dermal DC 
model (CD141
+
 DC) (see Materials and Methods Section 2.3.4) with full length 
HIV-1 in the presence or absence of SIV3-Vpx. I observed similar constitutive and 
Vpx-mediated down-regulation levels of SAMHD-1 expression in both cell types after 
24 hours (Figure 4.4A). Although the control for SAMHD-1 expression at 6 days 
time point has not been performed for this specific experiment, the results 
demonstrated in Figure 4.1.D show successful SIV3-Vpx mediated SAMHD-1 
depletion in MDDC up to at least 6 days. 
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Flow cytometry analysis of Gag
+
 cells revealed a significantly higher HIV-1 infection 
of CD141
+
 DC compared to MDDC (p=0.0387) 4 days post infection when SAMHD1 
expression was previously shut-down (Figure 4.4B). However, at day 6, the average 
infection of CD141
+
 DC in the absence of SAMHD-1 reached 73.8% (SEM=9.82) and 
was comparable to that observed in MDDC (75.1%, SEM=11.88) (Figure 4.4C). Of 
note, I could observe a significant HIV-1 infection in MDDC occurring at day 6, even 
when expressing SAMHD-1 (p24 Gag
+
 MDDC= 36.0%, SEM=12.6), but still 
susceptible to AZT inhibition (p24 Gag
+
 MDDC= 0.07%, SEM=0.032). All together, 
these data demonstrate similar high predisposition of both, MDDC and CD141+ DC 
to HIV-1 infection in the absence of SAMHD-1. 
Based on these results I confirmed that MDDC could therefore represent a relevant 
dendritic cell model for our studies of HIV-1 infection, particularly when considering 
mucosal DC subsets.  
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Figure 4.4. HIV-1 Infection is Comparable between MDDC and CD141
+
 Dendritic cells. 
Homologous MDDC and CD141
+
 cells were treated or not with SIV3-Vpx for 4 hours and 
infected with 25ng p24 HIV-1 (R8Bal). AZT [1µM] was added to indicated wells 1 hour prior 
to addition of HIV-1. (A) SAMHD-1 down-regulation in treated cells was analysed by 
western-blotting after 16 hours post SIV3-Vpx addition. The levels of p24 in cells at days 4 
and 6 post infection were measured. (B) A representative FACS analysis is shown. (C) Pooled 
data for days 4 and (D) 6 are shown in (n≥5) and (n≥3), respectively. NI indicates non-
infected cells, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Error bars represent ±SEM.   
The HIV-1 envelope glycoprotein was shown to bind Langerin, which has been 
previously reported to protect LC from HIV-1 infection by capturing incoming virions 
and targeting them for degradation in Birbeck granules (de Witte et al. 2007). 
Moreover the efficiency of viral entry into LC could be affected by differential 
expression of cell surface HIV receptors/co-receptors (CD4 and CCR5) compared to 
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other viral target cells. Therefore in order to evaluate if HIV-1 restriction occurred at 
the entry or post-entry level I transduced MDDC and MDLC with Vesicular 
Stomatitis Virus G protein (VSV-G)-pseudotyped HIV-1 lentiviral vectors encoding 
green fluorescent protein (GFP) (VSV-G HIV-GFP) (Dull et al. 1998). Vesicular 
Stomatitis Virus binds to low density lipoprotein receptor (LDLR) and fuses with the 
cell membrane only after pH change in lysosomes (Sun et al. 2005; Johannsdottir et al. 
2009; Cureton et al. 2010; Finkelshtein et al. 2013). Therefore, VSV-G pseudotyped 
lentivector would overcome entry receptor limitations imposed normally on HIV-1 
envelope and ensure effective and comparable entry into MDLC, MDDC and MuLC. 
The entry efficiency of VSV-G pseudotyped constructs is validated in this study by 
almost complete down regulation of SAMHD-1 in cells treated with VSV-G 
pseudotyped SIV3-Vpx (see Figure 4.1). 
Both MDDC and MDLC infected with VSV-G HIV-GFP demonstrated low 
transduction efficiency (Figure 4.5A and B). Surprisingly when these cells were 
previously transduced with Vpx-expressing SIV-derived lentivectors, only MDDC 
were strongly and significantly infected with VSV-G HIV-GFP (Figure 4.5B), 
reminiscent of the productive infection observed with full length HIV-1 R5 (see 
Figure 4.2). Indeed after down-regulation of SAMHD1 expression I observed that 
53.8% (SD=22.1, SEM =9.874, MFI=2292) of MDDC were expressing GFP 
compared to only 5.9% (SD=1.6, SEM=0.816, MFI=628) of MDLC (Figure 4.5B). 
Addition of SIV3-Vpx to MDDC prior to infection with VSV-G HIV-GFP, triggered 
72.6 fold (SEM=12.1, SD=34.25) increase percentage of GFP+ cells (p=0.0001), 
while susceptibility of MDLC increased by 16.4 fold (SEM=5.6, SD=15.0) 
(p=0.0187) (Figure 4.5C). As mentioned above, poor permissiveness of MDLC to 
VSV-G envelope can be ruled out as a reason for the observed discrepancies in 
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MDLC and MDDC susceptibility to infection with VSV-G HIV-GFP. This statement 
is based on the ability of VSV-G pseudotyped SIV3-Vpx to down modulate SAMHD-
1 levels to comparable extend in both cell types. Additionally, as these cells originate 
from the same precursors, the LDLR composition of the cell membrane would not be 
expected to vary, thus making VSV-G HIV-GFP entry comparable in both MDLC and 
MDDC. However, as VSV-G HIV-GFP fuses with endosomal membrane, it bypasses 
most of the cytoplasm. This can differentially affect interaction of lentiviral capsid 
with cytoplasmic proteins in MDLC and MDDC, possibly resulting in different 
kinetics of the infection.  
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Figure 4.5. MDLC Infection with VSV-G HIV-GFP Lentivirus. Autologous MDLC and 
MDDC were transduced (or not) with VSV-G pseudotyped Vpx encoding SIV3 lentivector 
(SIV3-Vpx) prior to challenge with VSV-G HIV-GFP (VSV-G HIV-GFP) (30ng p24/10
5
 
cells) and the percentage of GFP positive cells was analyzed by flow cytometry after 3 days. 
(A) A representative experiment and (B) quantification of pooled data for MDLC and MDDC 
are shown (n=7). (C) Fold increase of HIV-1 infection in MDLC and MDDC in the presence 
of SIV3-Vpx is shown (n=7). The statistical significance of the data was calculated using 
student t-test and significant values indicated (*) as described in Materials and Methods. Error 
bars represent ±SEM. 
 
This low infection pattern of MDLC was further confirmed using MuLC, which were 
only 2.2 fold (SD=1.31, SEM=0.655) more sensitive to VSV-G HIV-GFP when 
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SAMHD1 expression was down regulated (p=0.1545) (Figure 4.6A). In contrast, in 
the presence of SIV3-Vpx, susceptibility of MDDC to infection increased 55 fold 
(SD=25.512, SEM=12.756) (p=0.0241). This profile was reflected in significantly 
higher infection of MDDC compared to MuLC (p=0.011). On average 63% (SD=25.1, 
SEM=12.593) of MDDC became GFP positive after VSV-G HIV-GFP + SIV3-Vpx 
challenge, however MDDC remained refractory to transduction in the presence of 
SAMHD-1 (Figure 4.6B (representative experiment) and C (pooled data)). When 
compared to MDDC, MuLC appeared less permissive to VSV-G HIV-GFP if pre-
treated with SIV3-Vpx (mean=17.1%, SD=3.517, SEM=1.758), yet small percentage 
of MuLC (8.6%, SD=2.344, SEM= 1.172) seemed to support lentivirus transduction 
even when SAMHD-1 remained in the cells.  
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Figure 4.6. Low VSV-G HIV-GFP Infection of SAMHD-1 Depleted MuLC. MuLC and 
MDDC were transduced (or not) with VSV-G pseudotyped Vpx encoding SIV3 lentivector 
(SIV3-Vpx) prior to challenge with VSV-G HIV-GFP (VSV-G HIV-GFP) (30ng p24/10
5
 
cells) and the percentage of GFP positive cells was analyzed by flow cytometry. (A) Fold 
increase of HIV-1 infection in MuLC and MDDC in the presence of Vpx is showed in graph 
(n=7). (B) A representative experiment and (C) quantification of pooled data for MuLC and 
MDDC are shown (n=7). The statistical significance of the results was calculated using 
student t-test and significant values indicated (*) as described in Materials and Methods. Error 
bars represent ±SEM. 
 
Further analysis of VSV-G HIV-GFP transduced MDDC, previously treated with 
Vpx-encoding lentivectors, revealed a significant effect of Zidovudine (AZT) on the 
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GFP expression in MDDC (p<0.01), which was, however, absent in MuLC (p=0.859) 
(Figure 4.7. A and B (representative FACS plot)). Indeed GFP expression in AZT 
pre-treated MuLC decreased from 12.8% to 12.45% only (SEM=1.69% and 1.06, 
n=4) compared to inhibition of 50.1% GFP positive MDDC (SEM==6.01%, n=3). In 
contrast, AZT pre-treatment of MDLC successfully stalled lentivector infection from 
4.4% (SEM=0. n=1) to 0.2% (SEM=0, n=1) in these cells (Figure 4.7. A and B). The 
lack of AZT effect on GFP expression in MuLC was unexpected since this 
pharmacological compound used in the clinics is a potent HIV-1 reverse transcriptase 
inhibitor. Although I have not gone into the details of such phenotype, a possible 
explanation could be that MuLC derived from tumour cell line harbour higher levels 
of nucleotides in their cytoplasm that renders AZT weakly efficient. Alternatively, 
infection “positive” cells could represent a passive transfer of GFP that may be 
present in the producer cells (HEK293T) supernatant (Nash and Lever 2004).  This 
process termed pseudotransduction can especially influence the readout of infection at 
early time points of the experiments. However, passively transferred GFP does not 
amplify and is degraded within a few days (Nash and Lever 2004). Therefore, 
infection readout at later time points of experiment indicate newly synthesised GFP 
protein and is unlikely “contaminated” by pseudotransduced molecules. However, this 
does not explain why GFP levels are increased in SIV3-Vpx pre-treated MuLC (see 
Figure 4.6) and why they remain insensitive to AZT treatment even after 3 days of 
infection.  
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Figure 4.7. AZT Inhibits Virus Infection in MDDC and MDLC but not MuLC. MuLC, 
MDLC and MDDC were pre-treated with VSV-G pseudotyped Vpx encoding SIV3 
lentivector (SIV3-Vpx) and AZT [1μM] (where indicated) for 3 hours before being 
transduction with VSV-G HIV-GFP (30ng of p24). After 3 days of infection, cells were 
collected and analyzed by FACS for GFP expression. (A) AZT-mediated inhibition of GFP 
expression in MDDC (p=0.0049) (n=3), MDLC (n=1) but not MuLC is shown (n=4). (B) 
Representative FACS plot for VSV-G HIV-GFP + SIV3-Vpx infection of MDDC, MDLC and 
MuLC in the absence and presence of AZT treatment is shown. Error bars represent ±SEM. 
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Interestingly, even in the absence of SAMHD1 viral restriction in MDLC could not be 
overcome with increasing doses of VSV-G HIV-GFP (Figure 4.8A). At high virus 
dose (100ng p24) MDLC infection remained below 12% (SD=9.291, SEM=4.155), 
while MDDC were on average 35.8% (SD=17.151, SEM=7.67) GFP positive 
(p=0.024) (Figure 4.8B). Furthermore a high inoculation dose of HIV-1 was not 
enough to pass restriction within MDLC, which even in the presence of SIV3-Vpx 
reached only 3.95% infection (SEM=1.59). In the same conditions, 33.1% (SEM=4.9) 
of MDDC became positive for GFP. However, the results suggest that the dose of 
100ng HIV-1 p24 is possibly toxic for cells, as a drop in infection of MDDC and 
MDLC could be observed at this dose (Figure 4.8C). Together these results highlight 
that SAMHD-1-independent post-entry restriction to HIV-1 in MDLC cannot be 
overcome by increasing dose of viral input. 
Interestingly, titration of viral infections in both MDDC and MDLC was quite poor. 
Doubling of viral dose resulted in less than 10% increase of GFP positive MDDC 
(Figure 4.8.B). This effect was more pronounced in HIV-1 infected MDDC 
(approximately 15% increase), possibly because in contrast to VSV-G HIV-GFP, 
HIV-1 is a replication competent virus and can spread in the cell culture. Perhaps, 
titration effect would be more evident at lower inoculums of p24 (0.1-25ng p24). 
Additionally, low infection of the cells at high doses of virus could result from 
incomplete degradation of SAMHD-1. 
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Figure 4.8. Challenge of MDLC and MDDC with Increasing Dose of VSV-G HIV-GFP. 
Autologous MDLC and MDDC were pre-treated with VSV-G pseudotyped Vpx encoding 
SIV3 lentivector (SIV3-Vpx) for 3 hours before challenge with various dose of VSV-G HIV-
GFP or R5 HIV-1. (A) A representative flow cytometry analysis for VSV-G HIV-GFP and 
(B) pooled data for 3 donors are showed. (C) Profile of HIV-1 infection of MDDC and 
MDLC is demonstrated in graph (n≥4). The statistical significance of the results was 
calculated using student t-test and significant values indicated (*) as described in Materials 
and Methods. Error bars represent ±SEM. 
In the above experiments, where indicated, SIV3-Vpx was added to cells and the 
susceptibility of MDDC, MDLC and MuLC to infection with wild type HIV-1 or 
VSV-G pseudotyped HIV-GFP construct was investigated. As considered before, in 
addition to Vpx, SIV3-Vpx carries Vpr protein that when present in cells can 
modulate their biology and immune responses to the infection (Ayyavoo et al. 2002; 
Muthumani et al. 2002). One of the functions of Vpr in vivo is enhancement of 
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integrated pro-virus transcription from viral LTR, that is achieved by binding of Vpr 
to LTR and transcription factors (Cohen et al. 1990; Agostini et al. 1996). Similarly, 
high HIV-1 infection of MDDC and CD141+ MDDC was observed in this study 
following addition of SIV3-Vpx (see Figure 4.4). Although SAMHD-1 down 
regulation in myeloid cells was demonstrated to have pronounced effect on cell 
infectability (Hrecka et al. 2011; Laguette et al. 2011; Lahouassa et al. 2012) also 
confirmed in this work, the additional enhancement of infection by SIV3-Vpx derived 
Vpr cannot be excluded unless SIV3-Vpx ΔVpr is used as an additional control. A 
potential effect of Vpr on virus propagation in MDLC and MuLC is more difficult to 
interpret due to low p24 gag readout in these cells. However, lack of HIV-1/VSV-G 
HIV-GFP infection stimulation in these cells after SIV3-Vpx addition suggest that 
despite effective SAMHD-1 down modulation in these cells, neither Vpr or Vpx are 
able to lift additional cellular restriction to HIV-1 present in these cells.  
 
4.2.2. Ex Vivo Infection of Primary Skin Isolated Epidermal LC and 
Dermal DC with VSV-G HIV-GFP 
Importantly, I extended our findings to physiologically more relevant cells by 
comparing infection levels in primary epidermal LC and dermal DC freshly isolated 
from skin (see Materials and Methods, Section 2.5, and Chapter 3 Section 3.2.5). 
Briefly, cells isolated from the dermis or epidermis of freshly excised patient skin 
explants were transduced with VSV-G HIV-GFP with or without pre-treatment with 
Vpx-expressing SIV-derived lentivectors. Using antibodies against characteristic 
lineage markers, I was able to select pure dermal DC and epidermal LC populations 
and evaluate the efficiency of VSV-G HIV-GFP infection in these cell subsets. T cells 
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that constitute a significant proportion of dermis walkout cells were gated out during 
flow cytometry analysis, based on their size and granularity (lower FSC and SCC 
values compared to derma DC) and HLA-DR negative phenotype. 
Western blot analysis of epidermal and dermal walkout cells showed clear but not 
complete down regulation of SAMHD-1 in the cells after SIV3-Vpx treatment 
(Figure 4.9A). This result demonstrates a successful entry of VSV-G pseudotyped 
SIV3-Vpx construct in epidermal LC and dermal DC, suggesting that VSV-G HIV-
GFP lentivirus can also infect these cells. However, based on the efficiency of 
SAMHD-1 degradation, it seems that only a small proportion of target cells are not 
infected by SIV3-Vpx. The presence of keratinocytes and other cells in dermis and 
epidermis walkout populations could limit the effect of SIV3-Vpx and VSV-G HIV-
GFP as VSV-G pseudotyped particles can bind and enter keratinocytes. Thus, 
incomplete SAMHD-1 degradation in skin samples could result from limited entry of 
SIV3-Vpx into epidermal LC and dermal DC rather than a defect in SIV3-Vpx 
particles. Infection experiments with VSV-G HIV-GFP demonstrated low infection 
efficiency in both immature dermal DC (2.0%, SD=1.7%) and immature epidermal 
LC (1.9%, SD=1.1). However, SIV3-Vpx-mediated removal of SAMHD1 rendered 
dermal DC significantly more susceptible to infection (16.5% GFP positive cells, 
SD=15.6). In contrast, pre-treatment of LC with Vpx-expressing lentivectors did not 
lead to a significant enhancement of VSV-G HIV-GFP infection (total GFP positive 
LC 4.9%, SD=3.6%) when compared to dermal DC subsets (p=0.037) (Figure 4.9B 
(representative experiment) and C (pooled data)). Quantification confirmed a 
statistically significant difference in infection rates between skin-derived DC subsets 
(11.1 fold increase on average upon VSV-G HIV-GFP infection of dermal DC 
compared to a modest 2.5 fold increase for epidermal LC) (Figure 4.9D). However, 
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remaining low levels of SAMHD-1 present in target cells (Figure 4.9A) or lower entry 
of VSV-G HIV-GFP into epidermal LC due to low numbers of these cells in 
epidermal walkout population (see Chapter 3, Figure 3.7) could mediate this effect. 
 
Figure 4.9. Skin-isolated Epidermal LC Remain Refractory to VSV-G HIV-GFP in the 
Presence of SIV3-Vpx, in Contrast to Dermal DC. Primary ex vivo DC/LC isolated from 
dermal and epidermal skin sheets were infected with VSV-G HIV-GFP (40ng p24/10
5
 cells) 
with (VSV-G HIV-GFP + SIV3-Vpx) or without (VSV-G HIV-GFP) SIV3-Vpx pre-treatment 
and infection levels were measured 3 days post-infection. (A) A representative experiment 
and (B) a quantification of GFP
+
 cells from all donors (n=4) are shown. (C) Data were 
normalised to VSV-G HIV-GFP values in order to eliminate inter-patient variability and to 
show fold-change in infection occurring in the presence of SIV3-Vpx. NI indicates non-
infected cells. Error bars represent ±SEM; * p < 0.05. 
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I have further investigated our results to exclude non-specific infection of skin tissue 
cells. Accordingly the analysis showed that upon infection with VSV-G HIV-GFP, 
GFP
+
 cells were predominantly among the HLA-DR
+
 population of epidermal 
walkout cells (i.e. Langerhans cells (see Figure 3.7)) (Figure 4.10) and among 
CD45/HLA-DR double positive cells acquired from the dermis (Figure 4.11). In 
addition, only marginal levels of GFP expression were recorded in remaining 
epidermal and dermal walkout cells. Thus, our data suggest that lower VSV-G HIV-
GFP infection of epidermal LC, compared to dermal DC, results from block to virus 
infection in these cells rather than by a limited proportion of LC in the epidermal 
walkout population. However, an unproductive entry of VSV-G HIV-GFP into skin 
tissue cells cannot be excluded. 
Taken together our data indicate that SAMHD1 is not a major HIV-1 restriction factor 
in primary epidermal LC, reminiscent of the phenotype obtained with in vitro 
differentiated primary LC and cell lines. However, it is also likely that an additional 
restriction operating in LC plays a dominant role in viral inhibition, therefore making 
it impossible to identify SAMHD-1 function in these cells. This restriction is not 
affected by the function of SIV3-Vpx or SIV3-Vpx derived Vpr, which are both 
delivered to cells in SIV3-Vpx particles. Therefore, our results clearly demonstrate 
that the SAMHD1-independent HIV-1 restriction activity found in in vitro derived 
immature LC is apparently operating at a post-entry level in viable primary LC 
isolated from skin. 
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Figure 4.10. GFP Expression in VSV-G HIV-GFP + SIV3-Vpx Transduced Epidermal 
Walkout Cells is Predominantly Detected in HLA-DR
+
 Cells. The extended analysis of 
skin epidermal walkout cells transduced with VSV-G HIV-GFP (40ng p24/10
5
 cells) + SIV3-
Vpx. HLA-DR negative population (bottom left panel) indicates non-Langerhans cells. 
Bottom right panel shows HLA-DR positive population consisting of Langerhans cells.  Total 
epidermal walkout population (top panel).      
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Figure 4.11. GFP Expression in VSV-G HIV-GFP + SIV3-Vpx Transduced Dermal 
Walkout Cells is Predominantly Detected in CD45
+
/HLA-DR
+
 Cells. The extended 
analysis of skin dermal walkout cells challenged with VSV-G HIV-GFP (40ng p24/10
5
 cells) 
+ SIV3-Vpx. Predominant GFP expression in CD45
+
/HLA-DR
+
 (top right panel) is shown. 
Little infection in non-dermal DC populations is illustrated (bottom panel). Total dermal 
walkout population (central panel).    
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4.2.3. IFN-α Restricts HIV-1 Infection of LC.   
IFN-α is a potent antiviral cytokine which increases expression of several HIV-1 
cellular restriction factors, including BST-2/Tetherin (Van Damme et al. 2008), 
members of the APOBEC3 family (Peng et al. 2006), MX2 (Goujon et al. 2013; Kane 
et al. 2013) and other Interferon stimulated genes (ISG) (Neil and Bieniasz 2009; 
Schoggins et al. 2011; Pillai et al. 2012). IFN-α was shown to induce an antiviral state 
in myeloid cells, thus potently restricting HIV-1 infection. Indeed, I confirmed that 
VSV-G HIV-GFP infection of IFN-α treated MDDC was restricted even after Vpx-
mediated degradation of SAMHD1 (Figure 4.12A). While IFN-α pre-treatment also 
appeared to restrict viral infection in MDLC, the effect was less pronounced, possibly 
due to the dominant pre-existing antiviral state in immature MDLC (Figure 4.12B 
and C). Interestingly, SIV3-Vpx appears to rescue some GFP expression in MDLC 
treated with interferon (Figure 4.12.C) although the total percentage of infected cells 
is much lower compared to MDLC infected in the absence of the interferon treatment. 
Indeed, addition of SIV3-Vpx to MDLC increases VSV-G HIV-GFP infection by 1.7 
fold and this effect is amplified in IFN treated cells where the fold induction is 4.15 
(Figure 4.12.C). As Vpr is also present in SIV3-Vpx particles, it is likely that this 
accessory protein modulates interferon-induced restriction to HIV lentivectors, 
allowing partial rescue of VSV-G HIV-GFP infection. In fact, recently Vpr was 
described to regulate several interferon-stimulated genes in MDDC (Zahoor et al. 
2015), many of which were up-regulated. The result described above was limited to 
one donor in my study and similar pattern was not observed in remaining 2 donors 
(analysis not shown). As the effect did not reach a statistical significance, no further 
investigation was undertaken. 
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In order to control MDLC responsiveness to IFN-α, I analyzed the IFN-α-mediated 
increase in expression of antiviral restriction factors, in particular A3G, BST-
2/tetherin, SAMHD1 and MX2, as well as ISG family members such as retinoic acid 
inducible gene I (RIG-I) (Kato et al. 2005). In line with our previous observations (see 
Chapter 3), I observed no significant differences in expression of these restriction 
factors upon IFN-α treatment of both MDLC and MDDC (Figure 4.12D). 
Accordingly IFN-α could induce expression or up-regulation of BST-2/tetherin, RIG-I 
and A3G in both MDDC and MDLC (Figure 4.12D). The presence of SIV3-Vpx had 
no effect on APOBEC3G protein levels in MDDC and MDLC, despite recent reports 
suggesting Vpr mediated decrease of APOBEC3A mRNA in MDDC (Zahoor et al. 
2015). APOBEC3G is unlikely restriction to VSV-G HIV-GFP due to its main 
restriction activity on de novo produced viruses. As a single round construct, VSV-G 
HIV-GFP is not under pressure from APOBEC3G, although APOBEC3G has been 
described to block a viral reverse transcription in single round assays in primary cells 
such as DC and human CD4+ T cells (Pion et al. 2006; Gillick et al. 2013). 
Interestingly I observed no changes in SAMHD1 expression in both cell types, in 
agreement with recent reports showing that its expression is not modulated upon IFN-
α treatment of DC (St Gelais et al. 2012; Cribier et al. 2013). Recently the MX2 
protein was described to act as an IFN-α-inducible HIV-1 restriction factor in myeloid 
cells (Goujon et al. 2013; Kane et al. 2013). In agreement, Figure 4.8.D shows that 
MX2 is also expressed in MDLC, but only after IFN-α stimulation, and this may 
account for the enhanced IFN-α-mediated HIV-1 restriction activity observed in 
MDLC, although this was not investigated in our study. While MX2 might play a role 
in HIV-1 restriction, it is only expressed after IFN-α treatment (Figure 4.12D) and 
thus, unlikely to act in steady-state immature LC. Human Vpr protein was recently 
 155 | P a g e  
 
described to increase MX2 levels in Vpr transduced MDDC (Zahoor et al. 2015). I 
have not observed any significant changes in MX2 levels in MDDC in the presence of 
SIV3-Vpx, but it appeared to down modulate the levels of MX2 in interferon treated 
MDLC.  The measurement of proteins levels based on western blot readout offers only 
semi quantitative evaluation. Additional RT-PCR or more quantitative WB assays 
could be performed in the future to verify any effect of SIV3-Vpx derived Vpr on 
MX2 levels in MDLC.  
As interferon-induced restriction to HIV-1 is manifested usually at early stages of 
virus replication, in depth evaluation of the steps of the reverse transcription process 
in MDLC and MDDC would provide important information regarding interferon 
inducible restriction in these cells. PCR targeting early and late reverse transcription 
products as well as a total number of integrated proviruses could be used to achieve 
this goal.  
Attempts to reproduce these results in a MuLC cell line were not undertaken because 
these cells were seemingly unresponsive to IFN-α (see Chapter 3, Figure 3.8). I have 
previously described the inefficient response of MuLC to type I Interferon in Chapter 
3, and concluded that a lack of IFN-α receptor, or impaired downstream IFN-α 
signalling pathway in these cells may be the cause for the observed phenotype. Taken 
together these results show that MX2 is exclusively expressed in Interferon stimulated 
MDLC, suggesting it may not take part in VSV-G HIV-GFP restriction in these cells. 
However, MX2 expression during cells infection has not been investigated. However, 
clearly, a further enhanced antiviral state in MDLC could be efficiently induced upon 
type-I Interferon treatment on top of the naturally refractory phenotype of these cells.  
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Figure 4.12. IFN-α-mediated Decrease of VSV-G HIV-GFP Infection in MDLC and 
MDDC. MDLC and MDDC were pre-treated with 1000U/ml IFNα for 24 hours followed by 
VSV-G HIV-GFP infection with or without SIV3-Vpx pre-treatment. Pooled data for (A) 
MDLC and (B) MDDC infection in the presence of IFNα is represented in graphs (n=4). (C) 
A representative infection analysis after 4 days is shown for MDLC. (D) Analysis of cellular 
restriction factors expression in MDLC and MDDC after 24 hours IFNα treatment, and SIV3-
Vpx transduction where indicated, was performed by western blot analysis. Actin served as a 
loading control. NI indicates non-infected cells.  Error bars represent ±SEM.    
 
4.2.4. HIV-1 Restriction in LC Does not Require IFN type-I 
Production. 
To further investigate whether VSV-G HIV-GFP restriction in MDLC is dependent on 
type-I Interferon release from infected cells, I transduced MDLC and MDDC with 
VSV-G HIV-GFP with or without addition of SIV3-Vpx. I observed, that at early 
points of infection (6-12 hrs), VSV-G HIV-GFP and Vpx-expressing lentivectors do 
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not significantly stimulate IFNβ mRNA synthesis in MDLC (mean 6 hrs 1.472 and 
mean 12 hrs 4.09) compared to the negative control (Figure 4.13A). The lack of 
stimulation of IFNβ mRNA at early time points of infection (up to 48 hrs) was also 
observed in MDDC (Figure 4.13.A). However, significant increase of IFNβ mRNA 
levels was demonstrated in MDDC at 48 and 72 hours post VSV-G HIV-GFP 
transduction (mean 48 hrs 9.9-fold, 72 hrs 8.1-fold) and at 24 hours onwards in 
MDLC (24 hrs mean 17.72). As viral integration takes place in the first 12 hours of 
infection, the above data suggests limited lentivirus sensing in both cell types prior to 
integration. Addition of poly dA:dT used to stimulate a strong IFN response induced 
272- and 837-fold stronger IFNβ mRNA synthesis in both MDLC and MDDC 
compared to unstimulated cells (p<0.0001) (Figure 4.13.A). In line with IFNβ 
stimulation in infected MDLC and MDDC at later stages of VSV-G HIV-GFP 
(+SIV3-Vpx) infection (48h), both cell types showed partial maturation (Figure 
4.13.B and C), although the effect was more significant in MDDC, when compared to 
MDLC, possibly due to partial maturation of MDDC already before infection. 
Alternatively, lower rates of VSV-G HIV-GFP infection of MDLC may be 
responsible for total lower expression of CD86 compared to MDDC. Thus, our data 
suggest that a pre-existing block to virus infection operates in MDLC and it does not 
require type I IFN stimulation for its action. Accordingly, IFN inducible restriction 
factor MX2 was not up-regulated in MDLC until 24 hours post infection with VSV-G 
HIV-GFP (+SIV3-Vpx) (Figure 4.13.D) in line with our IFNβ stimulation results. 
Late expression of MX2 in MDLC transduced with VSV-G HIV-GFP (+SIV3-Vpx) 
confirms that an early block to lentivirus replication in MDLC is independent of MX2 
and type I IFN function. However, a delayed involvement of sensing mechanisms in 
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MDLC might further contribute to limiting virus propagation at later stages of 
infection (e.g. 48hrs post infection).  
Figure 4.13. Lack of IFN-β Release from MDDC and MDLC after Transduction with 
VSV-G HIV-GFP Lentivector. (A) Homologous MDDC and MDLC were pre-treated or not 
with SIV3-Vpx for 4 hours and infected with 30ng p24 VSV-G HIV-GFP for indicated times 
(0,6,12,24,48 and 72) or were treated with poly dA;dT for 6 hours and IFNβ mRNA levels 
were measured (n=3). (B) Similarly, infected or poly I:C (25μg) treated MDLC and MDDC 
were stained with CD86 and HLA-DR antibody and maturation of the cells was investigated 
after 48 hours (representative experiment) and (C) (pooled data (n=3)). (D) Expression of 
MX2 mRNA in VSV-G HIV-GFP + SIV3-Vpx infected MDLC and MDDC was measured 
after 0,6,12,24,48 and 72 hours (n=3). Poly dA:dT served as a positive control for interferon 
stimulation and MX2 expression. NI indicates non-infected cells.  *p < 0.05, ***p < 0.001, 
**** p < 0.0001. Error bars represent ±SEM.    
In confirmation of these assumptions VSV-G HIV-GFP + SIV3-Vpx infection of 
MDLC induced higher Langerin expression in these cells, similarly to the effect of 
type-I Interferon treatment (see Chapter 3, Figure 3.9) (Figure 4.14A). 
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Figure 4.14. Lack of Langerin Up-regulation in MDLC Transduced with VSV-G HIV-
GFP + SIV3-Vpx. MDDC and MDLC were transduced with 30ng p24 VSV-G HIV-GFP 
(±SIV3-Vpx) for 3 days. Langerin levels on infected MDLC are shown. NI indicates non-
infected cells.  
 
4.2.5. HIV-1 Post-entry Restriction in LC is Partially Abolished by 
TLR-2 Agonists and TNF-α, and Correlates with NF-κβ Pathway 
Activation. 
Previous reports suggested that stimulation of LC with TNF-α or TLR2 agonists 
promoted HIV-1 infection of these cells (de Jong et al. 2008; Ogawa et al. 2009). Such 
observations are particularly relevant in the context of co-infections between HIV-1 
and other STIs, including gram-positive bacteria and HSV-2. The mechanisms of this 
increase in infection of mature LC are not well understood, but may result from a 
reduction of Langerin expression in mature LC (Ogawa et al. 2009). Our study 
therefore aimed at also deciphering if the increased infection of LC observed upon 
bacterial co-infection or TNF-α exposure would correlate with the modulation of a 
post-entry viral restriction activity in LC. The following experiment was performed in 
MDLC and MDDC transduced with SIV3-Vpx prior infection, in order to exclude the 
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role of SAMHD-1 block on HIV-GFP-VSVG infection in a setting mimicking co-
infections.  
I observed an enhancement of VSV-G HIV-GFP infection of LC pre-treated with 
Pam3CSK4 (mean 3.28% or 2.4 fold increase) and TNF-α (mean 7% or 4.1 fold 
increase) (Figure 4.15A and B). Pre-treatment with TNF-α also increased MDDC 
susceptibility to VSV-G HIV-GFP (+SIV3-Vpx) infection by average 11.1% (1.5 
fold) (p=0.095 ns) while Pam3CSK4 had no significant effect (mean 0.2% of 2.3 fold 
decrease) (Figure 4.15C). In contrast VSV-G HIV-GFP transduction of poly I:C 
treated MDDC was 10 fold decreased compared to non-stimulated cells (p=0.022) 
(Figure 4.15A and C). Surprisingly while MDLC were poorly responsive to poly I:C 
in terms of type-I IFN response (see Figure 4.13A), this TLR-3 agonist rendered 
MDLC significantly more restrictive to VSV-G HIV-GFP infection (Figure 4.15A 
and B). However the involvement of Interferon in poly I:C induced inhibition of 
VSV-G HIV-GFP infection in MDLC cannot be excluded as maturation of these cells 
was observed after 48hours treatment (see Figure 4.13).  
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Figure 4.15. TLR Agonists and TNF-α Regulate VSV-G HIV-GFP Infection of MDLC 
and MDDC. MDLC and MDDC were pre-treated with TLR agonists: Pam3CSK4 (5µg/ml) 
(TLR-2), Poly I:C (25µg/ml) (TLR-3) or TNF-α (0.1µg/ml) for 8-16 hours, then transduced 
with SIV3-Vpx for 4 hours and infected with 20ng p24 VSV-G HIV-GFP for 3 days. Cells 
were fixed, washed and GFP expression was analyzed by flow cytometry. (A) A 
representative infection profiles for MDLC and MDDC. (B) A graph representing the 
infection profile for each of donors in MDLC (n=6), and MDDC (C) (n=5) are depicted. The 
horizontal line on graphs represents the mean % of GFP positive cells. NI indicates non-
infected cells. NT indicates non-treated infected cells.   
 
As TLR-2 or TNF-α-treated LC were more susceptible to infection I therefore 
investigated whether expression of known HIV-1 restriction factors could be 
modulated upon treatment with TLR agonists in mature MDLC and MDDC. I 
detected no change in APOBEC3G expression in both cell types. However, SAMHD1 
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expression levels were slightly decreased upon TNF-α treatment in MDLC (Figure 
4.16), which cannot be clearly confirmed in MDDC due to lower protein content in 
TNF-α treated sample. Together these results suggest that LC maturation with TLR-
1/TLR-2 agonists and TNF-α, but not TLR-3 agonists, promotes HIV-1 infection 
independently of SAMHD1, A3G or Langerin expression.  
Figure 4.16. The Effect of TNF-α and TLR Agonist Stimulation on Restriction Factors 
Levels in MDLC and MDDC. Autologous MDDC and MDLC were treated with TLR 
agonists: Pam3CSK4 (5µg/ml) (TLR-2) or TNF-α (0.1µg/ml) for 8-16 hours with or without 
SIV-3 Vpx transduction. Expression of APOBEC3G and SAMHD-1 was analysed by western 
blotting.  
Most of the TLR agonists and pro-inflammatory mediators are known to signal 
through the NF-κβ pathway and I therefore investigated NF-β activation status in 
MDLC and MDDC upon LPS or TNF-ɑ stimulation. I noticed increased levels of the 
active phosphorylated form of NF-β (p-NF-β p65) in MDDC and MDLC after both 
LPS and TNF-ɑ treatments (Figure 4.17). These results correlated with a timely 
decrease of expression of IB-, a major negative NF-β regulator. Of note, 
unstimulated MDLC were evidencing less p-NF-β, compared to MDDC 
counterparts, suggesting that at a resting state MDLC might have a lower background 
activity than MDDC. Although NF-β signalling was efficiently induced in MDLC 
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upon TNF-ɑ stimulation (see Figure 4.17, rescue of VSV-G HIV-GFP infection was 
far from complete, as observed by the remaining low infection level of these cells 
even after SAMHD1 depletion (see Figure 4.15). SIV3-Vpx, that also contains Vpr 
protein, has been used in this experiment to down modulate SAMHD-1 expression in 
the cells prior infection. Multiple conflicting descriptions of Vpr effect on NF-κβ are 
published, some suggesting activation (Varin et al. 2005; Hoshino et al. 2010) others 
inhibition (Ayyavoo et al. 1997; Mariani et al. 2001; Majumder et al. 2005) of this 
pathway. In context of this study, recently published research by Kogan M et al (2013) 
demonstrated that Vpr inhibits NF-κβ signalling induced by TNF-α, but it does not 
have this effect in LPS treated macrophages and U1 cells (Kogan et al. 2013). If that is 
also the case in MDLC and MDDC, the effect on GFP expression in TNF-α treated 
cells may depend on other than NF-κβ signalling pathway induced by this cytokine, 
such as p28 mitogen-activated protein kinases (p38-MAPK) (see Chapter 4 
Discussion). Taken together it is plausible that the partial restoration of VSV-G HIV-
GFP infection in MDLC treated with TNF-α is mediated by increased cellular activity 
of the cells, activation of transcription factors or down modulation of present post-
entry restrictions. 
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Figure 4.17. The Effect of LPS and TNF-α on NF-κβ Signalling Pathway in MDDC and 
MDLC. Autologous MDLC and MDDC were treated with LPS (1μg/ml) or TNF-α 
(0.1µg/ml) and after 1 hour activation of NFκβ pathway was investigated by western blot. 
Actin served as a loading control. 
 
4.2.6. TGF-β Triggers HIV-1 Restrictive Phenotype in Langerhans 
Cells. 
In this study MDDC and MDLC were derived from the same donors, yet 
demonstrated high divergence in susceptibility to HIV-1 infection.  The unique 
notable difference between both DC subsets relied on the presence of TGF-β, which 
when added to monocytes induced cell differentiation into MDLC. Indeed, MDDC 
and MDLC are both differentiated from monocytes using GM-CSF and IL-4, while 
TGF- was only added in MDLC culture medium. In order to investigate the role of 
TGF- in the post-entry resistance of MDLC to HIV-1 infection I infected monocytes 
with VSV-G HIV-GFP, in the presence of SIV3-Vpx, at different time points during 
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differentiation (Figure 4.18A). MDLC progenitors supplemented with TGF-β became 
more resistant to VSV-G HIV-GFP infection after 1 day of differentiation, reaching 
16.3% (SD=3.9) GFP positive cells compared to 24.9% (SD=12.2) in monocytes 
differentiated to MDDC (Figure 4.18B and C). The resistance to HIV-1 infection in  
 
Figure 4.18. TGF-β Triggers a Post-entry Restriction to VSV-G HIV-GFP in MDLC. 
Monocytes obtained from the same donor were seeded for differentiation into MDDC (GM-
CSF+IL-4) and MDLC (GM-CSF+IL-4+TGF-β). At days 0, 1, 3 and 5 of differentiation cells 
were infected for 4 days with 25ng p24/10
5
 cells of VSV-G HIV-GFP + SIV3-Vpx. (A) A 
schematic design of the experiment is represented. (B) A representative infection analysis 
after 4 days is shown for MDDC (top panel) and MDLC (bottom panel). (C) Pooled data for 
MDLC and MDDC is represented in graph (n=2). NI indicates non-infected cells. *p < 0.05, 
** p < 0.01. Error bars represent ±SEM.    
MDLC was even more pronounced after 5 days of differentiation as only 7.4% 
(SD=6.4) of differentiating MDLC became positive for GFP, in contrast to more than 
30% for monocytes derived without TGF-. Interestingly resistance to HIV-1 
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infection of differentiating monocytes followed the pattern of TGF- supplementation 
with a maximal restriction observed at day 5, which is typical of terminal 
differentiation to functional LC in this ex vivo system. 
In agreement with the role of TGF-β in MDLC viral restriction, pharmacological 
inhibition of its downstream signalling molecule SMAD2 restored infectivity of these 
cells regardless of the SAMHD-1 (Figure 4.19). Signalling studies confirmed that 
phosphorylation of SMAD2 was successfully inhibited at both lower (5µM) and 
higher (10µM) concentration of LY2109761 (Figure 4.19A). The strongest phenotype 
was observed using 5µM concentration of LY2109761, where the mean VSV-G HIV-
GFP + SIV3-Vpx infection of MDLC reached 80.7% (SEM=1.6) compared to average 
15.1% (SEM=5.3) in MDLC (Figure 4.19B). Interestingly even in the presence of 
SAMHD-1, LY2109761 (5µM) induced significant level of GFP expression in the 
cells (p=0.0004, mean=6.3%, SEM=0.45, compared to NT MDLC mean=0.1, 
SEM=0.05), highlighting the importance of this signalling molecules for TGF-β-
mediated effect. Higher doses of SMAD2 inhibitor had less pronounced effect on 
VSV-G HIV-GFP infection in the presence of SIV3-Vpx (mean=54.5, SEM=13.6), 
possibly due to toxic effect of the drug on MDLC.   
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Figure 4.19. Inhibition of SMAD2 Signalling Prevents Development of VSV-G HIV-GFP 
Restriction in MDLC. MDLC derived in the presence or absence of SMAD2 inhibitor 
LY2109761 (5 or 10µM final concentration) (see Materials and Methods, Section 2.9.4) were 
transduced with VSV-G HIV-GFP (±SIV3-Vpx) for 3 days. (A) Inhibition of SMAD2 
phosphorylation in two donors is showed. (B) GFP expression in MDLC (NT) and MDLC 
derived in the presence of LY2109761 are illustrated in (n=3). NI indicates non-infected cells. 
**p < 0.01, *** p < 0.001. Error bars represent ±SEM.    
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Interestingly supplementation of TGF-β into fully differentiated MDDC rendered 
them less permissive to VSV-G HIV-GFP infection (Figure 4.20. A) reminiscent of 
results obtained with MDLC. MDDC pre-treated with TGF-β (24hours) presented 3 
fold less susceptibility to VSV-G HIV-GFP infection (mean infection = 2.12%, 
SEM=1.49, n=2) compared to non-treated MDDC (mean infection = 6.02, SEM=1.24, 
n=2), although the effect remained statistically insignificant (p=0.090), perhaps due to 
limited number of replicates. In contrast Vpx-mediated degradation of SAMHD-1 
rescued VSV-G HIV-GFP infection in TGF-β treated cells and allowed high GFP 
expression in MDDC (NT MDDC mean = 82.65%, SEM=4.55, n=2; MDDC + TGF-β 
mean=85.6%, SEM=3.4, n=2) (Figure 4.20.B). Thus suggesting that, although a TGF-
β-mediated restriction activity could be induced in MDDC, SAMHD1 remains the 
most prominent viral restriction factor in these cells and down regulation of SAMHD-
1 allows effective high viral infection of MDDC.  
 
Figure 4.20. TGF-β Enhances Restriction of VSV-G HIV-GFP Infection in MDDC in the 
Presence of SAMHD-1.  At day 6 of differentiation, MDDC were treated with 10ng/ml of 
TGF-β for 24 hours. Cells were then pre-treated or not with Vpx-expressing lentivectors and 
infected for 3 days with 25ng p24/10
5
 cells of VSV-G HIV-GFP. (A) Data for infections in 
the absence and (B) in the presence of SIV3-Vpx are shown (n=2). NT indicates cells non-
treated with TGF-β. Error bars represent ±SEM.    
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4.2.7. Virus Infection in MDLC is Affected at the Reverse 
Transcription Step  
To further investigate the step of VSV-G HIV-GFP infection affected in MDLC, I 
isolated DNA from infected MDLC and MDDC for Quantitative real time PCR 
analysis. Using established GFP primers, I observed a higher accumulation of GFP 
DNA in MDDC samples infected with VSV-G HIV-GFP (± SIV3-Vpx) as compared 
to autologous MDLC. Although the infection susceptibility differed between donors, 
the trend remained the same, that is GFP DNA in VSV-G HIV-GFP transduced 
MDDC was quantified to be 1,1 and 257.6 in donor 1, 2 and 3, accordingly (Figure 
4.21A, B and C). In contrast, the amount of GFP DNA in MDLC ranged between 
0.06 and 17.0 (donor 2 and 3 accordingly) (Figure 4.21B and C). Reminiscent of 
infection profiles, removal of SAMHD-1 by SIV3-Vpx supplementation to cells 
resulted in a substantial increase of GFP DNA in MDDC that remained marginal in 
MDLC. Accordingly, relative quantification of GFP DNA in MDDC was the highest 
in donor 3 and was equal to 1444, while it reached insignificant 98.1 in MDLC 
(Figure 4.21 C). Interestingly a substantial difference in the amount of GFP DNA was 
recorded between used donors, suggesting unsuccessful degradation of SAMHD-1 in 
one of the donors or divergent genetic susceptibility of blood samples to infection. If 
in fact cells were not completely depleted of SAMHD-1, acquired results do not allow 
to exclude the role of this restriction factor in VSV-G HIV-GFP inhibition, even if it 
was reduced in both MDDC and MDLC to the same extend. However, the difference 
in GFP DNA levels between VSV-G HIV-GFP infected MDLC and MDDC in donor 
3 reflected this observed in GFP protein expression analysis for the each cell type. 
Based on this preliminary data I suggest that a block at the RT step upon VSV-G HIV-
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GFP infection is present in MDLC and it could be partially lifted by SAMHD-1 
degradation.  
 
Figure 4.21. Relative Quantification of GFP in VSV-G HIV-GFP Infected MDDC and 
MDLC. Homologous MDDC and MDLC were pre-treated or not with SIV3-Vpx for 4 hours 
and infected with 30ng p24 VSV-G HIV-GFP. After 6 hours DNA was extracted from the 
cells for GFP quantification. (A, B and C) Analysis of GFP expression levels by qRT-PCR is 
shown for 3 donors, donor 1 (A), donor 2 (B) and donor 3 (C) (n=2). NI indicates non-
infected cells. Primers used: GFP forward primer 5’-aagttcatctgcaccaccg-3’ GFP reverse 
primer 5’- tccttgaagaagatggtgcg-3’ (Eurofins MWG Operon, Germany). 
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4.3. Discussion 
Myeloid cells, such as macrophages and DC subsets, are able to partially restrict HIV-
1 infection due to the presence of cellular restriction factors like SAMHD1 (Berger et 
al. 2011a; Hrecka et al. 2011; Laguette et al. 2011) or A3G (Pion et al. 2006). 
Whereas a growing body of evidence is available on the role of SAMHD1 in myeloid 
cells very little is known about restriction of HIV-1 infection of LC. These are among 
the first immune cells that can encounter HIV-1 during sexual transmission due to 
their localization in epithelia and mucosal surfaces. In this study, primary skin-
resident epidermal LC, MDLC and the LC-like cell line (MuLC) have been used to 
investigate HIV-1 restriction mechanisms in LC. Our results show that the cellular 
restriction factor SAMHD1 is expressed in LC and that Vpx mediates its degradation 
in a time-dependent manner, as expected. However, in contrast to other myeloid DC 
subsets, SAMHD1 degradation in LC was not associated with increased susceptibility 
to HIV-1 infection.  
Langerin or the availability of entry receptors can restrict entry of HIV-1 to LC 
(Kawamura et al. 2000; de Witte et al. 2007). Therefore, VSV-G pseudotyped GFP 
expressing HIV-lentivectors, which can bypass Langerin-mediated binding and the 
influence of HIV-1 surface receptors/co-receptors to efficiently enter into the cell was 
used in this study. Exploiting an ex vivo model of skin-resident primary epidermal LC, 
I report restriction of VSV-G HIV-GFP infection in these cells, even upon Vpx-
mediated SAMHD1 degradation. The infection pattern was quite similar when using 
ex vivo monocyte-derived LC (MDLC) and the Langerhans-like cell line (MuLC). 
This is in sharp contrast to dermal DC and MDDC, which became considerably more 
susceptible to VSV-G HIV-GFP transduction in the absence of SAMHD1 expression. 
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Based on our results restriction of VSV-G HIV-GFP infection in LC might occur at 
the reverse transcription step, as lower levels of GFP DNA were detected in MDLC at 
6 hours post-infection. Pre-treatment with the reverse-transcription inhibitor AZT led 
to a strong block of VSV-G HIV-GFP transduction in MDLC and in MDDC. 
Intriguingly GFP expression in MuLC, although already very low, remained 
unaffected by this treatment possibly due to unsuccessful inhibition of reverse-
transcriptase activity by AZT or, more probably, suggesting that the residual GFP 
signal would come from the viral input and not related to viral infection, however this 
is unlikely.  
As considered above, SIV3-Vpx particles employed in this study contain SIV Vpr 
protein. In HIV-1, Vpr promotes virus replication by increasing transcription of 
provirus and by deregulation of immune responses (Majumder et al. 2005; Mashiba et 
al. 2014; Reinhard et al. 2014; Zahoor et al. 2015) (see Introduction Section 1.2). 
Therefore, a possible effect of SIV Vpr present in SIV3-Vpx particles on experimental 
outcomes has been considered in the result section of this chapter. Accordingly, 
incoming SIV Vpr could boost transcription of provirus from both LTR by directly 
binding to LTR and transcription factors and via induction of NFκβ (Roux et al. 2000; 
Gangwani et al. 2013). Consequently, higher readouts for p24 Gag in SIV3-Vpx 
treated cells could be due to the presence of SIV Vpr protein as well as due to 
SAMHD1 depletion. In case of VSV-G HIV-GFP transduction experiments, GFP 
levels in cells could be elevated by cellular activation triggered by SIV3-Vpx derived 
Vpr protein. However, the effect of Vpr-mediated transcription activation could be 
difficult to detect, especially in MDDC, where SAMHD-1 down regulation results in 
significant boost to infection. Both SIV3-Vpx derived proteins, Vpx and Vpr could 
influence the level of infection in MDDC, however they fail to achieve similar 
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outcome in MDLC possibly due to the presence of other dominant restriction factor in 
these cells. Therefore, I hypothesise, that the presence of SIV Vpr in SIV3-Vpx could 
have some effect on biology of the cells used in this study and their susceptibility to 
infection. However, I believe that this effect does not influence the main conclusion of 
the above study that a very potent restriction, other than SAMHD-1, operates in 
Langerhans cells. Actually, the fact that two influential HIV accessory proteins cannot 
overcome this blockage does imply a great effectiveness of the TGF-β induced HIV-1 
restriction observed in LC.  
Viral infections are sensed by infected cells leading to release of type-I Interferon. In 
the case of HIV-1, virus “hides” from cell intrinsic sensing through the shielding 
action of capsid (Lahaye et al. 2013; Rasaiyaah et al. 2013) and by the employment of 
the cellular DNase, Trex1 (Goldfeld et al. 1991; Yan et al. 2010). Trex1 keeps the 
amount of viral reverse transcription products in check, which directly prevents 
sensing of HIV-1 dsDNA by cGas and other cellular DNA sensors. Depletion of 
Trex1 in cells leads to Interferon production in HIV-1 infected cells (Yan et al. 2010) 
highlighting the role of this protein in successful HIV-1 progression. Similarly, HIV-
2, which encodes the Vpx protein counteracting SAMHD-1 in cells, is less pathogenic 
in human due to increased immune responses towards the virus. Thus to exclude the 
involvement of Interferon in VSV-G HIV-GFP restriction in MDLC I investigated the 
amount of IFN-β transcripts in infected MDLC and MDDC. Importantly, at early time 
points (up to 24 hours) I could not detect a significant induction of IFN-β mRNA 
expression in MDLC or MDDC transduced with VSV-G HIV-GFP, in presence or 
absence of SIV3-Vpx. However, lack of IFN-β detection in cells could be explained 
by using single round replication VSV-G HIV-GFP lentiviral vectors, which do not 
encode Gag/Pol viral proteins and the agreement with reports showing that newly 
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synthesized HIV-1 capsid is required to induce full DC maturation in absence of 
SAMHD1 expression (Manel et al. 2010). Additionally, HIV-1 Vpr protein was 
demonstrated to inhibit interferon stimulation in infected dendritic cells and 
macrophages (Mashiba et al. 2014; Harman et al. 2015). If this function is conserved 
in SIV Vpr that is present in SIV3-Vpx particles, Vpr could block early release of 
interferon from infected cells and rescue virus replication in MDDC, but not MDLC. 
Despite lack of IFN-β stimulation, I did observe, a partial maturation of both MDDC 
and MDLC at later stages of VSV-G HIV-GFP + SIV3-Vpx infection leading to an 
increase in cell surface expression of CD86, which suggests that some level of vector 
sensing could take place in both myeloid subsets. Since even a partial maturation of 
DC could initiate their migration from mucosa to lymph nodes this suggests that LC 
could, however, limit HIV-1 transmission to CD4
+
 T cells (Harman et al. 2006) due to 
their capacity in potently restricting viral replication.  
Other restriction factors can potentially operate in DC subsets, including BST-
2/Tetherin and A3G. The former was reported to act on the last stages of HIV-1 
replication and more precisely during viral release, therefore making unlikely for 
BST-2/Tetherin to have any role as a post-entry restriction factor in LC in the context 
of single round replication lentiviral vectors such as VSV-G HIV-GFP (Berger et al. 
2011a). On the other hand A3G was reported to generate lethal editing of nascent 
reverse transcripts upon infection of target cells (Mangeat et al. 2003) and was also 
involved in post-entry restriction of HIV-1 infection of DC (Pion et al. 2006) and in 
the direct inhibition of reverse transcripts elongation (Bishop et al. 2008). Our results 
showed that A3G levels are seemingly not modulated in immature MDLC compared 
to MDDC and, as expected, A3G expression increased in both cell types upon IFN-α 
treatment. APOBEC3G acts at early steps of HIV-1 replication and it exerts its 
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restriction in new infection only when incorporated into virus particle in producer 
cells (Mangeat et al. 2003; Newman et al. 2005). For that reason, critical role of A3G 
in VSV-G HIV-GFP inhibition in LC is unlikely. Recently, IFN-α-inducible MX2 was 
reported to restrict HIV-1 infection at a pre-integration step of the viral replication 
cycle (Goujon et al. 2013; Kane et al. 2013). I confirmed in our study that MX2 
expression can be, almost exclusively, induced by IFN-α treatment of both MDLC and 
MDDC, while immature LC are totally lacking MX2 expression. MX2 expression was 
also previously reported to be stimulated in cells treated with TLR3 agonists (e.g. Poly 
I:C), independently of IFN-α (Farina et al. 2011). I evidenced in our study that IFN-α 
and poly I:C further inhibit VSV-G HIV-GFP infection of MDLC, suggesting 
therefore, that MX2 could be likely involved in the restriction of VSV-G HIV-GFP in 
IFN-α or poly I:C stimulated MDLC. In fact, I recorded a significant MX2 mRNA 
increase in synthetic double-stranded DNA sequence (poly dA:dT) treated MDLC and 
MDDC. However, neither steady-state nor VSV-G HIV-GFP + SIV3-Vpx transduced 
MDLC express MX2 at protein or mRNA level thus virus restriction activity is 
unlikely to rely on this ISG. 
Interestingly I observed an increased susceptibility of MDLC to VSV-G HIV-GFP 
infection in MDLC matured with TNF-α or TLR-2 agonists, found on gram-positive 
bacteria, in agreement with previous results obtained with full length replication-
competent virus (de Jong et al. 2008; Ogawa et al. 2009). This is in contrast to other 
subsets of DC, which become more resistant to HIV-1 infection after maturation. Co-
infections with other pathogens, such as Chlamydia or HSV-2, were reported to 
significantly raise the risk of HIV-1 acquisition; possibly, in part due to increased 
ability of mature LC to deliver HIV-1 from mucosal surfaces to susceptible CD4
+
 T 
cells (Sewankambo et al. 1997; Galvin and Cohen 2004; Peretti et al. 2005; Ogawa et 
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al. 2013). This enhanced efficiency of virus transmission by matured LC was shown 
to result from stimulated HIV-1 de novo production in matured LC rather than 
increased viral capture by Langerin (Kawamura et al. 2000; de Jong et al. 2008; 
Ogawa et al. 2009; Ganor et al. 2013). Our results with VSV-G HIV-GFP lentiviral 
vectors, which bypass Langerin and HIV-1 receptors/co-receptors (CD4/CCR5), 
showed that LC stimulated with TNF-α or TLR-2 agonists became more prone to 
infection, seemingly due to a partial elimination of post-entry viral restriction. Hence 
the mechanisms by which TNF-α and PAM3CSK4 promote virus infection are 
seemingly independent of SAMHD1, as the expression of this restriction factor was 
down regulated with SIV3-Vpx in LC prior to viral infection. TNF-α induces NF-κβ 
signalling and was previously described to enhance HIV-1 transcription from LTR in 
cells (Duh et al. 1989). In this study, GFP expression in VSV-G HIV-GFP construct is 
mediated via human elongation factor-1 alpha (EF-1α) promoter, which is not known 
to be responsive to NF-κβ. Therefore, TNF-α-mediated increase of GFP expression in 
the cells results from changes to the cell imposed by general cell activation and 
unlikely the induction of provirus transcription. 
At this point it is worth to consider the presence of Vpr protein in SIV3-Vpx particles, 
as this protein was demonstrated to have an inhibitory effect of NF-κβ stimulation 
downstream of TNF-α receptor in macrophages (Kogan et al. 2013). If NF-κβ signal 
transduction is impaired in my systems due to the presence of Vpr, the results would 
suggest the involvement of other signalling pathway in stimulation of GFP expression 
in the cells. Apart from NF-κβ signalling, binding of TNF-α to either of its receptor I 
or II triggers activation of Erk/MAPK dependent and MAPK-p38-dependent 
signalling pathways and downstream activation of transcription factors, such as ATF2, 
c-Jun and Elk (Chang and Karin 2001; Wajant et al. 2002). Additionally, Vpr protein 
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itself activates infected cells that might consequently partially alleviate the restriction 
operating in the cells. However, if in fact TNF-α effect on GFP expression in cells 
relies on enhanced transcription of integrated provirus, the step in virus life cycle prior 
integration will orchestrate the magnitude of TNF-α effect. For instance, if reverse 
transcription is lower in MDLC compared to MDDC, less viral dsDNA integrates into 
host genome resulting in weaker effect of TNF-α. However, that was not the case in 
this study as about 4-fold increase of GFP positive MDLC was observed in the 
presence of TNF-α compared to average 2-fold increase in MDDC in the same 
conditions. Eventually, multiple effect of TNF-α excreted simultaneously on the cells 
could results in boost to GFP expression observed in MDLC and MDDC. Regardless 
the mechanism, my results support an increased incidence of HIV-1 transmission 
during co-infection with other pathogens due to maturation of LC and a greater 
propensity for HIV-1 infection (de Jong et al. 2008; Ogawa et al. 2009; de Jong et al. 
2010c; Ogawa et al. 2013). It is remarkable that maturation of LC with Poly I:C, a 
TLR-3 agonist, strongly increased further their resistance to HIV-1 infection, while 
exposure to gram-positive bacteria components (TLR-2 agonists) had the opposite 
effect. A better understanding of the mechanisms behind these phenomena would 
undoubtedly benefit the development of new microbicides aimed at decreasing the 
incidence of HIV-1 acquisition during co-infections.  
The variable susceptibility of epidermal LC and dermal DC, derived from the same 
donor, to HIV-1 infection may be linked to the status of the local environment in each 
skin layer, such as cytokine levels. However, this hypothesis requires further 
investigation. In contrast, ex vivo monocyte-derived LC and DC are grown in strictly 
controlled conditions and their differentiation environment differs uniquely by the 
presence of TGF-β in MDLC culture medium. Our results show that monocytes 
 178 | P a g e  
 
differentiating in the presence of TGF-β became more resistant to HIV infection, soon 
after initial supplementation of medium with this cytokine, compared to monocytes 
grown in conditions lacking this cytokine. Pharmacological inhibition of TGF-β 
signalling restores infectability of these cells. Additionally, TGF-β treatment of fully 
differentiated MDDC renders them less permissive to VSV-G HIV-GFP, suggesting 
that a TGF-β dependent viral restriction activity could be transferable to other cells. In 
agreement with these results it has been shown that TGF-β also restrains HIV-1 
infection in monocytes and macrophages (Poli et al. 1991). However, the 
immunosuppressive and anti-inflammatory actions of this cytokine may also support 
HIV-1 progression in infected hosts, possibly by interfering with endocytic rates and 
antigen presentation capacities of DC (Cerwenka and Swain 1999; Kobie et al. 2003; 
Li et al. 2006b). Furthermore elevated plasma levels of TGF-β were described in HIV-
1 infected patients with high viremia but not in patients naturally controlling HIV-1 
infection (Card et al. 2012). An increased expression of the CXCR4 co-receptor was 
also proposed to favour HIV-1 entry into macrophages exposed to TGF-β (Chen et al. 
2005). Whereas inhibition of T cell activation in a TGF-β environment may support 
HIV-1 systemic progression initial events of virus acquisition may be affected 
differently by TGF-β, depending on the nature of immune cells targeted by the virus. 
In this study, I demonstrated that the presence of TGF-β correlated with an induced 
natural post-entry resistance to HIV-1 infection of immature LC.  
Our data conclusively support the existence of a novel, SAMHD1-independent and 
Interferon-independent, post-entry HIV-1 restriction mechanism present in immature 
monocyte-derived and freshly isolated skin LC. Importantly this TGF--dependent 
natural post-entry restriction activity was lowered upon treatment with pro-
inflammatory molecules such as TNF-α and TLR-2 agonists, a context relevant to co-
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infections with STIs including bacteria or HSV-2. Further characterisation of this 
restriction mechanism present in LC may offer potent means to control early events of 
HIV-1 infection and spread.  
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5. General Discussion 
5.1. Restriction of HIV-1/VSV-G HIV-GFP Infection in Langerhans 
cell Models 
Dendritic cell subsets residing at the mucosal surfaces play a crucial role in early 
events of HIV-1 infection and contribute to viral transmission to CD4
+
 T cells. HIV-1 
poorly replicates in myeloid cells due to the expression of restriction factors while 
preserving the ability to highjack these cells in order to favour systemic dissemination. 
Recent reports suggest that the cellular factor SAMHD-1 greatly inhibits the viral 
reverse transcription step by limiting the availability of the cellular deoxynucleotide 
triphosphates (dNTP) pool due to its dNTP hydrolase activity (Goldstone et al. 2011; 
Powell et al. 2011) (see General Introduction, Section 1.4.1). Interestingly, a recent 
report challenged this finding by demonstrating that SAMHD-1 could directly bind 
and degrade viral RNA (Ryoo et al. 2014). Indeed, the authors claimed that the 
SAMHD-1 RNase activity, but not the dNTPase function, was essential for HIV-1 
restriction as a specific SAMHD-1 mutant (SAMHD1D137N), possessing a functional 
RNase activity but not the DNase, was able to restrict HIV-1 infection. In contrast, a 
mutated form of SAMHD-1 (SAMHD1Q548A) with an active DNase function but 
lacking RNase activity was defective in HIV-1 restriction (Ryoo et al. 2014). 
Although Langerhans cells also originate from myeloid precursors the role of 
SAMHD-1 in these cells has never been investigated. In this study I hypothesise that 
SAMHD-1 could also operate in Langerhans cells, but it appears that it was not acting 
as the main HIV-1 restriction in these cells. Using two Langerhans cell models, 
Monocytes-derived LC (MDLC) and MUTZ-3 derived LC (MuLC), in parallel with 
primary skin isolated epidermal LC, I discovered that degradation of SAMHD-1 by 
Vpx-expressing SIV-derived lentivectors does not lead to a major increase in 
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susceptibility to HIV-1 infection of either Langerhans cell models or primary 
Langerhans cells, possibly due to a TGF-β-induced HIV-1 restriction in these cells. 
Therefore, I challenge the notion that SAMHD-1 is the major restriction to HIV-1 
infection in Langerhans cells. Instead, I hypothesise that the environmental factors, 
such as the presence of TGF-β can induce in these cells more potent restriction to 
HIV-1 infection. Although, SAMHD-1 function would still operate in Langerhans 
cells, its function may be imperceptible due to the predominant restriction imposed by 
the action of TGF-β. MDLC and MuLC are commonly used systems to study 
Langerhans cells functions (Masterson et al. 2002; Santegoets et al. 2006). Given the 
phenotypic and functional similarities of these cells to real LC, their popularity does 
not come as a surprise. However, both MuLC and MDLC show some dissimilarity to 
each other. For instance, considerable amounts of DC-SIGN are found in MDLC 
while Langerin is a predominant C-type lectin in MuLC (see Figure 3.3 for MDLC 
and Figure 3.2 for MuLC). Expression patterns of these lectins in MDLC and MuLC 
is particularly important for our research, as DC-SIGN and Langerin could have 
opposite functions in respect to HIV-1 infection (Lee et al. 2001; de Witte et al. 2007). 
Accordingly, attachment of virions to Langerin results in their degradation in Birbeck 
granules (Kawamura et al. 2000; de Witte et al. 2007). In contrast, DC-SIGN is known 
to support entry of HIV-1 into Dendritic Cells and to further enhance DC-mediated 
virus transmission to CD4
+
 T cells (Lee et al. 2001). Therefore, direct comparison of 
wild type HIV-1 infection of MuLC and MDLC might have conflicting outcomes. 
Additionally, functional studies of MuLC might be misleading because of the partial 
maturation and impaired responsiveness of these cells to interferon stimulation (see 
Figure 3.8).  
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As SAMHD-1 induces an efficient post-entry block to HIV-1 replication in myeloid 
cells, cells were treated with VSV-G-pseudotyped Vpx-expressing SIV-derived 
lentivector.  Effective SIV3-Vpx-mediated SAMHD-1 degradation was recorded for 
MuLC, MDLC and MDDC (see Figure 4.1) as soon as 3-4 hours post exposure to 
SIV3-Vpx addition. Rapid and consistent disappearance of SAMHD-1 between 
donors in SIV3-Vpx treated cells confirmed the feasibility of this method aimed at 
investigating HIV-1 restriction in LC in the presence or absence of SAMHD-1 
expression. Furthermore, the stable effect of SIV3-Vpx ensured the absence of 
SAMHD-1 in the cells during the whole duration of virus infection experiments (3-4 
days). Despite complete down-regulation of SAMHD-1 in the model cells, 
susceptibility of MuLC and MDLC to HIV-1 infection remained negligible in contrast 
to robust infection observed in MDDC following SIV3-Vpx-mediated SAMHD-1 
degradation. The apparent increase of Gag-p24
+
 MDDC observed in the experiments 
validated previous findings describing a predominant viral restrictive function of this 
cellular factor in Dendritic Cells (Berger et al. 2011a; Hrecka et al. 2011; Laguette et 
al. 2011). However, infection results obtained from LC models suggested the presence 
of a SAMHD-1-independent HIV-1 restriction in these cells. A closer analysis of 
infection results in MuLC revealed a reproducibly low MFI of p24-gag positive 
MuLC population barely distinguishable from the main population suggesting a very 
limited viral production in this cell line even when considering cells productively 
infected (see Figure 4.3). In contrast, the p24 positive populations from productively 
HIV-1 infected MDDC and MDLC were clearly separated (see Figure 4.2) and 
significantly affected in the presence of AZT (see Figure 4.7). The p24-gag readout of 
HIV-1 infection does not distinguish between virus capture and productive infection. 
Thus gag
+
 MuLC population might represent weakly effective replicating HIV-1 but 
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also langerin-captured particles destined for lysosomal degradation. The slight 
increase in gag
+
 MuLC during SIV3-Vpx co-infection, compared to the infection in 
the presence of SAMHD-1, indicates productive infection of the virus rather than 
capture, however both processes could be taking place in MuLC. Although the capture 
of HIV-1 in MuLC by Langerin would significantly decrease the percentage of gag 
positive cells, similar infection susceptibility of these cells compared to MDLC could 
results from partial maturation of MuLC derived in the presence of TNF-α. In fact, I 
observed that TNF-α signalling can favour virus infection in cells (see Figure 4.15). 
Nevertheless, to eliminate the possibility of C-type lectin involvement in HIV-1 entry 
in LC models, VSV-G envelope pseudotyped GFP expressing HIV-1 virus (VSV-G 
HIV-GFP) (Naldini et al. 1996; Dull et al. 1998) was used in this work instead of wild 
type HIV-1. The use of VSV-G HIV-GFP brings numerous benefits into the system 
including the easy readout of productively infected cells by a measurement of GFP 
expression, which excludes the potential background of captured particles such as in 
the case of p24-gag staining. However, during VSV-G HIV-GFP stock production, 
GFP mRNA or a translated protein itself can be packaged into lentiviral particles, and 
be consequently detected in target cells. This process called a retroviral 
pseudotransduction may lead to the expression of foreign proteins, without delivering 
integrating proviral DNA (Haas et al. 2000; Galla et al. 2004; Nash and Lever 2004). 
Thus, some levels of GFP detected in cells transduced with VSV-G HIV-GFP cells 
may represent pseudotyped molecules rather than a result of productive lentiviral 
infection. However, GFP protein expression in both MDLC and MDDC was sensitive 
to AZT suggesting the productive infection is the main source of GFP in these cells. 
Although, susceptibility of cells to pseudotransduction could introduce some low 
variation in the total amount of GFP+ cells between MDDC and MDLC, the effect of 
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SAMHD-1 degradation is mostly attributed to release of productive infection 
restriction in MDDC, which does not have the same effect in MDLC.  
In addition to easy readout method in VSV-G HIV-GFP infection studies, VSV-G 
envelope bypasses the requirement for entry receptors (CD4) and co-receptor (CCR5) 
for lentivirus fusion and prevents binding of lentivirus to C-type lectins. Entry 
receptors of VSV-G are poorly characterised but recent reports underline the role of 
plasma membrane fatty acids in VSV-G envelope attachment to the cell (Finkelshtein 
et al. 2013). The origin of MDLC and MDDC from the same monocytic pool would 
predict comparable content of these molecules in cell membranes and therefore an 
equal efficiency of VSV-G binding. In addition to the above features, VSV-G HIV-
GFP retains all the initial HIV-1 infection steps, including reverse transcription and 
integration, making it a subject to post-entry viral restriction factors. Although, usage 
of VSV-G pseudotyped particles overcomes entry restrictions associated with wild 
type HIV-1 gp120, VSV-G HIV-GFP also largely bypass cytoplasm as it fuses with 
endosomal membrane for entry. Upon binding low density lipoproteins (LDLR) on the 
cell surface, VSV-G HIV-GFP is endocytosed and fuses with endosomal membrane 
only after pH change imposed by lysosomal fusion (Sun et al. 2005; Finkelshtein et al. 
2013). This different route of entry compared to HIV-1 localise VSV-G HIV-GFP 
close to the nucleus and possibly prevents interaction of lentivirus with cytoplasmic 
sensing mechanism or restriction factors. On the other hand, it could also impair 
binding of viral core to CPSF6 or Nup proteins, which were described to be essential 
for early infection steps of HIV-1 (Price et al. 2012; Rasaiyaah et al. 2013). Therefore, 
the exact consequence of endosomal entry route of VSV-G HIV-GFP on its host 
protein interaction is largely unknown. However, accordingly to this study, SAMHD-
1 remains the main restriction to VSV-G HIV-GFP infection in MDDC, leading to 
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assertive assumption that efficiency of early infection steps is not affected in these and 
related cells, such as MDLC. The use of VSV-G HIV-GFP concomitantly with the 
down-regulation of SAMHD-1 expression confirmed the refractory phenotype of 
MDLC and MuLC to lentivirus infection in these cells. MDLC susceptibility to 
infection remained unchanged compared to HIV-1 experiments, possibly confirming 
little involvement of Langerin in HIV-1 infection blockage. In contrast, VSV-G 
pseudotyped HIV-1 (+SIV3-Vpx) successfully bypassed Langerin restriction in MuLC 
resulting in increased lentiviral infection of these cells, as compared to HIV-1. 
Although the GFP signal in MuLC theoretically indicates only successful infection 
VSV-G HIV-GFP, AZT pre-treatment of lentiviral transduced cells did not result in 
lower percentage of GFP
+
 MuLC. The defect of AZT can be excluded from the 
possible explanation of this result because VSV-G HIV-GFP infection performed in 
parallel in MDDC and MDLC was almost completely abolished in these cells in the 
presence of AZT (see Figure 4.7). Being a tumour-derived cell line MuLC could have 
a higher concentration of cytoplasmic nucleotides compared to blood-derived MDLC. 
In such case, high availability of these components for viral reverse-transcription 
might have not been fully altered by supplementation with AZT, consequently leading 
to low infection of the lentivirus. Possibly, observed GFP levels in MuLC may be a 
result of pseudotransduction that would be insensitive to AZT treatment. In that case, 
increase of GFP detection in MuLC upon SAMHD-1 degradation could result from 
inhibition of RNase activity of SAMHD-1 thus increased stability of 
pseudotransduced GFP mRNA. However, this would not explain the evident 
difference in GFP expression levels between MuLC and MDDC transduced with 
equal VSV-G HIV-GFP dose in the absence of SIV3-Vpx pre-treatment (see Figure 
4.6). If pseudotransduction contributes to GFP levels in MuLC, the same background 
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detection should be theoretically recorded for MDDC. Whether partial activation of 
MuLC could influence the expression of GFP mRNA was not investigated in this 
study, however, infection of MuLC with VSV-G HIV-GFP cannot be excluded from 
the above data. Nevertheless, limited understanding of HIV-1/VSV-G HIV-GFP 
infection in MuLC influenced the choice not to use this cell model for further 
experiments in this study, including the fact that MuLC poorly mimic other 
immunological functions from LC. Instead, the investigation of VSV-G HIV-GFP 
restriction in LC models was performed in MDLC in comparison to MDDC. Although 
CD141
+
 DC delivered in the presence of Vitamin D3 were recently considered as 
appropriate dermal DC model (MacDonald et al. 2002; Jongbloed et al. 2010; Chu et 
al. 2012), MDDC have been also extrapolated as a model mimicking dermal DC 
subsets. These cells were therefore used in this work due to their good characterization 
in the literature, growing conditions like those in MDLC medium (except for TGF-β) 
and comparable to CD141
+
 DC in their susceptibility to HIV-1 infection (see Figure 
4.4). Together the results showed that restriction to HIV-1/VSV-G HIV-GFP infection 
in model LC cells is not eliminated after SAMHD-1 degradation, therefore suggesting 
some other major cellular mechanisms of viral restriction in these cells.  
 
5.2. Primary Skin Isolated Epidermal LC and Dermal DC Confirm 
Restriction of HIV-1 in LC 
In order to validate the results obtained in cell lines and primary cells I set up 
conditions to obtain primary skin isolated dermal DC (dDC) and epidermal LC (eLC). 
Challenge of dermis and epidermis walkout populations with VSV-G HIV-GFP, with 
or without SIV3-Vpx pre-treatment, demonstrated similar infection profiles to those 
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observed in MDDC and MDLC respectively. Accordingly, epidermal Langerhans 
cells were weakly permissive to VSV-G HIV-GFP in contrast to higher proportion of 
GFP positive dermal DC (see Figure 4.9). However, skin walkout cells comprise 
mixed population of immune cells and tissue cells, which all could be susceptible to 
VSV-G HIV-GFP entry. To address the possibility of lentivirus entry into other 
targets than myeloid cells, epidermal and dermal walkout population have been 
analysed by considering GFP expression related to specific eLC or dDC cell surface 
markers (Figure 4.10 and Figure 4.11). Results showed a predominant localization of 
GFP into LC and DC populations of epidermis and dermis respectively, suggesting a 
lack of significant infection of other skin cells. Nevertheless, a limited VSV-G HIV-
GFP entry into other cells than DC and LC remains probable and our GFP readout 
method cannot rule out a non-productive infection, therefore possibly underestimating 
viral skin targets. The pseudotyping of lentivectors with other amphotropic or 
pantropic envelopes (Hemagglutinin from Influenza virus, MLV envelope, etc) could 
have helped in answering which was, however, beyond the scope of our study.  As 
LCs appear in lower numbers in the epidermis, compared to DC population in the 
dermis, the corresponding virus/cell ratio might be different and the results obtained in 
this work could be skewed due to reduced entry of VSV-G HIV-GFP into LC. 
Similarly, viral-like particles carrying Vpx could have reached the other epidermis 
walkout cells than LC, leading to incomplete degradation of SAMHD-1 in these cells. 
In both cases, epidermal LC infection would appear lower compared to dermal DC. 
Additional staining of stimulated cells with p24-gag antibody could identify cells 
targeted by lentivirus; however, this readout was not used in this work. Increase of the 
initial VSV-G HIV-GFP input in epidermal infections could also partially resolve the 
underestimate of infection in eLC occurring due to their low numbers in walkout 
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population. In such case, the amount of particles reaching eLC would equalise to this 
entering dDC, thus allowing better comparison of these cells types. Although skin 
walkout cells infection challenge insinuate lower susceptibility of epidermal LC than 
dermal DC to HIV-1-like vector infection, the experiment protocol could be modified 
to address the above concerns. Nevertheless my results strongly suggest that ex vivo 
eLC, in contrast to dDC, remain strongly refractory to HIV-1 infection even upon 
SIV3-Vpx-mediated SAMHD-1 degradation. 
 
5.3. Matured MDLC are More Permissive to VSV-G HIV-GFP 
Infection 
The data obtained from this work (see Chapter 4) suggest that MuLC and MDLC are 
refractory to HIV-1/VSV-G HIV-GFP infection due to downstream action of TGF-β 
signalling. However, partial maturation of MuLC triggered by TNF-α can possibly lift 
the restriction imposed during differentiation resulting in slightly higher expression of 
GFP in these cells, compared to MDLC. The effect of TGF-β on cells depends on the 
cumulative impact of the microenvironments factors, such as cytokines, activation 
stimuli and inflammation. For instance TGF-β has a weaker effect on activated T cells 
possibly due to down-regulation of TGFβRII expression on these cells (Cottrez and 
Groux 2001). Indeed, I have also reported a significant, yet limited, effect of TGF-β 
on VSV-G HIV-GFP infection in differentiated MDDC (see Figure 4.20). Similarly, 
restrictive effect of TGF-β exerted on MuLC could be partially eliminated by TNFα-
mediated maturation of these cells resulting in increased infection. Eventually the 
origin of MuLC from immortalized cell line might also promote GFP expression in 
these cells possibly due to the presence of high levels of factors required for cell 
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division and virus infection. However, this statement is only a speculation, which 
requires verification. 
However, in agreement with the role of TNF-α on induction of GFP expression in 
MuLC treatment of differentiated MDLC with this cytokine or TLR-2 agonist 
increased VSV-G HIV-GFP infection of these cells (see Figure 4.10). TLR2 and 
TNF-α signalling pathways converge towards the activation of the master 
transcription factor NF-κβ that regulates expression of genes involved in multiple 
immune processes like cytokine production, inflammation or pyroptosis (Nabel and 
Baltimore 1987). However, NF-κβ is also known to bind several viral promoters 
including the Cytomegalovirus (CMV) promoter (Roux et al. 2000; Gangwani et al. 
2013) and the long terminal repeat sequences flanking HIV-1 genome (Legrand-Poels 
et al. 1990; Kretzschmar et al. 1992). In fact, the HIV-1 encoded Tat protein mediates 
binding of NF-κβ to its LTR (Dandekar et al. 2004) supporting expression of 
integrated HIV-1 DNA. The phosphorylation of NF-κβ p62 at serine 536 in parallel 
with the degradation of its negative regulator IκBα are potential indicators of the 
activation of this signalling pathway. Indeed phosphorylated IκBα (p-IκBα) becomes 
ubiquitinated and is degraded in the proteasome, resulting in the release and 
phosphorylation of NF-κβ p62 and activation of gene expression. In agreement, 
phosphorylation of NF-κβ p62 and IκBα were observed in TNF-α stimulated MDLC 
(see Figure 4.16) suggesting activation of the cells. The results correlated with the 
increased GFP expression in transduced cells, suggesting the involvement of this 
signalling pathway in enhancement of VSV-G HIV-GFP infection of MDLC and 
MDDC. As EF1α promoter upstream of GFP in VSV-G HIV-GFP lentivector is not 
known to be directly bound by NF-κβ, related GFP expression increase could be a 
result of general cell activation. Thus, addition of TNF-α to MDLC culture would 
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activate the cells and consequently alleviate the virus restriction operating in these 
cells. In vivo, TNF-α induced NF-κβ signalling promotes activation of chronically 
infected T cells (Duh et al. 1989; Aukrust et al. 1994), but at the same time it was 
demonstrated to inhibit HIV-1 infection of peripheral blood mononuclear cells and 
alveolar macrophages (Herbein et al. 1996; Lane et al. 1999). However, elevated 
levels of TNF-α are detected in HIV-1 positive patients and these correlate with 
increased viral replication and systemic depletion of CD4+ T cells (Dezube et al. 
1997; Valdez and Lederman 1997). Thus, in vivo TNF-α plays an notable role in HIV-
1 progression and pathogenesis.  
As discussed before (see Introduction Section 1.4.3) apart from Vpx, SIV3-Vpx 
particles used in this study deliver also Vpr proteins for which multiple conflicting 
functions regarding NF-κβ were described (Ayyavoo et al. 1997; Majumder et al. 
2005; Varin et al. 2005; Hoshino et al. 2010). A study by Roux P (2000) demonstrated 
that Vpr uses NF-κβ signalling cascade in macrophages and T cells to induce IL-8 and 
to promote transcriptional activation of viral promoter such as LTR of HIV-1. 
However, recent study suggest that Vpr blocks TNF-α induced NF-κβ signalling in 
macrophages (Kogan et al. 2013). Thus, the TNF-α-mediated NF-κβ signalling in cells 
observed in this study could have been restricted by the presence of Vpr protein. This 
could explain why Pam3CSK and TNF-α induced maturation of MDLC were 
insufficient to fully release viral restriction in MDLC. 
Interestingly Pam3CSK supplementation to MDDC brought the opposite effect to this 
observed in MDLC and resulted in a decreased percentage of GFP positive MDDC 
population. Although, both MDDC and MDLC respond to Pam3CSK by release of 
TNF-α/IL-10 cytokines (see Figure 3.12 and 3.13) production of other pro-
inflammatory cytokines might differ in these cells. As Langerhans cells are constantly 
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exposed to bacterial components they induce mostly tolerogenic responses. This is in 
contrast to Dendritic Cells that induce strong pro-inflammatory response when 
stimulated with TLR agonists of bacterial origin, which could possibly also decrease 
susceptibility of these cells to other infections, for example HIV-1. However, the 
change in VSV-G HIV-GFP expression in Pam3CSK treated MDDC was not 
significant compared to non-stimulated MDDC, possibly suggesting a lack of strong 
immune response to this TLR1/2 agonist.  
In contrast to Pam3CSK and TNF-α, poly I:C stimulation of MDLC and MDDC 
almost completely blocked VSV-G HIV-GFP infection in these cells possibly due to 
the establishment of a potent antiviral state in the cell. Activation of TLR-3 signalling 
was reported to be associated with induction of type-I interferon (IFN-I) response in 
the cells. Consequently, IFN from both, paracrine and endocrine source induces 
expression of interferon-stimulated genes (ISG) among which some of them are 
known to be potent antiviral. Thus, as expected 6 hours stimulation of MDDC and 
MDLC with poly dA:dT resulted in accumulation of IFN-β mRNA (see Figure 4.13) 
possibly involved in the late restriction of VSV-G HIV-GFP transduction of these 
cells. In contrast, IFN-β response was not detected in SAMHD-1 depleted MDLC 
infected with VSV-G HIV-GFP until 24 hours post infection. This effect was even 
more delayed in case of MDDC, where IFN-β mRNA was recorded only at 48 hours 
post infection. Interestingly, induction of IFN-β mRNA timely correlated with 
increase of MX2 mRNA in MDLC and MDDC, suggesting that this restriction factor 
has limited function at early time points of VSV-G HIV-GFP infection. In addition to 
PCR studies, blocking antibodies to IFN receptor or disruption to IFN signalling 
cascade could be employed in this research to identify the exact involvement of 
interferon in MDLC infection control. Restoration of GFP expression in such treated 
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MDLC would allow identification of an early role of interferon in VSV-G HIV-GFP 
restriction in these cells. 
A robust reverse-transcription of VSV-G HIV-GFP in MDLC in the absence of 
SAMHD-1 could be a target for cytoplasmic DNA sensors, which consequently 
inhibit GFP expression. In fact high levels of the early products of HIV-1 infection of 
SAMHD-1 depleted cells could be detected in MDDC by cyclic-GMP-AMP 
(cGAMP) synthase (cGAS), resulting in induction of interferon response and cells 
maturation (Manel et al. 2010; Manel and Littman 2011; Gao et al. 2013). However, 
accordingly to other studies, intracellular sensing of HIV-1 cDNA in MDDC is 
ineffective as viral capsid shields it from detection by cGAS and other DNA sensors, 
even in the presence of Vpx (Manel et al. 2010; Lahaye et al. 2013; Rasaiyaah et al. 
2013). Instead, it was suggested that a newly synthesised gag protein of HIV-1 would 
be required to fully activate infected DC (Luban et al. 1993; Manel et al. 2010). As a 
single round replication construct, VSV-G HIV-GFP does not encode gag gene, which 
excludes sensing of this gene product in stimulated MDDC or MDLC. Additionally, 
entry of VSV-G HIV-GFP to cell cytoplasm from endosomal compartments could 
possibly limit the exposure of lentiviral genome to sensing molecules. On the other 
hand, bypassing of the cytoplasm may limit binding of CPSF6 and other cellular 
proteins to VSV-G HIV-GFP capsid thus affect shielding of viral nucleic acids. A 
successful infection of VSV-G HIV-GFP in SIV3-Vpx-treated MDDC confirms the 
lack of lentivirus restriction imposed by DNA/RNA sensing, which however cannot 
exclude viral detection by a cell.   
Only in the absence of SAMHD-1 does VSV-G HIV-GFP trigger maturation of 
MDDC and MDLC. If a high virus infection was required for this phenotype CD86 
increase recorded in MDLC would strongly suggest the successful reverse 
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transcription of VSV-G HIV-GFP in these cells. Consequently sensing of infection 
products by MDLC would impose the restrictive phenotype observed in these cells 
that efficiently stalls GFP expression. However, the measurement of IFN-β mRNA in 
VSV-G HIV-GFP (+SIV3-Vpx) transduced MDLC at 5 hours post infection did not 
show any changes compared to non-infected cells. Perhaps this was performed too 
early in the infection to detect cellular activation. In contrast 48 hours after 
transduction the increase of expression of some maturation markers (CD86, HLA-DR) 
at the surface of MDLC could be observed, suggesting that infection could modulate 
the immune response of these cells depending on the context. Investigation of 
interferon response in MDLC at later stages of infection should be performed to 
clearly establish the role of interferon in VSV-G HIV-GFP inhibition in these cells. 
The blockade of IFN-mediated signalling by IFN receptor antagonists (antagonizing 
Abs) could be used to assess such role for example. If interferon-inducible restriction 
factors mediate the observed inhibition of VSV-G HIV-GFP infection of MDLC, 
measurement of these proteins levels after few days infection could also provide a 
clear indication. Unfortunately, this experiment has not been performed in this work 
however, available data shows no induction of MX2 or BST-2/Tetherin in SIV3-Vpx-
treated MDDC or MDLC (see Figure 4.12) suggesting that down-regulation of 
SAMHD-1 itself does not induce Interferon responses in the MDDC/MDLC. 
Additionally, it is possible that Interferon independent mechanisms of VSV-G HIV-
GFP restriction operate in LC. This is particularly valid in the light of VSV-G HIV-
GFP infection inhibition in MuLC that I demonstrated to be irresponsive to IFN-α 
stimulation.  
Regardless of the mechanism of virus sensing in LC, IFN-α pre-treatment of MDLC 
further restricts GFP expression in infected cells (see Figure 4.12). A range of 
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restriction factors are unregulated in these cells including MX2, APOBEC3F/G, RIG-I 
and BST-2/Tetherin (see Figure 4.12). MX2 (also called MXB) is a member of the 
IFN-inducible GTPase superfamily closely related to MX1, which was recently 
described to act as an IFN-dependent inhibitor of HIV-1 infection of macrophages 
(Goujon et al. 2013; Kane et al. 2013). MX2 acts at early stages of HIV-1 replication 
seemingly targeting the HIV-1 uncoating process (Kane et al. 2013; Buffone et al. 
2015). For the first time expression of this restriction factor could be demonstrated in 
MDLC but, as expected, exclusively after IFN-α stimulation (see Figure 4.12). As 
MX2 affects early infection steps of the virus, the induction of MX2 in interferon 
treated MDLC could potentially explain LC restriction to VSV-G HIV-GFP. However 
this is unlikely as at early time points of VSV-G HIV-GFP infection (up to 24 hours) 
MX2 mRNA is absent in MDLC (see Figure 4.13), suggesting that MX-2 role in 
VSV-G HIV-GFP inhibition is limited unless cells are pre-treated with interferon. 
Similarly, as a single replication construct, VSV-G HIV-GFP is not susceptible to the 
action of APOBEC3G/F that is constrained to secondary infection (Mangeat et al. 
2003; Newman et al. 2005; Malim 2009). However, it was showed that APOBEC3G 
could limit HIV-1 infection in monocyte-derived DC during primary infection (Pion et 
al. 2006). Down regulation of APOBEC3G would be necessary to fully exclude it 
from the list of restrictions operating in MDLC. Whether function of APOBEC3G 
could be modulated by TGF-β remains to be determined. 
Interestingly the results suggest that HIV-1 infection in type I interferon stimulated 
MDLC could be also restricted by increased expression of surface and intracellular 
Langerin in these cells (see Figure 3.9). Langerin plays an important function in 
pathogen capture therefore an increased expression of this CLR mediated could be an 
additional innate mechanism operating during infection. Although the exact signalling 
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triggering Langerin expression during interferon treatment has not been identified it 
could be expected to involve common signalling components within the type-I 
interferon signalling cascade. Such mechanism, if verified, would further emphasize 
the role of Langerin in viral and possibly bacterial infections. Additionally, if levels of 
Langerin on MDLC could represent an indirect measure of interferon signalling in the 
cells increased expression of this CLR in MDLC transduced with SIV3-Vpx and 
VSV-G HIV-GFP would again suggest an antiviral response in these cells. The 
mechanism of Interferon-mediated Langerin increase is not understood, hence not 
verified in freshly isolated epidermal Langerhans cells.  
Thus, the above data provide an interesting observation regarding the SAMHD-1-
independent inhibition of HIV-1 infection in TGF-β derived MDLC. Although no 
interferon release could be observed in MDLC at initial stages of VSV-G HIV-GFP 
infection, such response cannot be excluded to take part at later time-points. 
Additionally, Infection related maturation of MDLC and up-regulation of Langerin 
could correlate with the involvement of sensing mechanism in these cells that blocks 
viral propagation. However, such mechanism has not been confirmed in this work. 
 
5.4. TGF-β Induces an Anti-retroviral State in MDLC  
The fact that MDLC and MDDC derived from the same monocytes show such 
distinguished profile of HIV-1 infection is intriguing. Available data suggest that the 
action of TGF-β present exclusively in MDLC differentiating medium imposes cells 
restrictive phenotype. TGF-β is known for its strong immunosuppressive activity on 
various cell types (Borkowski et al. 1996; Letterio and Roberts 1998; Kobie et al. 
2003; Li et al. 2006a). For instance, TGF-β treated DC fail to up-regulate MHCII and 
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other co-stimulatory molecules when activated with pathogens (Geissmann et al. 
1999). This immunosuppressive activity of TGF-β also affects the responses of 
Langerhans cells to bacterial components. Limited TLR repertoire and tolerogenic 
activity of LC prevents pro-inflammatory responses to commensal bacteria and 
sustains body mucosal homeostasis. Correspondingly, TGF-β activity also modulates 
the permissiveness of MDLC to HIV-1 infection as demonstrated in this work. 
Accordingly, soon after the first supplementation of TGF-β differentiating monocytes 
become more restrictive to VSV-G HIV-GFP infection, compared to monocytes 
grown in the absence of this cytokine. This TGF-β mediated effect amplifies during 
cell culture and reaches its greatest restriction upon full differentiation (see Figure 
4.18). However, prior to establishment of the restrictive phenotype, differentiating 
MDLC show a variable susceptibility to infection, which corresponds to TGF-β 
supplementation. In fact at day 3 of differentiation, 2 days since last addition of TGF-
β to the cells medium, VSV-G HIV-GFP susceptibility of SAMHD-1 depleted cells 
increases substantially in comparison to an infection challenge performed a day after 
TGF-β supplementation. Perhaps at this time, restriction in MDLC is not yet fully 
developed and it depends purely on the recent TGF-β signalling. Alternatively, during 
differentiation TGF-β induced restriction can operates on different levels, including 
brief decrease of dNTP levels in the cells or general, transient suppression of the cell 
activity. In contrast, fully developed cells may acquire a new permanent mechanism 
that leads to inhibition of HIV-1 infection in these cells. Such mechanism could 
include down-regulation of viral dependency factors or up-regulation of restriction 
factors levels or activity mediated by TGF-β. A systematic analysis (microarrays, 
proteomics…) of MDLC and MDDC could potentially indicate candidate genes that 
differ between these cells and could be responsible for viral restriction in MDLC. 
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Further testing of each candidate would have to follow in order to identify the exact 
mechanism of HIV-1 restriction imposed by TGF-β.   
TGF-β signals via SMAD2 and SMAD3, which form a complex in the cytoplasm. 
Activation of this complex and consequent translocation of SMAD2/3 to the nucleus 
is achieved by phosphorylation of both SMAD2 and SMAD3 at Ser465/467 and 
Ser423/425 respectively. The pharmacological component LY2109761 is a small 
molecule inhibitor of the TGF-β receptor type 1/type II kinase activity and inhibits, 
therefore, the phosphorylation and activation of downstream effectors of the TGF--
mediated signalling pathway such as SMAD2 and SMAD3. The effectiveness of 
LY2109761 in the inhibition of SMAD2 activation was analyzed in differentiating 
MDLC and was subsequently shown to prevent the establishment of the viral 
restriction in these cells. As a result, the level of VSV-G HIV-GFP infection in MDLC 
increased, particularly when SAMHD-1 expression was previously down modulated 
(see Figure 4.19). Therefore the infection results obtained in LY2109761 treated 
MDLC showed that these cells were behaving like MDDC thus confirming that TGF-
β signalling is crucial for induction of non-permissive state in MDLC.  
Although the exact mechanism of viral inhibition in MDLC could not be fully 
characterised during this study, attempts to identify the stage of HIV-1 infection 
affected in these cells indicated a possible block at the viral reverse transcription step. 
Quantitative PCR of VSV-G HIV-GFP (+/-SIV3-Vpx) transduced cells showed lower 
accumulation of gfp DNA in MDLC compared to MDDC (see Figure 4.21), reflecting 
an infection pattern observed in these cells (see Figure 4.5). Perhaps a block to virus 
propagation is elicited only at later stages of virus reverse transcription as 
accumulation of some gfp DNA products could be observed in the cells. In that case 
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sensing of reverse transcription products could be a plausible explanation. However, 
synthesis of viral DNA from its RNA genome could be also restricted independently 
of sensing by a pre-existing restriction. As a result, gfp DNA detected in MDLC might 
originate from a restriction escape. Perhaps the arising transcript would be incomplete 
additionally leading to inhibition of further VSV-G HIV-GFP infection steps 
including integration or transcription. The fact that some particles could avoid 
restriction would eliminate the possibility that MDLC are completely depleted in a 
viral replication dependency factor.  
Based on the data collected in this work I have characterised several aspects of a 
mechanism involved in HIV-1 restriction in LC. Apparently HIV-1 infection is 
restrained in MDLC prior to integration, possibly during the reverse transcription 
process, however several explanation as to the mode of restriction are possible. These 
are considered as follows: 
1) Firstly, SAMHD-1-independent restriction in MDLC could be mediated by 
expression of a yet unidentified cellular factor in these cells. This restriction 
could act on dNTP levels similarly to SAMHD-1, or have another function that 
blocks early steps of HIV-1 reverse transcription. Western blot analysis of 
APOBEC3 in MDDC and MDLC showed comparable levels of this protein in 
both cells types excluding it from potential candidates although a difference in 
APOBEC3G complexes could mediated this effect as shown for other myeloid 
cells (Stalder et al. 2010). Lack of MX2 detection in non-stimulated MDLC 
also suggests that TGF-β itself does not trigger expression of this protein. 
Other anti-retroviral restriction factors operate in cells including TRIM5α and 
Fv1 but their expression has not been investigated in our experiments. 
Eventually TGF-β action could focus on the qualitative improvement of 
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restriction factors (other than SAMHD-1) activity rather than stimulating their 
amount. 
2) Ultimately, instead of acting on restriction factors TGF-β could induce, as 
evoked already, an effective sensing mechanism in MDLC. In that case 
detection of VSV-G HIV-GFP early during infection could trigger an antiviral 
state in the cells resulting in low GFP expression. In line with this hypothesis, 
maturation of SAMHD-1 depleted MDLC after transduction with VSV-G 
HIV-GFP was observed (see above 5.3). The same conditions also induced 
expression of Langerin on MDLC suggesting that Interferon could play a role 
in inducing a resistance to HIV-1 in MDLC. Although, IFN-β mRNA 
production in these cells has not been observed, the experiment was performed 
at very early steps of VSV-G HIV-GFP infection, and possibly more time is 
required to induce an Interferon response.  
3) HIV-1 relies almost entirely on cellular factors and components for its 
replication. For instance the viral reverse transcription step requires the 
presence of deoxynucleotides in the cell cytoplasm, and SAMHD-1 mediated 
depletion of these nucleotide derivatives efficiently blocks virus propagation. 
Similarly, TGF-β signalling could result in restriction or depletion of proteins 
or molecules required for HIV-1 replication in MDLC. As mentioned above 
such dependency factor would be limited but not completely depleted from 
MDLC as some level of infection is observed in these cells. The knowledge 
about the nature of these reduced factors would definitely contribute towards 
development of treatment strategies.   
4) Another hypothesis to explain TGF-β induced restriction of VSV-G HIV-GFP 
in MDLC relies on the biology of these cells. Langerhans cells are long-lived 
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cells critically contributing to tolerogenic immune responses. Perhaps the 
activity of cellular factors required for HIV-1 infection in these cells is also 
reduced, therefore resulting in an unfavourable environment for virus. This 
situation would mimic the one observed in T lymphocytes for which quiescent 
T cells are strongly resistant to productive HIV-1 infection (Zack et al. 1990; 
Zack et al. 1992; Vatakis et al. 2010). Activation of these cells restores the 
transcription factors activity and promotes expression of latent virus. 
Similarly, activation of MDLC with TLR signalling or pro-inflammatory 
cytokines (ex. TNFα) partially relieves VSV-G HIV-GFP restriction in these 
cells (see Figure 4.15). Therefore, inactive state of Langerhans cells could 
explain their resistance to infection. It is worthwhile to remember that results 
for this work were acquired in LC models that could differ in some aspects to 
LC at steady state in mucosal surfaces. Although low infection susceptibility 
of MDLC was reproduced in epidermal LC interferon and maturation studies 
were limited to MDLC. Strictly controlled differentiating conditions in MDLC 
are different to those present in epidermal microenvironment, which could 
possibly result in slightly different experimental outcomes. For instance, 
maturation of epidermal LC might result in much higher or lower infection by 
of VSV-G HIV-GFP in these cells. Therefore, further work on this project 
should concentrate on deciphering the exact mechanism of HIV-1 inhibition in 
both MDLC and real epidermal LC.   
Regardless of the mechanism, the results presented in this work are unexpected, 
especially in the light of other studies that describe TGF-β to support HIV-1 
propagation. Some reports suggested that TGF-β contributes to apoptosis and 
depletion of HIV-1 positive lymphocytes (Wang et al. 2001), consequently speeding 
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up the progression to AIDS. Non-cytotoxic mechanism of TGF-β induction of 
immunodeficiency was also suggested and proposed to rely on the impaired 
proliferation ability of antigen stimulated CD4
+ 
T cells (Kekow et al. 1990). Infected 
astrocytes, macrophages, monocytes, T cells and Dendritic cells, all can produce TGF-
β (Wahl and Chen 2005), which acts in paracrine and autocrine manner to promote 
virus spread. For instance TGF-β increases expression of HIV-1 co-receptor, CXCR4, 
on monocyte-derived macrophages (Chen et al. 2005), T cells (Wang et al. 2001), 
monocyte-derived Dendritic cells (Sato et al. 2000) and Langerhans cells (Zoeteweij 
et al. 1998) hence promoting HIV-1 attachment and entry into cells, while R5-tropic 
viruses are usually the ones found at infection sites. The importance of this cytokine in 
HIV-1 infection is also highlighted by the fact that HIV-1 encoded Tat protein induces 
TGF-β in antigen-stimulated T cells and monocytes (Gibellini et al. 1994; Reinhold et 
al. 1999). However, the study described above showed the effect of TGF-β on already 
differentiated or HIV-1
+
 cells, which are possibly less susceptible to TGF-β-induced 
changes. In agreement, I showed that in terms of VSV-G HIV-GFP inhibition TGF-β 
effect on differentiated MDDC is limited. In contrast, the same monocytes derived in 
the presence of this immunosuppressive cytokine show the opposite phenotype, 
clearly demonstrating the role of TGF-β in mediating this effect in MDLC.  
Therefore, I conclude that TGF-β induces major changes in monocytes biology during 
differentiation that perhaps cannot be recapitulated in already differentiated cells, such 
as MDDC. These changes arise via the SMAD signalling cascade and trigger a 
SAMHD-1 independent restriction in MDLC.   
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5.3. Summary and Future Directions 
Modern advances in antiretroviral therapy extend life expectancy of HIV-1
+
 
individuals comparable to this of a healthy individual. However, life-long treatments 
come with a decreased quality of life, appearance of serious side effects and hefty 
price tag for the government. Therefore, the attempts to develop preventative 
measures against HIV-1 transmission are urgently required. Recently the scientific 
community advised on the implementation of prophylactic approach in form of a free 
access to Truvada (Heneine and Kashuba 2012; Administration 2013; CDC.com 
2014). Accordingly, available data suggests this strategy to limit the number of new 
HIV-1 transmission and to reduce the costs of life-long treatment of infected patients.  
As Langerhans cells are believed to be the first targets for HIV-1 infection during 
sexual transmission it is important to understand the events taking place at the 
mucosa. This work adds on to the knowledge of LC-HIV-1 interactions by 
investigating a post entry blockade event occurring in infected cells. Importantly the 
potential presence of TGF-β induced HIV-1 restriction in fully differentiated MDLC 
and fresh epidermal LC is described. TGF-β plays a crucial role in mediating a non-
permissive phenotype in MDLC and blocking TGF-β-mediated signalling pathway 
reverses the effect. Operating at post entry level MDLC restriction appears 
independent of SAMHD-1 expression and possibly involves sensing of replicating 
virus. Preliminary data suggest block to HIV-1 infection in MDLC prior to 
integration, thus making viral DNA a likely target for sensing. TGF-β mediated 
activation of restriction factors, expression of new antiviral protein, or down-
regulation of some molecules required for virus propagation might also be possible 
explanations for TGF-β action in MDLC. Although a single mechanism cannot be 
indicated based on available data, it is undisputable that TGF-β mediates the observed 
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effect. Further investigation into the topic could benefit from the microarrays or 
proteomics studies looking at expression or down modulation of genes in response to 
TGF-β treatment. If such genes/proteins are identified, possible modulation of their 
expression by gene knockdown could provide the answers as to the exact mechanism 
of TGF-β induced HIV-1 restriction in LC.  
Interestingly, I observed that Langerin is up regulated in response to type I interferon 
stimulation, an observation not published before. Commonly recognised as a potent 
antimicrobial barrier for the first time Langerin is described to be responsive to 
warning signals such as type I interferon. It would be interesting to see if other pro-
inflammatory cytokines induce similar effect on Langerin levels in these cells. 
Verification of the above data in skin-isolated cells would also benefit to our 
understanding of Langerhans cells behaviour in inflammatory condition. 
In summary, this work provides new insight into Langerhans cells interactions with 
HIV-1. For the first time I describe the role of SAMHD-1 in these cells in preventing 
virus replication. Additionally, I shown that additional, TGF-β inducible restriction to 
virus infection operates in these cells and its function cannot be overcome by the 
presence of SIV Vpx or Vpr proteins. Decoding the role of this cellular restriction to 
HIV-1 infection in MDLC could offer new insights into the development of 
preventative vaccines or microbicides, which could help, prevent over 2 million of 
new HIV-1 transmissions happening each year worldwide.    
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Appendix 1 
Appendix 1. TLR expression profile in cells and their agonists.  
 
 
Receptor Ligand 
(origin) 
Agonists used in 
our study 
(concentration) 
Location in 
cells 
expression 
in vivo* 
monocyte 
derived models 
expression* 
TLR 1 Lipopeptides 
(bacteria) 
Pam3CSK4 
(1µg/ml) 
Cell surface DC: LC:++ MDDC+/- 
MDLC + 
TLR 2 Zymosam 
(fungi); 
lipotechoic 
acid 
(bacteria) 
Peptidoglycan 
(10µg/ml) 
Cell surface DC 
LC+ 
MDDC+/- 
MDLC+ 
TLR 3 ds-RNA 
(viruses) 
Poly I:C 
(2.5µg/ml) 
Intracellular 
compartments 
DC 
LC 
MDDC 
MDLC 
TLR 4 Lipopolysacc
haride 
(bacteria) 
LPS (1 g/ml) Cell surface DC 
LC- 
MDDC+/- 
MDLC+ 
TLR 5 Flagellin 
(bacteria) 
Flagellin 
(1µg/ml) 
Cell surface DC 
LC+ 
MDDC++ 
MDLC++ 
TLR 6 Diacyl 
lipopeptides 
(mycoplasma
) 
FSL1 (1µg/ml) Cell surface DC 
LC++ 
MDDC++ 
MDLC++ 
TLR 7 Small 
syntetic 
compounds; 
ssRNA 
(viruses) 
Imiquimod 
(100µg/ml) 
Intracellular 
compartments 
DC 
LC- 
MDDC 
MDLC 
TLR 8 ssRNA 
(viruses) 
ssRNA (1µg/ml) Intracellular 
compartments 
DC 
LC 
MDDC 
MDLC 
TLR 9 Unmethylate
d CpG 
oligodeoxyn
ucleotide 
DNA 
(bacteria, 
viruses)  
E.coli ssDNA 
(5µg/ml) 
Intracellular 
compartments 
DC 
LC++ 
MDDC++ 
MDLC++ 
TLR 10 unknown Not investigated  DC 
LC 
 
